

GLP-1R Agonist and Therapeutic Method Thereof**Cross-reference to related applications**

The present disclosure claims the benefits of the Chinese patent application No. 202311189557.X entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed September 14, 2023 with the China National Intellectual Property Administration, the U.S. provisional application No. 63/538,892 entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed September 18, 2023 with the U.S. Patent and Trademark Office, the Chinese patent application No. 202311371725.7 entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed October 23, 2023 with the China National Intellectual Property Administration, the U.S. provisional application No. 63/545,615 entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed October 25, 2023 with the U.S. Patent and Trademark Office, the Chinese patent application No. 202311582240.2 entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed November 24, 2023 with the China National Intellectual Property Administration, the U.S. provisional application No. 63/603,854 entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed November 29, 2023 with the U.S. Patent and Trademark Office, the Chinese patent application No. 202311686034.6 entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed December 8, 2023, No. 202410142451.2 entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed January 31, 2024, No. 202410202078.5 entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed February 22, 2024, No. 202410398964.X entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed April 2, 2024, No. 202410584679.7 entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed May 11, 2024, No. 202410963587.X entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed July 17, 2024 with the China National Intellectual Property Administration, the U.S. provisional application No. 63/673,453 entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed July 19, 2024 with the U.S. Patent and Trademark Office, and the Chinese patent application No. 202411237048.4 entitled “GLP-1R Agonist and Therapeutic Method Thereof” filed September 4, 2024 with the China National Intellectual Property Administration, which are incorporated herein by their entireties.

30

FIELD

The present disclosure generally relates to compounds that bind to and act as agonists or modulators of the glucagon-like peptide-1 receptor (GLP-1R), as well as the use of such compounds for the treatment and/or prevention of GLP-1R-mediated diseases and conditions.

BACKGROUND


Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted from the enteroendocrine cells in the gut in response to a meal. GLP-1 is believed to play a role in regulation of post-prandial glycemia, via directly augmenting meal-induced insulin secretion from the pancreatic beta-cells, as well as in promoting satiety by delaying the transit of food through the gut. GLP-1 mediates intracellular signaling via the GLP-1 receptor (GLP-1R), which belongs to a family of G-protein coupled receptors that are present on the cell membrane and can result in the accumulation of the secondary messenger cyclic adenosine monophosphate (cAMP) upon activation. Non-alcoholic steatohepatitis (NASH) can be associated with features of metabolic syndrome, including obesity, type 2 diabetes, insulin resistance, and cardiovascular disease.

GLP-1R agonists are currently being investigated in connection with diabetes, obesity, and NASH. GLP-1R agonists include peptides, such as exenatide, liraglutide, and dulaglutide, that have been approved for the management of type 2 diabetes. Such peptides are predominantly administered by subcutaneous injection. Oral GLP-1 agonists are also under investigation for treatment of type 2 diabetes. Some GLP-1R agonists, such as liraglutide, dulaglutide, and exenatide, are resistant to rapid degradation by dipeptidyl peptidase 4, resulting in longer half-lives than endogenous GLP-1.

There remains a need for compounds, such as agonists of GLP-1R, with desirable therapeutic properties, metabolic properties, and/or easy administration in the treatment of GLP-1R-mediated diseases and conditions.

SUMMARY

One aspect of the present disclosure provides a compound of Formula (I), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:



Formula (I)

wherein:

X is selected from the group consisting of N and $-CR^a$; wherein R^a is selected from the group consisting of hydrogen, halogen, and C_{1-6} alkyl;

Y is $-C(=O)-$;

each of $Z_3, Z_4, Z_5, Z_6, Z_7, Z_8, Z_9, Z_{10}, Z_{11}, Z_{12}$ and Z_{13} is independently selected from the group consisting of N and C;

wherein Q_1 is selected from the group consisting of C_{6-10} aryl and 5- to 10-membered heteroaryl, wherein C_{6-10} aryl or 5- to 10-membered heteroaryl is optionally substituted by one to five substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl and C_{1-6} alkoxy;

wherein Q_2 is selected from the group consisting of 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, and $-NR^{Qa}R^{Qb}$, or wherein two C_{1-6} alkyl groups optionally together with the carbon atoms to which they are attached form C_{3-8} carbocyclic ring; wherein R^{Qa} and R^{Qb} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl and $(C_{1-6}$ alkyl) carbonyl;

wherein each of $R_1, R_2, R_3, R_1', R_2'$ and R_3' is independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cycloalkyl and heterocycloalkyl; wherein C_{1-6} alkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C_{1-6} alkoxy and hydroxyl; or

wherein R_2 and R_3 together with the carbon atom to which they are attached form 4- to 8-membered heterocycloalkyl;

each of R₄, R₅ and R₆ is independently selected from the group consisting of hydrogen, halogen and C₁₋₆ alkyl;

each of R₇ and R₈ is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents

5 independently selected from the group consisting of halogen and C₃₋₁₅ cycloalkyl;


or R₇ and R₈ together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring, wherein the C₃₋₁₅ carbocyclic ring is optionally substituted by one to three C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxyl, -NR^{7a}R^{7b}, C₁₋₆ alkoxy and 3- to 12-membered heterocyclic, and R^{7a} and R^{7b} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; and any two C₁₋₆ alkyl optionally together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring;

n1 is 0, 1, 2 or 3;

15 n2 is 0, 1, 2, 3, 4 or 5;

n_3 is 0 or 1;

R₉ is selected from the group consisting of:



each of R^{9a}, R^{9b}, R^{9c}, R^{9d} and R^{9g} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₁₋₆ alkoxy;


R^{9c} is selected from the group consisting of hydrogen and C₁₋₆ alkyl optionally substituted by one or more halogen;

25 R^{9f} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

R^{9h} is selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl) carbonyl, cyano and -S(=O)_{n9}-R⁹ⁱ; n₉ is 0, 1 or 2;

R⁹ⁱ is C₁₋₆ alkyl;

Z_1 is selected from the group consisting of:



wherein R^{za} is selected from the group consisting of hydrogen, C_{1-6} alkyl and $(C_{1-6}$ alkyl) carbonyl, and each of R^{zb} and R^{zc} is independently selected from the group consisting of hydrogen and C_{1-6} alkyl;


n_4 is 1, 2 or 3;

5 each of n_5 and n_6 is independently an integer selected from 0 to 10;

Z_2 is 5- to 10- membered heteroaryl, and Z_2 is substituted with one halogen and one of C_3 - C_{15} cycloalkyl and C_1 - C_6 alkyl- C_3 - C_{15} cycloalkyl; wherein the cycloalkyl or alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C_{1-6} alkyl, C_{1-6} alkoxy and $(C_{1-6}$ alkyl) carbonyl, wherein each of

10 alkyl and alkoxy is optionally substituted with halogen.

Another aspect of the present disclosure provides a compound of Formula (III), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:



Formula (III)

wherein:

15 X is $-CR^a$; R^a is H;

Y is $-C(=O)-$;

$Z_3, Z_4, Z_5, Z_6, Z_8, Z_9, Z_{10}, Z_{12}$ and Z_{13} are C;

Z_7 and Z_{11} are N;

Q_1 is C_{6-10} aryl, wherein C_{6-10} aryl is optionally substituted with one to five substituents

20 independently selected from the group consisting of halogen and C_{1-6} alkyl;

Q_2 is 3- to 12-membered heterocyclic; wherein 3- to 12-membered heterocyclic is optionally substituted with 1-3 substituents independently selected from the group consisting of halogen and C_{1-6} alkyl, or wherein two C_{1-6} alkyl groups optionally together with the carbon atoms to which they are attached form C_{3-8} carbocyclic ring;

wherein each of R₁, R₂, R₁' and R₂' is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl;

R₃ and R₃' are independently selected from the group consisting of hydrogen and C₁₋₆ alkyl;



5 R₄, R₅ and R₆ are H;

each of R₇ and R₈ is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl; or R₇ and R₈ together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring, wherein the C₃₋₁₅ carbocyclic ring is optionally substituted by one to three C₁₋₆ alkyl;

10 n₁ is 0 or 1;


n₂ is 0 or 1;

n₃ is 1;



15 Z₂ is 5- to 10- membered heteroaryl, and Z₂ is substituted with one halogen and one of C₃₋₁₅ cycloalkyl and C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl; wherein the cycloalkyl or alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, oxo, C₁₋₆ alkyl, C₁₋₆ alkoxy and (C₁₋₆ alkyl) carbonyl, wherein each of alkyl and alkoxy is optionally substituted with halogen.

20 Still another aspect of the present disclosure provides a compound of Formula (IV), a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof:



Formula (IV)

wherein:


each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;

5 R_{Z1} is selected from the group consisting of halogen, C₁₋₃ alkyl, and C₃₋₈ cycloalkyl;

R_{Z2} is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl- C₃₋₈ cycloalkyl; and R_{Z2} is optionally substituted with substituents independently selected from the group consisting of halogen, -OH, C₁₋₆ alkyl, and C₁₋₆ alkoxy;

m₁ is 0, 1, 2 or 3.

10 Yet still another aspect of the present disclosure provides a compound of Formula (V), a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof:




Formula (V)

wherein:

15 each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;

Q₂ is selected from the group consisting of




R_n is selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy;

5 m is 0, 1, 2 or 3;

R_{z2} is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl- C₃₋₈ cycloalkyl; and R_{z2} is optionally substituted with substituents independently selected from the group consisting of halogen, hydroxyl, C₁₋₆ alkyl and C₁₋₆ alkoxy.

Yet still another aspect of the present disclosure provides a compound of Formula
10 (VIII), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:



Formula(VIII)

wherein:

each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;

15 R_m is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy;

R_{n1} and R_{n3} are each independently selected from the group consisting of hydrogen,

halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy; R_{n2} is selected from halogen;

R₃ is selected from the group consisting of hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy;

- 5 R_{z1} is selected from the group consisting of hydrogen, halogen, C₁₋₃ alkyl and C₃₋₈ cycloalkyl;


R_{z2} Selected from the group consisting of



;

- 10 R_{qm} and R_{qn} are each independently selected from the group consisting of H, methyl, and ethyl, or R_{qm} and R_{qn} together with the carbon atom to which they are attached to form a C₃₋₆ cycloalkyl.

Yet still another aspect of the present disclosure provides a compound of Formula (IX), a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof:




15

Formula (IX)

wherein:

each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;


Z₂ is selected from the group consisting of



R_n is selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl and C_{1-6} alkoxy;

m is 0, 1, 2 or 3.

- 5 Yet still another aspect of the present disclosure provides a compound of Formula (X), a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof:




Formula (X)

wherein:

- 10 each of X , Z_4 and Z_6 is independently selected from the group consisting of N and CH ;
 m is 0, 1, 2 or 3;
 R_p is selected from the group consisting of $-CH_2-P(=O)R^{zm}R^{zn}$ and $-P(=O)OR^{zm}OR^{zn}$;
 R_q is selected from the group consisting of halogen, $-NH-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl, $-O-C_{1-6}$ alkyl, 3- to 12-membered heterocyclic, $-C_3-C_{15}$ cycloalkyl and C_1-C_6 alkyl- C_3-C_{15} cycloalkyl;
 15 wherein each of R^{zm} and R^{zn} is independently selected from the group consisting of hydrogen, C_{1-6} alkyl and C_{6-10} aryl; or R^{zm} and R^{zn} together with the phosphorous atom to which they are attached form 5- to 8- membered heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with 1-3 C_{1-6} alkyl.





Yet still another aspect of the present disclosure provides a compound of Formula (XI), a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof:




wherein:


- 5 Q₁ is C₆₋₁₀ aryl, and the C₆₋₁₀ aryl is optionally substituted with one to five substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy;
- Q₂ is selected from the group consisting of 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents independently selected from the
- 10 group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆ alkoxy, wherein two C₁₋₆ alkyl groups optionally together with the carbon atoms to which they are attached form a C₃₋₈ carbocyclic ring;
- X₁, X₂, and X₃ are independently selected from the group consisting of N and C;
- X₄, and X₅ are independently selected from the group consisting of N and C;
- 15 R_m is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy;
- R₂₂ is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl- C₃₋₈ cycloalkyl.

- 20 Yet still another aspect of the present disclosure provides a compound, a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof, selected from the group consisting of:







7




8




9




10




11











12








14



15





Yet still another aspect of the present disclosure provides the composition comprising the compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of the present disclosure, and a pharmaceutically acceptable excipient.

Yet still another aspect of the present disclosure provides a method for treating GLP-1R mediated diseases or conditions, comprising administering to a subject in need thereof a therapeutically effective amount of the compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, or a pharmaceutical composition of the present disclosure.

DETAILED DESCRIPTION

In the following description, certain specific details are included to provide a

comprehensive understanding of the various disclosed embodiments. However, those skilled in the art will recognize that embodiments may be achieved without the use of one or more of these specific details and with the use of other methods, components, materials, etc.

Unless otherwise required in this disclosure, throughout the specification and subsequent claims, the words “including” and “comprising” are to be interpreted in an open-ended, inclusive sense, i.e., “including, without limitation”.

As used in this disclosure and the appended claims, singular referents without indication of quantity include plural referents unless the context clearly indicates otherwise.

Throughout this specification, references to “an embodiment” or “embodiments” or “in another embodiment” or “in some embodiments” means to include in at least one embodiment a specific reference element, structure or feature related to that embodiment as described in that embodiment. Accordingly, the phrases “in an embodiment” or “in an embodiment” or “in another embodiment” or “in some embodiments” appearing at various places throughout the specification are intended to mean that at least one embodiment includes a specific reference element or feature related to that embodiment as described therein. “in some embodiments” need not all refer to the same embodiment. In addition, specific elements, structures, or features may be combined in one or more embodiments in any suitable manner.

It should be understood that the singular form of the article “one” (corresponding to the English words “a”, “an”, and “the”) is used in the specification of the present disclosure and the appended claims. “the”) is used in the claims in the singular form to include objects in the plural unless the context explicitly states otherwise. Thus, for example, reference to an extended-release tablet comprising “pharmaceutically acceptable excipients” includes one pharmaceutically acceptable excipient or two or more pharmaceutically acceptable excipients.

It should be understood that the singular form of the article “a” (corresponding to the English “a”, “an”, and “the”) used in this disclosure and the accompanying claims includes plural objects unless otherwise explicitly stated in the text. Therefore, for example, a sustained-release tablet containing “pharmaceutically acceptable excipients” includes one pharmaceutically acceptable excipient or two or more pharmaceutically acceptable excipients.

Definition

Unless defined otherwise, all technical and scientific terms used herein have the same

meaning as commonly understood by one of ordinary skill in the art. A dash at the front or end of a chemical group is a matter of convenience to indicate the point of attachment to a parent moiety; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A prefix such as “C_{u-v}” or “C_u-C_v” indicates that the following group has from u to v carbon atoms, where u and v are integers. For example, “C₁₋₆ alkyl” or “C₁-C₆ alkyl” indicates that the alkyl group has from 1 to 6 carbon atoms. “C₃-C₁₀ cycloalkyl” describes a cycloalkyl group having a total of 3 to 10 carbon atoms.

The terms “and/or” are used in this disclosure to denote “and” or “or” unless otherwise indicated.

“Substituted” as used herein refers to wherein one or more hydrogen atoms of the group are independently replaced by one or more substituents (e.g., 1, 2, 3, or 4 or more) as indicated. The substituent is selected from the following substituents, but are not limited to: alkyl, cycloalkyl, aryl, heteroaryl, heteroaryl, hydroxy, protected hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylsulfanyl, cyano, halogenated, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl O-thiocarbamoyl, N-thiocarbamoyl, C-acylamino, N-acylamino, S-sulfinylamino, N-sulfinylamino, C-carboxylic, protected C-carboxylic, O-carboxylic, isocyanatocarbonyl, cyanothiocyanatocarbonyl, isothiocyanatocarbonyl, nitro, methyldimethylsilanyl, trihalomethanesulfonyl, -NR' R" (R' and R" are alkyl groups as defined in this disclosure) or a protected amino group.

“Alkyl” is a monovalent or divalent linear or branched saturated hydrocarbon radical. For example, an alkyl group can have 1 to 10 carbon atoms (i.e., C₁₋₁₀ alkyl) or 1 to 8 carbon atoms (i.e., C₁₋₈ alkyl) or 1 to 6 carbon atoms (i.e., C₁₋₆ alkyl) or 1 to 4 carbon atoms (i.e., C₁₋₄ alkyl). Examples of alkyl groups include, but are not limited to, methyl (Me, -CH₃), ethyl (Et, -CH₂CH₃), 1-propyl (*n*-Pr, *n*-propyl, -CH₂CH₂CH₃), 2-propyl (*i*-Pr, *i*-Propyl, -CH(CH₃)₂), 1-butyl (*n*-Bu, *n*-butyl, -CH₂CH₂CH₂CH₃), 2-methyl-1-propyl (*i*-Bu, *i*-butyl, -CH₂CH(CH₃)₂), 2-butyl (*s*-Bu, *s*-butyl, -CH(CH₃)CH₂CH₃), 2-methyl-2-propyl (*t*-Bu, *t*-butyl, -C(CH₃)₃), 1-pentyl (*n*-pentyl, -CH₂CH₂CH₂CH₂CH₃), 2-pentyl (-CH(CH₃)CH₂CH₂CH₃), 3-pentyl (-CH(CH₂CH₃)₂), 2-methyl-2-butyl (-C(CH₃)₂CH₂CH₃), 3-methyl-2-butyl (-CH(CH₃)CH(CH₃)₂), 3-methyl-1-butyl (-CH₂CH₂CH(CH₃)₂), 2-methyl-1-butyl (-CH₂CH(CH₃)CH₂CH₃), 1-hexyl (-CH₂CH₂CH₂CH₂CH₂CH₃), 2-hexyl (-CH(CH₃)CH₂CH₂CH₂CH₃), 3-hexyl (-CH(CH₂CH₃)(CH₂CH₂CH₃)), 2-methyl-2-pentyl (-C(CH₃)₂CH₂CH₂CH₃), 3-methyl-2-pentyl (-CH(CH₃)CH(CH₃)CH₂CH₃), 4-methyl-2-pentyl (-CH(CH₃)CH₂CH(CH₃)₂), 3-methyl-3-pentyl (-C(CH₃)(CH₂CH₃)₂), 2-methyl-3-pentyl (-CH(CH₂CH₃)CH(CH₃)₂), 2, 3-dimethyl-2-butyl (-C(CH₃)₂CH(CH₃)₂), 3, 3-dimethyl-2-butyl

(-CH(CH₃)C(CH₃)₃, and octyl (-CH₂)₇CH₃). Alkyl groups can be unsubstituted or substituted.

The alkyl group may be optionally substituted, i.e., substituted or unsubstituted. When substituted, the substituent group is individually and independently selected from one or more of the following: cycloalkyl, aryl, heteroaryl, heteroaryl, hydroxy, alkoxy, aryloxy, thiol, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-acylamino, N-acyl amino, S-sulfinylamino, N-sulfinylamino, C-carboxyl, O-carboxyl, isocyanato, cyanothio, isothiocyanato, nitro, methylsilyl, trihalomethanesulfonyl, -NR'R" (R' and R" are alkyl groups as defined in the present disclosure) or amino groups including mono- and di-substituted amino groups, and protected derivatives thereof.

In some embodiments, exemplary examples of alkyl groups that can be used in the present disclosure include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, and hexyl. Whenever a substituent is described as being “optionally substituted”, the substituent may be substituted with one of the above substituents.

“Alkoxy” refers to the group -O-alkyl, where alkyl is as defined above. For example, C₁₋₄ alkoxy refers to an -O-alkyl group having 1 to 4 carbons. Alkoxy groups can be unsubstituted or substituted.

“Alkoxyalkyl” is an alkoxy group attached to an alkyl as defined above, such that the alkyl is divalent. For example, C₂₋₆ alkoxyalkyl includes -CH₂-OMe, -CH₂-O-*i*Pr, -CH₂-CH₂-OMe, -CH₂-CH₂-O-CH₂-CH₃, and -CH₂-CH₂-O-*t*Bu. Alkoxyalkyl groups can be unsubstituted or substituted.

“Alkenyl” is a monovalent or divalent linear or branched hydrocarbon radical with at least one carbon-carbon double bond. For example, an alkenyl group can have 2 to 8 carbon atoms (i.e., C₂₋₈ alkenyl) or 2 to 6 carbon atoms (i.e., C₂₋₆ alkenyl) or 2 to 4 carbon atoms (i.e., C₂₋₄ alkenyl). Examples of alkenyl groups include, but are not limited to, ethenyl (-CH=CH₂), allyl (-CH₂CH=CH₂), and -CH₂-CH=CH-CH₃. Alkenyl groups can be unsubstituted or substituted.

“Alkynyl” is a monovalent or divalent linear or branched hydrocarbon radical with at least one carbon-carbon triple bond. For example, an alkynyl group can have 2 to 8 carbon atoms (i.e., C₂₋₈ alkynyl) or 2 to 6 carbon atoms (i.e., C₂₋₆ alkynyl) or 2 to 4 carbon atoms (i.e., C₂₋₄ alkynyl). Examples of alkynyl groups include, but are not limited to, acetylenyl (-C≡CH), propargyl (-CH₂C≡CH), and -CH₂-C≡C-CH₃. Alkynyl groups can be unsubstituted

or substituted.

“Oxo” as used herein refers to =O.

“Halogen” or “halo” refers to fluoro (-F), chloro (-Cl), bromo (-Br) and iodo (-I).

“Haloalkyl” is an alkyl as defined herein, wherein one or more hydrogen atoms of the
5 alkyl are independently replaced by a halogen, which may be the same or different, such that the alkyl is divalent. The alkyl group and the halogen can be any of those described above. In some embodiments, the haloalkyl defines the number of carbon atoms in the alkyl portion, e.g., C₁₋₄ haloalkyl includes CF₃, CH₂F, CHF₂, CH₂CF₃, CH₂CH₂CF₃, CCl₂CH₂CH₂CH₃, and C(CH₃)₂(CF₂H). Haloalkyl groups can be unsubstituted or substituted.

10 “Haloalkoxy” is an alkoxy as defined herein, wherein one or more hydrogen atoms of the alkyl in the alkoxy are independently replaced by a halogen, which may be the same or different, such that the alkyl is divalent. The alkoxy group and the halogen can be any of those described above. In some embodiments, the haloalkoxy defines the number of carbon atoms in the alkyl portion, e.g., C₁₋₄ haloalkoxy includes OCF₃, OCH₂F, OCH₂CF₃,
15 OCH₂CH₂CF₃, OCCl₂CH₂CH₂CH₃, and OC(CH₃)₂(CF₂H). Haloalkoxy groups can be unsubstituted or substituted.

“Cycloalkyl” is a monovalent or divalent single all carbon ring or a multiple condensed all carbon ring system wherein the ring in each instance is a non-aromatic saturated or unsaturated ring. For example, in some embodiments, a cycloalkyl group has 3 to 12 carbon
20 atoms, 3 to 10 carbon atoms, 3 to 8 carbon atoms, 3 to 6 carbon atoms, 3 to 5 carbon atoms, or 3 to 4 carbon atoms. Exemplary single ring cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, and cyclooctyl. Cycloalkyl also includes multiple condensed ring systems (e.g., ring systems comprising 2 rings) having about 7 to 12 carbon atoms. The rings of the multiple condensed
25 ring system can be connected to each other via fused, spiro, or bridged bonds when allowed by valency requirements. Exemplary multiple ring cycloalkyl groups include octahydropentalene, bicyclo[2. 2. 1]heptane, bicyclo[2. 2. 2]octane, bicyclo[2. 2. 2]oct-2-ene, and spiro[2. 5]octane. Cycloalkyl groups can be unsubstituted or substituted.

The term “cycloalkyl” is intended to include a cycloalkyl group as defined above option
30 substituted by one or more groups selected from the following substituents: cycloalkyl, aryl, heteroaryl, heteroaliphatic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thio carbonyl, isocyanate, cyanothionyl, isothiocyanate, nitro, -NR'R'' (R' and R'' are alkyl groups as defined in the present disclosure) or amino groups including mono- and di-substituted amino groups, and protected derivatives thereof.

In some embodiments, “C₃₋₆ cycloalkyl” refers to a cycloalkyl group as defined above having three to six carbon atoms. C₃₋₆ cycloalkyl groups may be optionally substituted as defined above for cycloalkyl.

In some embodiments, “C₃₋₈ cycloalkyl” refers to a cycloalkyl group having from three
5 to eight carbon atoms as defined above. C₃₋₈ cycloalkyl groups may be optionally substituted as defined above for cycloalkyl.

In some embodiments, the term “C₃₋₁₅ cycloalkyl” refers to a cycloalkyl group as defined above having from three to twelve carbon atoms. C₃₋₁₅ cycloalkyl groups may be optionally substituted as defined above for cycloalkyl.

10 “Aryl” as used herein refers to a monovalent or divalent single all carbon aromatic ring or a multiple condensed all carbon ring system wherein the ring is aromatic. For example, in some embodiments, an aryl group has 6 to 20 carbon atoms, 6 to 14 carbon atoms, 6 to 12 carbon atoms, or 6 to 10 carbon atoms. Aryl includes a phenyl radical. Aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having about
15 9 to 20 carbon atoms in which multiple rings are aromatic. The rings of the multiple condensed ring system can be connected to each other via fused bonds when allowed by valency requirements. It is also understood that when reference is made to a certain atom-range membered aryl (e.g., 6-10 membered aryl), the atom range is for the total ring atoms of the aryl. For example, a 6-membered aryl would include phenyl and a 10-membered aryl
20 would include naphthyl. Non-limiting examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, and the like. Aryl groups can be unsubstituted or substituted.

“Heterocyclyl” or “heterocycle” or “heterocycloalkyl” or “heterocyclic” or “heterocyclic ring” as used herein refers to a single saturated or partially unsaturated non-aromatic ring or a non-aromatic multiple ring system that has at least one heteroatom in the ring (i.e., at least
25 one annular (i.e., ring-shaped) heteroatom selected from oxygen, nitrogen, and sulfur). Unless otherwise specified, a heterocyclyl group has from 3 to about 20 annular atoms, for example from 3 to 12 annular atoms, for example from 4 to 12 annular atoms, 4 to 10 annular atoms, or 3 to 8 annular atoms, or 3 to 6 annular atoms, or 3 to 5 annular atoms, or 4 to 6 annular atoms, or 4 to 5 annular atoms. Thus, the term includes single saturated or partially
30 unsaturated rings (e.g., 3, 4, 5, 6 or 7- membered rings) having from about 1 to 6 annular carbon atoms and from about 1 to 3 annular heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The rings of the multiple condensed ring (e.g. bicyclic heterocyclyl) system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. Heterocycles include, but are not limited to,

azetidine, aziridine, imidazolidine, morpholine, oxirane(epoxide), oxetane, thietane, piperazine, piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, quinuclidine, 2-oxa-6-azaspiro[3. 3]heptan-6-yl, 6-oxa-1-azaspiro[3. 3]heptan-1-yl, 2-thia-6-azaspiro[3. 3]heptan-6-yl, 2, 6-diazaspiro[3. 3]heptan-2-yl, 2-azabicyclo[3. 1. 0]hexan-2-yl, 3-azabicyclo[3. 1. 0]hexanyl, 2-azabicyclo[2. 1. 1]hexanyl, 2-azabicyclo[2. 2. 1]heptan-2-yl, 4-azaspiro[2. 4]heptanyl, 5-azaspiro[2. 4]heptanyl, and the like. Heterocyclyl groups can be unsubstituted or substituted.

“5-10 membered heteroaryl” refers to an aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; “5-10 membered heteroaryl” also includes multiple condensed ring systems that have at least one such aromatic ring, which multiple condensed ring systems are further described below. Thus, “5-10 membered heteroaryl” includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic. Exemplary 5-10 membered heteroaryl ring systems include but are not limited to pyridyl, pyrimidinyl, oxazolyl or furyl. “5-10 membered heteroaryl” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a 5-10 membered heteroaryl group, as defined above, is condensed with one or more rings selected from 5-10 membered heteroaryls (to form for example 1, 8-naphthyridinyl) and aryls (to form, for example, benzimidazolyl or indazolyl) to form the multiple condensed ring system. Thus, a 5-10 membered heteroaryl (a single aromatic ring or multiple condensed ring system) can have about 1-20 carbon atoms and about 1-6 heteroatoms within the 5-10 membered heteroaryl ring. For example, tetrazolyl has 1 carbon atom and 4 nitrogen heteroatoms within the ring. The rings of the multiple condensed ring system can be connected to each other via fused bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is to be understood that the point of attachment for a 5-10 membered heteroaryl or 5-10 membered heteroaryl multiple condensed ring system can be at any suitable atom of the 5-10 membered heteroaryl or 5-10 membered heteroaryl multiple condensed ring system including a carbon atom and a heteroatom (e.g., a nitrogen). It also to be understood that when a reference is made to a certain atom-range membered (e.g., a 5-10 membered heteroaryl), the atom range is for the total ring atoms of the 5-10 membered heteroaryl and includes carbon atoms and heteroatoms. It is also to be understood that the rings of the multiple condensed ring system

may include an aryl ring fused to a heterocyclic ring with saturated or partially unsaturated bonds (e.g., 3, 4, 5, 6 or 7-membered rings) having from about 1 to 6 annular carbon atoms and from about 1 to 3 annular heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. For example, a 5-10 membered heteroaryl includes thiazolyl and a 5-10 membered heteroaryl includes quinolinyl. Exemplary 5-10 membered heteroaryls include but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2, 3-b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, and tetrazolyl. 5-10 membered heteroaryl groups can be unsubstituted or substituted.

The term “5-10 membered heteroaryl” is intended to include an aromatic ring group as defined above optionally substituted by one or more groups selected from the following substituents: cycloalkyl, aryl, heteroaryl, heteroaliphatic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thio carbonyl, isocyanate, cyanothionyl, isothiocyanate, nitro, -NR'R" (R' and R" are alkyl groups as defined in the present disclosure) or amino groups including mono- and di-substituted amino groups, and protected derivatives thereof.

“(C₁₋₆ alkyl)carbonyl” means the group: (C₁₋₆ alkyl)-C(O)- group, wherein alkyl is defined as mentioned above. The carbonyl refers to the C(O)- group, which is a carbon atom double-bonded to an oxygen atom. Examples include methyl carbonyl (acetyl), ethyl carbonyl (propionyl), n-propyl carbonyl, isopropyl carbonyl, n-butyl carbonyl, isobutyl carbonyl, sec-butyl carbonyl, tert-butyl carbonyl, 1-methylpropyl carbonyl, n-amyl carbonyl, isoamyl carbonyl, 2-methylbutyl carbonyl, 1,1-dimethylpropyl carbonyl, 1-ethylpropyl carbonyl, n-hexyl carbonyl, 4-methylpentyl carbonyl, and 2-ethylbutyl carbonyl. Carbonyl ethylpentane, 4-methylpentylcarbonyl, and 2-ethylbutylcarbonyl.

A “compound of the present disclosure” includes compound disclosed herein, for example a compound of the present disclosure includes compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (Ia), (Ib), (Ic), (Id), (Ie), (If), and (Ig), but also includes the compound of the examples.

“Pharmaceutically acceptable excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug

Administration as being acceptable for use in humans or domestic animals.

“Therapeutically effective amount” or “effective amount” as used herein refers to an amount that is effective to elicit the desired biological or medical response, including the amount of a compound that, when administered to a subject for treating a disease, is
5 sufficient to affect such treatment for the disease. The effective amount will vary depending on the compound, the disease, and its severity and the age, weight, etc., of the subject to be treated. The effective amount can include a range of amounts. As is understood in the art, an effective amount may be in one or more doses, i.e., a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in
10 the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved. Suitable doses of any co-administered compounds may optionally be lowered due to the combined action (e.g., additive or synergistic effects) of the compounds.

“Co-administration” as used herein refers to administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound of the present
20 disclosure is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of the present disclosure within seconds or minutes. In some embodiments, a unit dose of a compound of the present disclosure is
25 administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents. In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound of the present disclosure. Co-administration of a compound disclosed herein with one or more additional
30 therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one or more additional therapeutic agents, such that therapeutically effective amounts of each agent are present in the body of the subject.

Provided are also pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of the compounds described herein.

“Pharmaceutically acceptable” refers to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.

The compounds described herein may be prepared and/or formulated as

- 5 pharmaceutically acceptable salts or when appropriate as a free base. Pharmaceutically acceptable salts are non-toxic salts of a free base form of a compound that possesses the desired pharmacological activity of the free base. These salts may be derived from inorganic or organic acids or bases. For example, a compound that contains a basic nitrogen may be prepared as a pharmaceutically acceptable salt by contacting the compound with an inorganic
- 10 or organic acid. Non-limiting examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrate, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1, 4-dioates, hexyne-1, 6-dioates, benzoates, chlorobenzoates,
- 15 methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methylsulfonates, propylsulfonates, besylates, xylenesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ -hydroxybutyrates, glycolates, tartrates, and mandelates. Lists of other
- 20 suitable pharmaceutically acceptable salts are found in Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams and Wilkins, Philadelphia, Pa., 2006.

- Examples of “pharmaceutically acceptable salts” of the compounds disclosed herein also include salts derived from an appropriate base, such as an alkali metal (for example, sodium, potassium), an alkaline earth metal (for example, magnesium), ammonium and $N(C_1-C_4$
- 25 alkyl) $_4^+$. Also included are base addition salts, such as sodium or potassium salts.

- Provided are also compounds described herein or pharmaceutically acceptable salts, isomers, or a mixture thereof, in which from 1 to n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molecule. As known in the art, the deuterium atom is a non-radioactive isotope of the
- 30 hydrogen atom. Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof when administered to a mammal. See, e.g., Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism”, Trends Pharmacol. Sci., 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for

example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.

Examples of isotopes that can be incorporated into the disclosed compounds also include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{13}N , ^{15}N , ^{15}O , ^{17}O , ^{18}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , ^{36}Cl , ^{123}I , and ^{125}I , respectively. Substitution with positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of Formula I can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.

The compounds of the embodiments disclosed herein, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, tautomer, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids, as well as deuterated analogs thereof. The chemical formula shown in the present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. Where compounds are represented in their chiral form, it is understood that the embodiment encompasses, but is not limited to, the specific diastereomerically or enantiomerically enriched form. Where chirality is not specified but is present, it is understood that the embodiment is directed to either the specific diastereomerically or enantiomerically enriched form; or a racemic or scalemic mixture of such compound(s). As used herein, "scalemic mixture" is a mixture of stereoisomers at a ratio other than 1:1.

"Stereoisomer" as used herein refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not

interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another.

“Tautomer” as used herein refers to a proton shift from one atom of a molecule to another atom of the same molecule. In some embodiments, the present disclosure includes tautomers of said compounds.


“Prevention” or “preventing” means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.

“Prodrug” as used herein refers to a derivative of a drug that upon administration to the human body is converted to the parent drug according to some chemical or enzymatic pathway. In some embodiments, a prodrug is a biologically inactive derivative of a drug that upon administration to the human body is converted to the biologically active parent drug according to some chemical or enzymatic pathway.

“Treatment” or “treat” or “treating” as used herein refers to an approach for obtaining beneficial or desired results. For purposes of the present disclosure, beneficial or desired results include, but are not limited to, alleviation of a symptom and/or diminishment of the extent of a symptom and/or preventing a worsening of a symptom associated with a disease or condition. In one embodiment, “treatment” or “treating” includes one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, delaying the worsening or progression of the disease or condition); and c) relieving the disease or condition, e.g., causing the regression of clinical symptoms, ameliorating the disease state, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival. “At risk individual” as used herein refers to an individual who is at risk of developing a condition to be treated. An individual “at risk” may or may not have detectable disease or condition, and may or may not have displayed detectable disease prior to the treatment of methods described herein. “At risk” denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of a disease or condition and are known in the art. An individual having one or more of these risk factors has a higher probability of developing the disease or condition than an individual without these risk factor(s).

Compound

One aspect of the present disclosure provides a compound of Formula (I), a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof:



Formula (I)

wherein:

X is selected from the group consisting of N and $-CR^a$; wherein R^a is selected from the group consisting of hydrogen, halogen, and C_{1-6} alkyl;

10 wherein Y is $-C(=O)-$;

wherein each of $Z_3, Z_4, Z_5, Z_6, Z_7, Z_8, Z_9, Z_{10}, Z_{11}, Z_{12}$ and Z_{13} is independently selected from the group consisting of N and C;

15 wherein Q_1 is selected from the group consisting of C_{6-10} aryl and 5- to 10-membered heteroaryl, wherein C_{6-10} aryl or 5- to 10-membered heteroaryl is optionally substituted by one to five substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl and C_{1-6} alkoxy;

20 wherein Q_2 is selected from the group consisting of 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, and $-NR^{Qa}R^{Qb}$, or wherein two C_{1-6} alkyl groups optionally together with the carbon atoms to which they are attached form C_{3-8} carbocyclic ring; wherein R^{Qa} and R^{Qb} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl and $(C_{1-6}$ alkyl) carbonyl;

25 wherein each of $R_1, R_2, R_3, R_1', R_2'$ and R_3' is independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cycloalkyl and heterocycloalkyl; wherein C_{1-6} alkyl, cycloalkyl or heterocycloalkyl is optionally substituted

by one or more substituents independently selected from the group consisting of halogen, C₁₋₆ alkoxy and hydroxyl; or

wherein R₂ and R₃ together with the carbon atom to which they are attached form 4- to 8-membered heterocycloalkyl;

5 each of R₄, R₅ and R₆ is independently selected from the group consisting of hydrogen, halogen and C₁₋₆ alkyl;

each of R₇ and R₈ is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₃₋₁₅ cycloalkyl;


10 or R₇ and R₈ together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring, wherein the C₃₋₁₅ carbocyclic ring is optionally substituted by one to three C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxyl, -NR^{7a}R^{7b}, C₁₋₆ alkoxy and 3- to 12-membered heterocyclic, and R^{7a} and R^{7b} are independently selected from the
15 group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; and any two C₁₋₆ alkyl optionally together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring;

n₁ is 0, 1, 2 or 3;

n₂ is 0, 1, 2, 3, 4 or 5;

20 n₃ is 0 or 1;

R₉ is selected from the group consisting of:








each of R^{9a}, R^{9b}, R^{9c}, R^{9d} and R^{9g} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, wherein C₁₋₆ alkyl is optionally substituted
25 with one or more substituents independently selected from the group consisting of halogen and C₁₋₆ alkoxy;


R^{9e} is selected from the group consisting of hydrogen and C₁₋₆ alkyl optionally substituted by one or more halogen;

R^{9f} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

30 R^{9h} is selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl) carbonyl, cyano and -S(=O)_{n9}-R⁹ⁱ; n₉ is 0, 1 or 2;



In some embodiments, in the compound of Formula (I), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, the compound has a structure of Formula (II):



Formula (II)









wherein:


ring A is selected from the group consisting of cyclopropyl, cyclobutyl, and cyclopentyl.

5 t is 0 or 1; and


R_{qm} and R_{qn} are each independently selected from the group consisting of hydrogen and C_{1-6} alkyl;

In some embodiments, in the compound of Formula (I), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, the compound is
10 selected from the group consisting of:






69




70



74

and

Another aspect of the present disclosure provides a compound of Formula (III), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:



Formula (III)

5

wherein:

X is $-\text{CR}^a$; R^a is H;Y is $-\text{C}(=\text{O})-$; $\text{Z}_3, \text{Z}_4, \text{Z}_5, \text{Z}_6, \text{Z}_8, \text{Z}_9, \text{Z}_{10}, \text{Z}_{12}$ and Z_{13} are C; Z_7 and Z_{11} are N;

Q₁ is C₆₋₁₀ aryl, wherein C₆₋₁₀ aryl is optionally substituted with one to five substituents independently selected from the group consisting of halogen and C₁₋₆ alkyl;

Q₂ is 3- to 12-membered heterocyclic; wherein 3- to 12-membered heterocyclic is optionally substituted with 1-3 substituents independently selected from the group consisting of halogen and C₁₋₆ alkyl, or wherein two C₁₋₆ alkyl groups optionally together with the carbon atoms to which they are attached form C₃₋₈ carbocyclic ring;

wherein each of R₁, R₂, R₁', and R₂' is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl;

R₃ and R₃' are independently selected from the group consisting of hydrogen and C₁₋₆ alkyl;



R₄, R₅ and R₆ are H;

each of R₇ and R₈ is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl; or R₇ and R₈ together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring, wherein the C₃₋₁₅ carbocyclic ring is optionally substituted by one to three C₁₋₆ alkyl;

n₁ is 0 or 1;


n₂ is 0 or 1;

n₃ is 1;




Z₂ is 5- to 10- membered heteroaryl, and Z₂ is substituted with one halogen and one of C₃₋₁₅ cycloalkyl and C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl; wherein the cycloalkyl or alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, oxo, C₁₋₆ alkyl, C₁₋₆ alkoxy and (C₁₋₆ alkyl) carbonyl, wherein each of alkyl and alkoxy is optionally substituted with halogen.

In some embodiments, in the compound of Formula (III), the stereoisomer, the


pharmaceutically acceptable salt, or the deuterated compound thereof, Q₁ is .

and R_{n1} and R_{n3} are each independently selected from the group consisting of H, methyl, and ethyl; R_{n2} is halogen.

In some embodiments, in the compound of Formula (III), the stereoisomer, the


- pharmaceutically acceptable salt, or the deuterated compound thereof, Q_2 is , R_{qm} and R_{qn} are each independently selected from the group consisting of H, methyl, and ethyl; or R_{qm} and R_{qn} together with the carbon atom to which they are attached to form C₃₋₆ cycloalkyl; p is 0, 1, or 2.


In some embodiments, in the compound of Formula (III), the stereoisomer, the

- pharmaceutically acceptable salt, or the deuterated compound thereof, Z_2 is ; R_{z1} is halogen, m1 is 1;


R_{z2} is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl-C₃₋₈ cycloalkyl; and R_{z2} is optionally substituted with one or more substituents selected from the group consisting of halogen, C₁₋₆ alkyl, and C₁₋₆ alkoxy.

In some embodiments, in the compound of Formula (III), the stereoisomer, the

- pharmaceutically acceptable salt, or the deuterated compound thereof, Z_2 is ; R_{z1} is selected from the group consisting of F, Cl, and Br; R_{z2} is selected from the group consisting of




- In some embodiments, in the compound of Formula (III), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, Z_2 is selected from the group consisting of




Z₂ is substituted with one halogen.

In some embodiments, in the compound of Formula (III), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, Z₂ is selected from the

5 group consisting of



Still another aspect of the present disclosure provides a compound of Formula (IV), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:



Formula (IV)

wherein:

each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;

R_{Z1} is selected from the group consisting of halogen, C₁₋₃ alkyl, and C₃₋₈ cycloalkyl;

- 5 R_{Z2} is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl- C₃₋₈ cycloalkyl; and R_{Z2} is optionally substituted with substituents independently selected from the group consisting of halogen, -OH, C₁₋₆ alkyl, and C₁₋₆ alkoxy;

m₁ is 0, 1, 2 or 3.

- In some embodiments, in the compound of Formula (IV), the stereoisomer, the
10 pharmaceutically acceptable salt, or the deuterated compound thereof, R_m is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆ alkoxy;

R_n is selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆ alkoxy;

m is 0, 1, 2, or 3;


- 15 R₃ is selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy.

In some embodiments, in the compound of Formula (IV), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof,

- R_{Z1} is selected from the group consisting of F, Cl, Br, methyl, ethyl, n-Propyl,
20 isopropyl and cyclopropyl;

m is 0, 1, 2, or 3;

R_{Z2} is selected from the group consisting of




- R_m is independently selected from the group consisting of halogen, -CH₃, -CH₂CH₃ and -
25 OCH₃;

R_n is selected from the group consisting of methyl, ethyl, F, and Cl;

R₃ is methyl.

In some embodiments, in the compound of Formula (IV), the stereoisomer, the

- pharmaceutically acceptable salt, or the deuterated compound thereof, Q₂ is
30 and R_{qn} are each independently selected from the group consisting of H, methyl, and ethyl;




or R_{qm} and R_{qn} together with the carbon atom to which they are attached form C_{3-6}


Cycloalkyl; p is 0, 1, or 2.

In some embodiments, in the compound of Formula (IV), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, Q₂ is selected from the

5 group consisting of



Yet still another aspect of the present disclosure provides a compound of Formula (V), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:




Formula (V)

wherein:

each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;

Q_2 is selected from the group consisting of



15 R_n is selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy;

m is 0, 1, 2 or 3;

R₂₂ is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl- C₃₋₈


cycloalkyl; and R_{z2} is optionally substituted with substituents independently selected from the group consisting of halogen, hydroxyl, C_{1-6} alkyl and C_{1-6} alkoxy.

In some embodiments, in the compound of Formula (V), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, R_{z2} is selected from the group consisting of



R_n is selected from the group consisting of methyl, ethyl, F, and Cl.

In some embodiments, in the compound of Formula (V), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, the compound has a structure of Formula (VI),




Formula (VI)

wherein:

each of X, Z_4 and Z_6 is independently selected from the group consisting of N and CH;

R_{z2} is selected from the group consisting of C_{3-8} cycloalkyl and C_{1-6} alkyl- C_{3-8} cycloalkyl; and R_{z2} is optionally substituted with substituents independently selected from the group consisting of halogen, hydroxyl, C_{1-6} alkyl and C_{1-6} alkoxy;


Q_2 is selected from the group consisting of



In some embodiments, in the compound of Formula (VI), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, R_{Z2} is selected from the group consisting of



- 5 In some embodiments, in the compound of Formula (VII), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, the compound has a structure of Formula (VII),




Formula (VII)

10 wherein:


R_{Z2} is selected from the group consisting of C_{3-8} cycloalkyl and C_{1-6} alkyl- C_{3-8} cycloalkyl; and R_{Z2} is optionally substituted with substituents independently selected from the group consisting of halogen, hydroxyl, C_{1-6} alkyl and C_{1-6} alkoxy;

Q_2 is selected from the group consisting of



15


In some embodiments, in the compound of Formula (VII), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, Q_2 is selected from the group consisting of



In some embodiments, in the compound of Formula (VII), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, R_{z2} is selected from the group consisting of



- 5 Yet still another aspect of the present disclosure provides a compound of Formula (VIII), a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof:





;

R_{qm} and R_{qn} are each independently selected from the group consisting of H, methyl, and ethyl, or R_{qm} and R_{qn} together with the carbon atom to which they are attached to form a C₃₋₆ cycloalkyl.

In some embodiments, in the compound of Formula (VIII), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof,

R_m is independently selected from the group consisting of halogen, -CH₃, -CH₂CH₃ and -OCH₃


R_{n1} and R_{n3} are each independently selected from the group consisting of hydrogen, methyl, and ethyl;

R_{n2} is F;

R_3 is methyl;

R_{z1} is selected from the group consisting of hydrogen, F, Cl, methyl, ethyl, n-propyl, isopropyl, and cyclopropyl.

Yet still another aspect of the present disclosure provides a compound of Formula (IX), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:




Formula (IX)

wherein:

each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;

Z₂ is selected from the group consisting of



R_n is selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy,

m is 0, 1, 2 or 3.

- 5 In some embodiments, in the compound of Formula (IX), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof,

R_m is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆ alkoxy;

R_3 is selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy;

- 10 R_{10} and R_{11} is independently selected from the group consisting of H, F, Cl, methyl, ethyl, n-propyl, isopropyl, and cyclopropyl.


In some embodiments, in the compound of Formula (IX), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof,

- 15 R_m is independently selected from the group consisting of halogen, -CH₃, -CH₂CH₃ and -OCH₃;

R_n is independently selected from the group consisting of -CH₃, -CH₂CH₃, F, and Cl;

R_3 is -CH₃.


- In some embodiments, in the compound of Formula (IX), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, Z_2 is selected from the group consisting of
- 20




In some embodiments, in the compound of Formula (IX), the stereoisomer, the







- pharmaceutically acceptable salt, or the deuterated compound thereof, Q_2 is
 wherein R_{qm} and R_{qn} are each independently selected from the group consisting of H, methyl,
 5 and ethyl; or R_{qm} and R_{qn} together with the carbon atom to which they are attached to form a
 C_{3-6} Cycloalkyl; p is 0, 1, or 2.








In some embodiments, in the compound of Formula (IX), the stereoisomer, the
 pharmaceutically acceptable salt, or the deuterated compound thereof, Q_2 is selected from the
 group consisting of






In some embodiments, in the compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of the present disclosure, the compound is selected from the group consisting of:






and



Yet still another aspect of the present disclosure provides a compound of Formula (X), a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof:



Formula (X)

wherein:

each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;

5 m is 0, 1, 2 or 3;

R_p is selected from the group consisting of -CH₂-P(=O)R^{zm}R^{zn} and -P(=O)OR^{zm}OR^{zn};


R_q is selected from the group consisting of halogen, -NH-C₁₋₆ alkyl, -C₁₋₆ alkyl, -O- C₁₋₆ alkyl, 3- to 12-membered heterocyclic, -C₃₋₁₅ cycloalkyl and C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl;

wherein each of R^{zm} and R^{zn} is independently selected from the group consisting of

10 hydrogen, C₁₋₆ alkyl and C₆₋₁₀ aryl; or R^{zm} and R^{zn} together with the phosphorous atom to which they are attached form 5- to 8- membered heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with 1-3 C₁₋₆ alkyl.

In some embodiments, in the compound of Formula (X), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, R_p is selected from the group consisting of

15



;

R_m is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆ alkoxy;

R_n is selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆

20 alkoxy;


m is 0, 1, 2, and 3;

R₃ is selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆

haloalkoxy.


- In some embodiments, in the compound of Formula (X), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, R_m is selected from the group consisting of H, methyl, ethyl, and methoxy; R_n is selected from the group consisting of methyl, ethyl, F and Cl, R_3 is methyl.

In some embodiments, in the compound of Formula (X), the stereoisomer, the








- pharmaceutically acceptable salt, or the deuterated compound thereof, Q_2 is , wherein R_{qm} and R_{qn} are each independently selected from the group consisting of H, methyl, and ethyl; or R_{qm} and R_{qn} together with the carbon atom to which they are attached to form C_{3-6} Cycloalkyl; p is 0, 1, or 2.


In some embodiments, in the compound of Formula (X), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, Q_2 is selected from the group consisting of




- In some embodiments, in the compound of Formula (X), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, the compound is selected from the group consisting of:



and



Yet still another aspect of the present disclosure provides a compound of Formula (XI), a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof:



5 wherein

Q₁ is C₆₋₁₀ aryl, and the C₆₋₁₀ aryl is optionally substituted with one to five substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy;

Q₂ is selected from the group consisting of 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆ alkoxy, wherein two C₁₋₆ alkyl groups optionally together with the carbon atoms to which they are attached form a C₃₋₈ carbocyclic ring;


X₁, X₂, and X₃ are independently selected from the group consisting of N and C;

X₄, and X₅ are independently selected from the group consisting of N and C;


R_m is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy;

R_{Z2} is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl- C₃₋₈ cycloalkyl.


In some embodiments, in the compound of Formula (XI), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof,

Q₁ is , and R_{n1} and R_{n3} are each independently selected from the group consisting of H, methyl, and ethyl; R_{n2} is halogen;


Q₂ is selected from the group consisting of




R_{Z2} is selected from the group consisting of



In some embodiments, in the compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of the present disclosure, the compound is selected from the group consisting of:



Yet still another aspect of the present disclosure provides a compound of Formula (Ia), a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof:



Formula (Ia)

wherein X is selected from the group consisting of N and -CR^a; wherein R^a is selected from the group consisting of hydrogen, halogen, and C₁₋₆ alkyl;

Y is -C(=O)-;

each of $Z_3, Z_4, Z_5, Z_6, Z_7, Z_8, Z_9, Z_{10}, Z_{11}, Z_{12}$ and Z_{13} is independently selected from the
10 group consisting of N and C;

Q₁ is selected from the group consisting of C₆₋₁₀ aryl and 5- to 10-membered heteroaryl, wherein C₆₋₁₀ aryl or 5- to 10- membered heteroaryl is optionally substituted by one to five substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy;

Q₂ is selected from the group consisting of 3- to 12-membered heterocyclic, bridged ring, spiro ring, and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, and -NR^{Qa}R^{Qb}, wherein two C₁₋₆ alkyl groups optionally together with the carbon atoms to which they are attached form C₃₋₈ carbocyclic ring; wherein R^{Qa} and R^{Qb} are

independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and (C₁₋₆ alkyl) carbonyl;

each of R₁, R₂, R₃, R₁', R₂' and R₃' is independently selected from the group consisting of hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, cycloalkyl and

- 5 heterocycloalkyl; wherein C₁₋₆ alkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C₁₋₆ alkoxy and hydroxyl;

R₂ and R₃ together with the carbon atom to which they are attached form 4- to 8-membered heterocycloalkyl;

- 10 R₁ and R₁' optionally together with the carbon atom to which they are attached form C₃-C₈ cycloalkyl, and R₂ and R₂' optionally together with the carbon atom to which they are attached form C₃-C₈ cycloalkyl; and R₃ and R₃' optionally together with the carbon atom to which they are attached form C₃-C₈ cycloalkyl;

- each of R₄, R₅ and R₆ is independently selected from the group consisting of hydrogen, 15 halogen and C₁₋₆ alkyl;

each of R₇ and R₈ is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₃₋₁₅ cycloalkyl;


- or R₇ and R₈ together with the carbon atom to which they are attached form C₃₋₁₅ 20 carbocyclic ring, wherein the C₃₋₁₅ carbocyclic ring is optionally substituted by one to three C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxyl, -NR^{7a}R^{7b}, C₁₋₆ alkoxy and 3- to 12-membered heterocyclic, and R^{7a} and R^{7b} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; and any two C₁₋₆ alkyl 25 optionally together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring;

n₁ is 0, 1, 2 or 3;

n₂ is 0, 1, 2, 3, 4 or 5;

n₃ is 0 or 1;

- 30 R₉ is selected from the group consisting of:



each of R^{9a}, R^{9b}, R^{9c}, R^{9d} and R^{9g} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₁₋₆ alkoxy;


5 R^{9e} is selected from the group consisting of hydrogen and C₁₋₆ alkyl optionally substituted by one or more halogen atoms;

R^{9f} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

R^{9h} is selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl) carbonyl, cyano and -S(=O)_{n9}-R⁹ⁱ; n₉ is 0, 1 or 2;

10 R⁹ⁱ is C₁₋₆ alkyl;

Z_1 is selected from the group consisting of:




R^{za} is selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, and each of R^{zb} and R^{zc} is independently selected from the group consisting of

15 hydrogen and C₁₋₆ alkyl;

n4 is 1, 2 or 3; each of n5 and n6 is independently an integer selected from 0 to 10;

Z₂ is selected from the group consisting of C₁₋₆ alkyl, C₃₋₁₅ cycloalkyl, 3- to 12-membered heterocyclic, C₆₋₁₀ aryl, 5- to 10- membered heteroaryl,



20 wherein Z₂ is independently optionally substituted with one to five G;

m is 1, 2, or 3;

each of R_{10} and R_{11} is independently selected from the group consisting of hydrogen, C_{1-6} alkyl, (C_{1-6} alkyl) aryl, C_{1-6} haloalkyl, C_{3-15} cycloalkyl and C_{1-6} alkyl- C_{3-15} cycloalkyl;

wherein G is selected from the group consisting of:

a. Oxo;

5 b. Halogen;

c. Cyano;

d. $-NR^{zd}R^{ze}$; wherein R^{zd} and R^{ze} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl and (C_{1-6} alkyl) carbonyl; wherein C_{1-6} alkyl is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl,

10 halogen and C_{1-6} alkoxy;

e. $-C(=O)-NR^{zf}R^{zg}$; wherein R^{zf} and R^{zg} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl and (C_{1-6} alkyl) carbonyl; wherein C_{1-6} alkyl is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, halogen and C_{1-6} alkoxy;

15 f. $-S(=O)_{n7}-R^{zh}$; wherein $n7$ is 0, 1 or 2; R^{zh} is selected from the group consisting of hydrogen and C_{1-6} alkyl;

g. C_{1-6} alkyl; wherein C_{1-6} alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, $-NR^{zi}R^{zj}$, C_{1-6} alkoxy, C_{1-6} haloalkoxy and 3- to 12-membered heterocyclic; wherein each of R^{zi} and R^{zj} is

20 independently selected from the group consisting of hydrogen and C_{1-6} alkyl, wherein the 3- to 12-membered heterocyclic groups are optionally substituted with one or more substituents selected from the group consisting of cyano, C_{1-6} alkyl and 3- to 12-membered heterocyclic;

h. C_{1-6} alkoxy; wherein C_{1-6} alkoxy is optionally substituted by one or more substituents of hydroxyl, halogen and C_{1-6} alkoxy;

25 i. 3- to 12-membered heterocyclic; wherein 3- to 12-membered heterocyclic is optionally substituted by one or more substituents independently selected from the group consisting of C_{1-6} alkyl and (C_{1-6} alkyl) carbonyl;

j. C_{6-10} aryl; wherein C_{6-10} aryl is optionally substituted by one or more (C_{1-6} alkyl) carbonyl;

30 k. 5- to 10-membered heteroaryl; wherein the 5- to 10-membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy, $-NR^{zk}R^{zl}$, and 3- to 12-membered heterocyclic; wherein R^{zk} and R^{zl} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, and (C_{1-6} alkyl)carbonyl and wherein the 3- to 12-membered heterocyclic is optionally substituted


with one or more substituents independently selected from the group consisting of C₁₋₆ alkyl, and (C₁₋₆ alkyl)carbonyl;

- l. C₃₋₁₅ cycloalkyl or C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl; wherein cycloalkyl or alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C₁₋₆ alkyl, C₁₋₆ alkoxy and (C₁₋₆ alkyl) carbonyl, wherein each of alkyl and alkoxy is optionally substituted by halogen; and

m. $-P(=O)R^{zm}R^{zn}$, $-(CH_2)_{n8}-P(=O)R^{zm}R^{zn}$, $-NR^{zm}S(=O)R^{zn}$ and $-NR^{zm}S(=O)_2R^{zn}$,

- wherein each of R^{zm} and R^{zn} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and C₆₋₁₀ aryl; n₈ is 1 or 2; wherein C₁₋₆ alkyl is substituted by one to six substituents selected from the group consisting of C₁₋₆ alkoxy, C₃₋₆ cycloalkyl and halogen, and C₃₋₆ cycloalkyl is optionally substituted by one to three substituents selected from the group consisting of C₁₋₃ alkyl and halogen; wherein the C₆₋₁₀ aryl is optionally substituted by one to three substituents selected from the group consisting of C₁₋₃ alkyl; or R^{zm} and R^{zn} together with the phosphorous atom to which they are attached form a ring with 5 to 8 ring atoms, wherein 0 to 2 of the ring atoms other than phosphorus are heteroatoms each independently selected from: O, S, and N, wherein the ring is optionally substituted with from 1-3 independently selected C₁₋₆ alkyl.

Yet still another aspect of present disclosure provides a compound of Formula (Ib), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:



Formula (Ib)

X is selected from the group consisting of N and $-CR^a$; wherein R^a is selected from the group consisting of hydrogen, halogen, and C₁₋₆ alkyl;

Y is $-C(=O)-$;

- each of Z₃, Z₄, Z₅, Z₆, Z₇, Z₈, Z₉, Z₁₀, Z₁₁, Z₁₂ and Z₁₃ is independently selected from the group consisting of N or C;

Q₁ is selected from the group consisting of C₆₋₁₀ aryl and 5- to 10-membered heteroaryl, wherein C₆₋₁₀ aryl or 5- to 10-membered heteroaryl is optionally substituted by one to five substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy;

- 5 Q₂ is selected from the group consisting of 3- to 12-membered heterocyclic, bridged ring, spiro ring, and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, and -NR^{Q_a}R^{Q_b}, wherein two C₁₋₆ alkyl groups optionally together with the carbon
- 10 atoms to which they are attached form C₃₋₈ carbocyclic ring; wherein R^{Q_a} and R^{Q_b} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and (C₁₋₆ alkyl) carbonyl;

- each of R₁, R₂, R₃, R₁', R₂' and R₃' is independently selected from the group consisting of hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, cycloalkyl and
- 15 heterocycloalkyl; wherein C₁₋₆ alkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C₁₋₆ alkoxy and hydroxyl;

wherein R₂ and R₃ together with the carbon atom to which they are attached form 4- to 8-membered heterocycloalkyl;

- 20 wherein R₁ and R₁' optionally together with the carbon atom to which they are attached form C₃₋₈ cycloalkyl, and R₂ and R₂' optionally together with the carbon atom to which they are attached form C₃₋₈ cycloalkyl; and R₃ and R₃' optionally together with the carbon atom to which they are attached form C₃₋₈ cycloalkyl;

- each of R₄, R₅ and R₆ is independently selected from the group consisting of hydrogen,
- 25 halogen and C₁₋₆ alkyl;

each of R₇ and R₈ is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₃₋₁₅ cycloalkyl;

- or R₇ and R₈ together with the carbon atom to which they are attached form C₃₋₁₅
- 30 carbocyclic ring, wherein the C₃₋₁₅ carbocyclic ring is optionally substituted by one to three C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxyl, -NR^{7_a}R^{7_b}, C₁₋₆ alkoxy and 3- to 12-membered heterocyclic, and R^{7_a} and R^{7_b} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; and any two C₁₋₆ alkyl


optionally together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring;

n₁ is 0, 1, 2 or 3;

n₂ is 0, 1, 2, 3, 4 or 5;

5 n₃ is 0 or 1;

R₉ is selected from the group consisting of:



each of R^{9a}, R^{9b}, R^{9c}, R^{9d} and R^{9g} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₁₋₆ alkoxy;



R^{9e} is selected from the group consisting of hydrogen and C₁₋₆ alkyl optionally substituted by one or more halogen atoms;

R^{9f} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

15 R^{9h} is selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl) carbonyl, cyano and -S(=O)_{n9}-R⁹ⁱ; n₉ is 0, 1 or 2;

R⁹ⁱ is C₁₋₆ alkyl;


Z₁ is selected from the group consisting of:



20 wherein R^{za} is selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, and each of R^{zb} and R^{zc} is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl;

n₄ is 1, 2 or 3; each of n₅ and n₆ is independently an integer selected from 0 to 10;

25 Z₂ is selected from the group consisting of C₁₋₆ alkyl, C₃₋₁₅ cycloalkyl, 3- to 12-membered heterocyclic, C₆₋₁₀ aryl, 5- to 10- membered heteroaryl,



wherein Z_2 is independently optionally substituted with one to five G;

m is 1, 2, or 3;

each of R_{10} and R_{11} is independently selected from the group consisting of hydrogen, C₁-

5 6 alkyl, (C₁₋₆ alkyl) aryl, C₁₋₆ haloalkyl, C₃₋₁₅ cycloalkyl and C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl;

wherein G is selected from the group consisting of:

a. Oxo;

b. Halogen;

c. Cyano;

10 d. $-NR^{zd}R^{ze}$; wherein R^{zd} and R^{ze} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, halogen and C₁₋₆ alkoxy;

e. $-C(=O)-NR^{zf}R^{zg}$; wherein R^{zf} and R^{zg} are independently selected from the group
15 consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, halogen and C₁₋₆ alkoxy;

f. $-S(=O)_{n7}-R^{zh}$; wherein $n7$ is 0, 1 or 2; R^{zh} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

20 g. C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, $-NR^{zi}R^{zj}$, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy and 3- to 12-membered heterocyclic; wherein each of R^{zi} and R^{zj} is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein the 3- to 12-membered heterocyclic groups are optionally substituted with one or more substituents
25 selected from the group consisting of cyano, C₁₋₆ alkyl and 3- to 12-membered heterocyclic;

h. C₁₋₆ alkoxy; wherein C₁₋₆ alkoxy is optionally substituted by one or more substituents of hydroxyl, halogen and C₁₋₆ alkoxy;

i. 3- to 12-membered heterocyclic; wherein 3- to 12-membered heterocyclic is optionally substituted by one or more substituents independently selected from the group consisting of
30 C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl;

j. C₆₋₁₀ aryl; wherein C₆₋₁₀ aryl is optionally substituted by one or more (C₁₋₆ alkyl)


carbonyl;

- k. 5- to 10-membered heteroaryl; wherein the 5- to 10-membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy, -NR^{zk}R^{zl}, and 3- to 12-membered heterocyclic; wherein
- 5 R^{zk} and R^{zl} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, and (C₁₋₆ alkyl)carbonyl and wherein the 3- to 12-membered heterocyclic is optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₆ alkyl, and (C₁₋₆ alkyl)carbonyl;

- l. C₃₋₁₅ cycloalkyl or C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl; wherein cycloalkyl or alkyl is
- 10 optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C₁₋₆ alkyl, C₁₋₆ alkoxy and (C₁₋₆ alkyl) carbonyl, wherein each of alkyl and alkoxy is optionally substituted by halogen; and

- m. -P(=O)R^{zm}R^{zn}, -(CH₂)_{n8}-P(=O)R^{zm}R^{zn}, -NR^{zm}S(=O)R^{zn} and -NR^{zm}S(=O)₂R^{zn}, wherein each R^{zm} and R^{zn} is independently selected from the group consisting of hydrogen,
- 15 C₁₋₆ alkyl and C₆₋₁₀ aryl; n₈ is 1 or 2; wherein C₁₋₆ alkyl is substituted by one to six substituents selected from the group consisting of C₁₋₆ alkoxy, C₃₋₆ cycloalkyl and halogen, and C₃₋₆ cycloalkyl is optionally substituted by one to three substituents selected from the group consisting of C₁₋₃ alkyl and halogen; wherein the C₆₋₁₀ aryl is optionally substituted by one to three substituents selected from the group consisting of C₁₋₃ alkyl; or R^{zm} and R^{zn}
- 20 together with the phosphorous atom to which they are attached form a ring with 5 to 8 ring atoms, wherein 0 to 2 of the ring atoms other than phosphorus are heteroatoms each independently selected from: O, S, and N, wherein the ring is optionally substituted with from 1-3 independently selected C₁₋₆ alkyl.

- Yet still another aspect of the present disclosure provides a compound of Formula (Ic), a
- 25 stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:



Formula (Ic)

wherein,

X is selected from the group consisting of N and $-CR^a$; wherein R^a is selected from the group consisting of hydrogen, halogen, and C_{1-6} alkyl;

5 Y is $-C(=O)-$;

each of $Z_3, Z_4, Z_5, Z_6, Z_7, Z_8, Z_9, Z_{10}, Z_{11}, Z_{12}$ and Z_{13} is independently selected from the group consisting of N or C;

Q_1 is selected from the group consisting of C_{6-10} aryl and 5- to 10-membered heteroaryl, wherein C_{6-10} aryl or 5- to 10-membered heteroaryl is optionally substituted by one to five
10 substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl and C_{1-6} alkoxy;

Q_2 is selected from the group consisting of 3- to 12-membered heterocyclic, bridged ring, spiro ring, and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents
15 independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, and $-NR^{Qa}R^{Qb}$, wherein two C_{1-6} alkyl groups optionally together with the carbon atoms to which they are attached form C_{3-8} carbocyclic ring; wherein R^{Qa} and R^{Qb} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl and (C_{1-6} alkyl) carbonyl;

20 each of $R_1, R_2, R_3, R_1', R_2'$ and R_3' is independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cycloalkyl and heterocycloalkyl; wherein C_{1-6} alkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C_{1-6} alkoxy and hydroxyl;

25 wherein R_2 and R_3 together with the carbon atom to which they are attached form 4- to 8-membered heterocycloalkyl;

wherein R_1 and R_1' optionally together with the carbon atom to which they are attached form C_{3-8} cycloalkyl, and R_2 and R_2' optionally together with the carbon atom to which they are attached form C_{3-8} cycloalkyl; and R_3 and R_3' optionally together with the carbon atom
30 to which they are attached form C_{3-8} cycloalkyl;

each of R_4, R_5 and R_6 is independently selected from the group consisting of hydrogen, halogen and C_{1-6} alkyl;

each of R_7 and R_8 is independently selected from the group consisting of hydrogen and C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more substituents

independently selected from the group consisting of halogen and C₃₋₁₅ cycloalkyl;

or R₇ and R₈ together with the carbon atom to which they are attached form C₃₋₁₅

carbocyclic ring, wherein the C₃₋₁₅ carbocyclic ring is optionally substituted by one to three C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted by one or more substituents


5 independently selected from the group consisting of halogen, hydroxyl, -NR^{7a}R^{7b}, C₁₋₆ alkoxy and 3- to 12-membered heterocyclic, and R^{7a} and R^{7b} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; and any two C₁₋₆ alkyl optionally together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring;

10 n_1 is 0, 1, 2 or 3;

n2 is 0, 1, 2, 3, 4 or 5;

n3 is 0 or 1:

R₉ is selected from the group consisting of:



15 each of R^{9a}, R^{9b}, R^{9c}, R^{9d} and R^{9g} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₁₋₆ alkoxy;

R^{9e} is selected from the group consisting of hydrogen and C₁₋₆ alkyl optionally


20 substituted by one or more halogen atoms;

R^{9f} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

R^{9h} is selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl) carbonyl, cyano and -S(=O)_{n9}-R⁹ⁱ; n₉ is 0, 1 or 2;

R⁹ⁱ is C₁₋₆ alkyl;

25 Z_1 is selected from the group consisting of:




wherein R^{za} is selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, and each of R^{zb} and R^{zc} is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl;

n_4 is 1, 2 or 3;

5 each of n_5 and n_6 is independently an integer selected from 0 to 10;

Z_2 is selected from the group consisting of C₁₋₆ alkyl, C₃₋₁₅ cycloalkyl, 3- to 12-membered heterocyclic, C₆₋₁₀ aryl, 5- to 10- membered heteroaryl,



10 wherein Z_2 is independently optionally substituted with one to five G;

m is 1, 2, or 3;

each of R_{10} and R_{11} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl) aryl, C₁₋₆ haloalkyl, C₃₋₁₅ cycloalkyl and C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl;

wherein G is selected from the group consisting of:

15 a. Oxo;

b. Halogen;

c. Cyano;

d. $-NR^{zd}R^{ze}$; wherein R^{zd} and R^{ze} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, halogen and C₁₋₆ alkoxy;

e. $-C(=O)-NR^{zf}R^{zg}$; wherein R^{zf} and R^{zg} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, halogen and C₁₋₆ alkoxy;

f. $-S(=O)_{n7}-R^{zh}$; wherein n_7 is 0, 1 or 2; R^{zh} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

g. C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, $-NR^{zi}R^{zj}$, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy and 3- to 12-membered heterocyclic; wherein each of R^{zi} and R^{zj} is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein the 3-

to 12-membered heterocyclic groups are optionally substituted with one or more substituents selected from the group consisting of cyano, C₁₋₆ alkyl and 3- to 12-membered heterocyclic;

h. C₁₋₆ alkoxy; wherein C₁₋₆ alkoxy is optionally substituted by one or more substituents of hydroxyl, halogen and C₁₋₆ alkoxy;

5 i. 3- to 12-membered heterocyclic; wherein 3- to 12-membered heterocyclic is optionally substituted by one or more substituents independently selected from the group consisting of C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl;


j. C₆₋₁₀ aryl; wherein C₆₋₁₀ aryl is optionally substituted by one or more (C₁₋₆ alkyl) carbonyl;

10 k. 5- to 10-membered heteroaryl; wherein the 5- to 10-membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy, -NR^{zk}R^{zl}, and 3- to 12-membered heterocyclic; wherein R^{zk} and R^{zl} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, and (C₁₋₆ alkyl)carbonyl and wherein the 3- to 12-membered heterocyclic is optionally substituted
15 with one or more substituents independently selected from the group consisting of C₁₋₆ alkyl, and (C₁₋₆ alkyl)carbonyl;

l. C₃₋₁₅ cycloalkyl or C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl; wherein cycloalkyl or alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C₁₋₆ alkyl, C₁₋₆ alkoxy and (C₁₋₆ alkyl) carbonyl, wherein each of
20 alkyl and alkoxy is optionally substituted by halogen; and

m. -P(=O)R^{zm}R^{zn}, -(CH₂)_{n8}-P(=O)R^{zm}R^{zn}, -NR^{zm}S(=O)R^{zn} and -NR^{zm}S(=O)₂R^{zn},
wherein each of R^{zm} and R^{zn} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and C₆₋₁₀ aryl; n₈ is 1 or 2; wherein C₁₋₆ alkyl is substituted by one to six
25 substituents selected from the group consisting of C₁₋₆ alkoxy, C₃₋₆ cycloalkyl and halogen, and C₃₋₆ cycloalkyl is optionally substituted by one to three substituents selected from the group consisting of C₁₋₃ alkyl and halogen; wherein the C₆₋₁₀ aryl is optionally substituted by one to three substituents selected from the group consisting of C₁₋₃ alkyl; or R^{zm} and R^{zn} together with the phosphorous atom to which they are attached form a ring with 5 to 8 ring
30 atoms, wherein 0 to 2 of the ring atoms other than phosphorus are heteroatoms each independently selected from: O, S, and N, wherein the ring is optionally substituted with from 1-3 independently selected C₁₋₆ alkyl.

Yet still another aspect of the present disclosure provides a compound of Formula (Id), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:



Formula (Id)

wherein X is selected from the group consisting of N and $-CR^a$; wherein R^a is selected from the group consisting of hydrogen, halogen, and C_{1-6} alkyl;

5 wherein Y is $-C(=O)-$;

wherein each of $Z_3, Z_4, Z_5, Z_6, Z_7, Z_8, Z_9, Z_{10}, Z_{11}, Z_{12}$ and Z_{13} is independently selected from the group consisting of N and C;

wherein Q_1 is selected from the group consisting of C_{6-10} aryl and 5- to 10-membered heteroaryl, wherein C_{6-10} aryl or 5- to 10-membered heteroaryl is optionally substituted by
10 one to five substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl and C_{1-6} alkoxy;

wherein Q_2 is selected from the group consisting of 3- to 12-membered heterocyclic, bridged ring, spiro ring, and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents
15 independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, and $-NR^{Qa}R^{Qb}$, wherein two C_{1-6} alkyl groups optionally together with the carbon atoms to which they are attached form C_{3-8} carbocyclic ring; wherein R^{Qa} and R^{Qb} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl and (C_{1-6} alkyl) carbonyl;

20 wherein each of $R_1, R_2, R_3, R_1', R_2'$ and R_3' is independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cycloalkyl and heterocycloalkyl; wherein C_{1-6} alkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C_{1-6} alkoxy and hydroxyl;

25 wherein R_2 and R_3 together with the carbon atom to which they are attached form 4- to 8-membered heterocycloalkyl;

wherein R₁ and R₁' optionally together with the carbon atom to which they are attached form C₃-C₈ cycloalkyl, and R₂ and R₂' optionally together with the carbon atom to which they are attached form C₃-C₈ cycloalkyl; and R₃ and R₃' optionally together with the carbon atom to which they are attached form C₃-C₈ cycloalkyl;

5 each of R₄, R₅ and R₆ is independently selected from the group consisting of hydrogen, halogen and C₁₋₆ alkyl;

each of R₇ and R₈ is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₃₋₁₅ cycloalkyl;


10 or R₇ and R₈ together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring, wherein the C₃₋₁₅ carbocyclic ring is optionally substituted by one to three C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxyl, -NR^{7a}R^{7b}, C₁₋₆ alkoxy and 3- to 12-membered heterocyclic, and R^{7a} and R^{7b} are independently selected from the
15 group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; and any two C₁₋₆ alkyl optionally together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring;

n₁ is 0, 1, 2 or 3;

n₂ is 0, 1, 2, 3, 4 or 5;

20 n₃ is 0 or 1;

R₉ is selected from the group consisting of:



, -CO₂R^{9f} and -C(=O)-NR^{9g}R^{9h}; and

each of R^{9a}, R^{9b}, R^{9c}, R^{9d} and R^{9g} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, wherein C₁₋₆ alkyl is optionally substituted
25 with one or more substituents independently selected from the group consisting of halogen and C₁₋₆ alkoxy;


R^{9e} is selected from the group consisting of hydrogen and C₁₋₆ alkyl optionally substituted by one or more halogen atoms;

R^{9f} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

30 R^{9h} is selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl) carbonyl, cyano and -S(=O)_{n9}-R⁹ⁱ; n₉ is 0, 1 or 2;

R^{9i} is C₁₋₆ alkyl;

Z_1 is selected from the group consisting of:



- 5 wherein R^{za} is selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, and each of R^{zb} and R^{zc} is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl;

n_4 is 1, 2 or 3;

each of n_5 and n_6 is independently an integer selected from 0 to 10;

- 10 Z_2 is selected from the group consisting of C₁₋₆ alkyl, C₃₋₁₅ cycloalkyl, 3- to 12-membered heterocyclic, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl,



wherein Z_2 is independently optionally substituted with one to five G;

m is 1, 2, or 3;

- 15 R_{10} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl) aryl, C₁₋₆ haloalkyl, C₃₋₁₅ cycloalkyl and C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl;

wherein G is selected from the group consisting of:

a. Oxo;

b. Halogen;

- 20 c. Cyano;

d. $-NR^{zd}R^{ze}$; wherein R^{zd} and R^{ze} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, halogen and C₁₋₆ alkoxy;


- 25 e. $-C(=O)-NR^{zf}R^{zg}$; wherein R^{zf} and R^{zg} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, halogen and C₁₋₆ alkoxy;

- 30 f. $-S(=O)_{n7}-R^{zh}$; wherein n_7 is 0, 1 or 2; R^{zh} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

- g. C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, -NR^{zi}R^{zj}, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy and 3- to 12-membered heterocyclic; wherein each of R^{zi} and R^{zj} is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein the 3- to 12-membered heterocyclic groups are optionally substituted with one or more substituents selected from the group consisting of cyano, C₁₋₆ alkyl and 3- to 12-membered heterocyclic;
- h. C₁₋₆ alkoxy; wherein C₁₋₆ alkoxy is optionally substituted by one or more substituents of hydroxyl, halogen and C₁₋₆ alkoxy;
- i. 3- to 12-membered heterocyclic; wherein 3- to 12-membered heterocyclic is optionally substituted by one or more substituents independently selected from the group consisting of C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl;
- j. C₆₋₁₀ aryl; wherein C₆₋₁₀ aryl is optionally substituted by one or more (C₁₋₆ alkyl) carbonyl;
- k. 5- to 10-membered heteroaryl; wherein the 5- to 10-membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy, -NR^{zk}R^{zl}, and 3- to 12-membered heterocyclic; wherein R^{zk} and R^{zl} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, and (C₁₋₆ alkyl)carbonyl and wherein the 3- to 12-membered heterocyclic is optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₆ alkyl, and (C₁₋₆ alkyl)carbonyl;
- l. C₃₋₁₅ cycloalkyl or C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl; wherein cycloalkyl or alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C₁₋₆ alkyl, C₁₋₆ alkoxy and (C₁₋₆ alkyl) carbonyl, wherein each of alkyl and alkoxy is optionally substituted by halogen; and
- m. -P(=O)R^{zm}R^{zn}, -(CH₂)_{n8}-P(=O)R^{zm}R^{zn}, -NR^{zm}S(=O)R^{zn} and -NR^{zm}S(=O)₂R^{zn}, wherein each of R^{zm} and R^{zn} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and C₆₋₁₀ aryl; n₈ is 1 or 2; wherein C₁₋₆ alkyl is substituted by one to six substituents selected from the group consisting of C₁₋₆ alkoxy, C₃₋₆ cycloalkyl and halogen, and C₃₋₆ cycloalkyl is optionally substituted by one to three substituents selected from the group consisting of C₁₋₃ alkyl and halogen; wherein the C₆₋₁₀ aryl is optionally substituted by one to three substituents selected from the group consisting of C₁₋₃ alkyl; or R^{zm} and R^{zn} together with the phosphorous atom to which they are attached form a ring with 5 to 8 ring atoms, wherein 0 to 2 of the ring atoms other than phosphorus are heteroatoms each independently selected from: O, S, and N, wherein the ring is optionally substituted with

from 1-3 independently selected C₁₋₆ alkyl.

Yet still another aspect of the present disclosure provides a compound of Formula (Ie), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:



Formula (Ie)

wherein X is selected from the group consisting of N and -CR^a; wherein R^a is selected from the group consisting of hydrogen, halogen, and C₁₋₆ alkyl;

wherein Y is -C(=O)-;

wherein each of Z₃, Z₄, Z₅, Z₆, Z₇, Z₈, Z₉, Z₁₀, Z₁₁, Z₁₂ and Z₁₃ is independently selected from the group consisting of N and C;

wherein Q₁ is selected from the group consisting of C₆₋₁₀ aryl and 5- to 10-membered heteroaryl, wherein C₆₋₁₀ aryl or 5- to 10- membered heteroaryl is optionally substituted by one to five substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy;

wherein Q₂ is selected from the group consisting of 3- to 12-membered heterocyclic, bridged ring, spiro ring, and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, and -NR^{Qa}R^{Qb}, wherein two C₁₋₆ alkyl groups optionally together with the carbon atoms to which they are attached form C₃₋₈ carbocyclic ring; wherein R^{Qa} and R^{Qb} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and (C₁₋₆ alkyl) carbonyl;

wherein each of R₁, R₂, R₃, R₁', R₂' and R₃' is independently selected from the group consisting of hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, cycloalkyl and heterocycloalkyl; wherein C₁₋₆ alkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C₁₋₆

alkoxy and hydroxyl;

wherein R₂ and R₃ together with the carbon atom to which they are attached form 4- to 8-membered heterocycloalkyl;

wherein R₁ and R₁' optionally together with the carbon atom to which they are attached form C₃-C₈ cycloalkyl, and R₂ and R₂' optionally together with the carbon atom to which they are attached form C₃-C₈ cycloalkyl; and R₃ and R₃' optionally together with the carbon atom to which they are attached form C₃-C₈ cycloalkyl;

each of R₄, R₅ and R₆ is independently selected from the group consisting of hydrogen, halogen and C₁₋₆ alkyl;

each of R₇ and R₈ is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₃₋₁₅ cycloalkyl;


or R₇ and R₈ together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring, wherein the C₃₋₁₅ carbocyclic ring is optionally substituted by one to three C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxyl, -NR^{7a}R^{7b}, C₁₋₆ alkoxy and 3- to 12-membered heterocyclic, and R^{7a} and R^{7b} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; and any two C₁₋₆ alkyl optionally together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring;

n₁ is 0, 1, 2 or 3;

n₂ is 0, 1, 2, 3, 4 or 5;

n₃ is 0 or 1;

R₉ is selected from the group consisting of:



each of R^{9a}, R^{9b}, R^{9c}, R^{9d} and R^{9g} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₁₋₆ alkoxy;


R^{9e} is selected from the group consisting of hydrogen and C₁₋₆ alkyl optionally substituted by one or more halogen atoms;

R^{9f} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

R^{9h} is selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl) carbonyl, cyano and $-S(=O)_{n9}-R^{9i}$; $n9$ is 0, 1 or 2;

R^{9i} is C₁₋₆ alkyl;

5 Z_1 is selected from the group consisting of:



,

wherein R^{za} is selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, and each of R^{zb} and R^{zc} is independently selected from the group consisting of

10 hydrogen and C₁₋₆ alkyl;

$n4$ is 1, 2 or 3;

each of $n5$ and $n6$ is independently an integer selected from 0 to 10;

Z_2 is selected from the group consisting of C₁₋₆ alkyl, C₃₋₁₅ cycloalkyl, 3- to 12-membered heterocyclic, C₆₋₁₀ aryl, and 5- to 10- membered heteroaryl;

15 wherein C₃₋₁₅ cycloalkyl and 3- to 12-membered heterocyclic is independently optionally substituted with one to five G;

wherein G is selected from the group consisting of:

a. Oxo;

b. Halogen;

20 c. Cyano;

d. $-NR^{zd}R^{ze}$; wherein R^{zd} and R^{ze} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, halogen and C₁₋₆ alkoxy;

25 e. $-C(=O)-NR^{zf}R^{zg}$; wherein R^{zf} and R^{zg} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, halogen and C₁₋₆ alkoxy;

30 f. $-S(=O)_{n7}-R^{zh}$; wherein $n7$ is 0, 1 or 2; R^{zh} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

g. C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, $-NR^{zi}R^{zj}$, C₁₋₆ alkoxy,

C₁₋₆ haloalkoxy and 3- to 12-membered heterocyclic; wherein each of R^{zi} and R^{zj} is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein the 3- to 12-membered heterocyclic groups are optionally substituted with one or more substituents selected from the group consisting of cyano, C₁₋₆ alkyl and 3- to 12-membered heterocyclic;

5 h. C₁₋₆ alkoxy; wherein C₁₋₆ alkoxy is optionally substituted by one or more substituents of hydroxyl, halogen and C₁₋₆ alkoxy;


i. 3- to 12-membered heterocyclic; wherein 3- to 12-membered heterocyclic is optionally substituted by one or more substituents independently selected from the group consisting of C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl;

10 j. C₆₋₁₀ aryl; wherein C₆₋₁₀ aryl is optionally substituted by one or more (C₁₋₆ alkyl) carbonyl;

k. 5- to 10-membered heteroaryl; wherein the 5- to 10-membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy, -NR^{zk}R^{zl}, and 3- to 12-membered heterocyclic; wherein
15 R^{zk} and R^{zl} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, and (C₁₋₆ alkyl)carbonyl and wherein the 3- to 12-membered heterocyclic is optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₆ alkyl, and (C₁₋₆ alkyl)carbonyl; and

l. C₃₋₁₅ cycloalkyl or C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl; wherein cycloalkyl or alkyl is
20 optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C₁₋₆ alkyl, C₁₋₆ alkoxy and (C₁₋₆ alkyl) carbonyl, wherein each of alkyl and alkoxy is optionally substituted by halogen.

In some embodiments, in the compound of any one of Formula (Ia), (Ib), (Ic), (Id) or (Ie), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound
25 thereof, the compound has a Formula (If):



Formula (If)

wherein:

wherein X is selected from the group consisting of N and $-CR^a$; wherein R^a is selected from the group consisting of hydrogen, halogen and C_{1-6} alkyl;

wherein each of Z_4 , Z_6 , Z_7 , Z_8 , Z_9 , Z_{10} and Z_{11} is independently selected from the group consisting of N and C;

wherein Q_1 is selected from the group consisting of C_{6-10} aryl and 5- to 10-membered heteroaryl, wherein C_{6-10} aryl or 5- to 10-membered heteroaryl is optionally substituted by one to five substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl and C_{1-6} alkoxy;


wherein Q_2 is selected from the group consisting of 3- to 12-membered heterocyclic, bridged ring, spiro ring and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, and $-NR^{Qa}R^{Qb}$, wherein two C_{1-6} alkyl groups together with the carbon atoms to which they are attached form C_{3-8} carbocyclic ring; wherein R^{Qa} and R^{Qb} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl and (C_{1-6} alkyl) carbonyl;

wherein R_3 is independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cycloalkyl and heterocycloalkyl; wherein C_{1-6} alkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C_{1-6} alkoxy and hydroxyl;

each of R_5 and R_6 is independently selected from the group consisting of hydrogen, halogen and C_{1-6} alkyl;

R_m is C_{1-6} alkyl; wherein C_{1-6} alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, $-NR^{7a}R^{7b}$, C_{1-6} alkoxy and 3- to 12-membered heterocyclic, wherein R^{7a} and R^{7b} is independently selected from the group consisting of hydrogen, C_{1-6} alkyl and (C_{1-6} alkyl) carbonyl; and any two C_{1-6} alkyl optionally together with the carbon atom to which they are attached form C_{3-15} carbocyclic ring;

R_9 is selected from the group consisting of:



each of R^{9a} , R^{9b} , R^{9c} , R^{9d} and R^{9g} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₁₋₆ alkoxy;


- 5 R^{9e} is selected from the group consisting of hydrogen and C₁₋₆ alkyl optionally substituted by one or more halogen atoms;

R^{9f} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;


R^{9h} is selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl) carbonyl, cyano and $-S(=O)_{n9}-R^{9i}$; $n9$ is 0, 1 or 2;

- 10 R^{9i} is C₁₋₆ alkyl;

Z_1 is selected from the group consisting of:



Z_2 is selected from the group consisting of C₁₋₆ alkyl, C₃₋₁₅ cycloalkyl, 3- to 12-membered heterocyclic, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl,



- 15

wherein Z_2 is independently optionally substituted with one to five G;

m is 1, 2 or 3;

each of R_{10} and R_{11} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl)-aryl, C₁₋₆ haloalkyl, C₃₋₁₅ cycloalkyl and C₁₋₆ alkyl-C₃₋₁₅ cycloalkyl;

- 20 X_a is CH₂ or O;

wherein G is selected from the group consisting of:

a. Oxo;

b. Halogen;

c. Cyano;

- 25 d. $-NR^{zd}R^{ze}$; wherein R^{zd} and R^{ze} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; wherein C₁₋₆ alkyl is optionally substituted by

one or more substituents independently selected from the group consisting of hydroxyl, halogen and C₁₋₆ alkoxy;

e. -C(=O)-NR^{zf}R^{zg}; wherein R^{zf} and R^{zg} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, halogen and C₁₋₆ alkoxy;

f. -S(=O)_{n7}-R^{zh}; wherein n₇ is 0, 1 or 2; R^{zh} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

g. C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, -NR^{zi}R^{zj}, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy and 3- to 12-membered heterocyclic group; wherein each of R^{zi} and R^{zj} is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein the 3- to 12-membered heterocyclic groups are optionally substituted with one or more substituents selected from the group consisting of cyano, C₁₋₆ alkyl and 3- to 12-membered heterocyclic;

h. C₁₋₆ alkoxy; wherein C₁₋₆ alkoxy is optionally substituted by one or more substituents of hydroxyl, halogen and C₁₋₆ alkoxy;

i. 3- to 12-membered heterocyclic; wherein 3- to 12-membered heterocyclic is optionally substituted by one or more substituents independently selected from the group consisting of C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl;

j. C₆₋₁₀ aryl; wherein C₆₋₁₀ aryl is optionally substituted by one or more (C₁₋₆ alkyl) carbonyl;


k. 5- to 10-membered heteroaryl; wherein the 5- to 10-membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy, -NR^{zk}R^{zl}, and 3- to 12-membered heterocyclic; wherein R^{zk} and R^{zl} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, and (C₁₋₆ alkyl)carbonyl and wherein the 3- to 12-membered heterocyclic is optionally substituted with one or more substituents independently selected from the group consisting of C₁₋₆ alkyl, and (C₁₋₆ alkyl)carbonyl;

l. C₃-C₁₅ cycloalkyl or C₁-C₆ alkyl-C₃-C₁₅ cycloalkyl; wherein cycloalkyl or alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C₁₋₆ alkyl, C₁₋₆ alkoxy and (C₁₋₆ alkyl) carbonyl, wherein each of alkyl and alkoxy is optionally substituted by halogen; and

m. -P(=O)R^{zm}R^{zn}, -(CH₂)_{n8}-P(=O)R^{zm}R^{zn}, -NR^{zm}S(=O)R^{zn} and -NR^{zm}S(=O)₂R^{zn}, wherein each R^{zm} and R^{zn} is independently selected from the group consisting of hydrogen,

C₁₋₆ alkyl and C₆₋₁₀ aryl; n₈ is 1 or 2; wherein C₁₋₆ alkyl is substituted by one to six substituents selected from the group consisting of C₁₋₆ alkoxy, C₃₋₆ cycloalkyl and halogen, and C₃₋₆ cycloalkyl is optionally substituted by one to three substituents selected from the group consisting of C₁₋₃ alkyl and halogen; wherein the C₆₋₁₀ aryl is optionally substituted by one to three substituents selected from the group consisting of C₁₋₃ alkyl; Or R^{zm} and R^{zn} optionally together with the phosphorous atom to which they are attached form a ring with 5 to 8 ring atoms, wherein 0 to 2 of the ring atoms other than phosphorus are heteroatoms each independently selected from: O, S, and N, wherein the ring is optionally substituted with from 1-3 independently selected C₁₋₆ alkyl.

10 In some embodiments, in the compound of any one of Formula (Ia), (Ib), (Ic), (Id) or (Ie), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, the compound has a Formula (Ig),




Formula (Ig)

15 wherein each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;


R₃ is independently selected from the group consisting of hydrogen, halogen, C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogens;

R_m is C₁₋₆ alkyl; wherein C₁₋₆ alkyl is optionally substituted with one or more halogens;


20 Z₁ is selected from the group consisting of:



Z₂ is selected from the group consisting of C₆₋₁₀ aryl, 5- to 10-membered heteroaryl,



In some embodiments, in the compound of any one of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), or (Ig), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, Z₂ is selected from



5

and Z₂ is substituted by one to five substituents selected from the group consisting of halogen, C₁₋₆ alkyl and C₁₋₆ alkoxy.


In some embodiments, in the compound of any one of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), or (Ig), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, Q₁ is C₆₋₁₀ aryl.

In some embodiments, in the compound of any one of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), or (Ig), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, Q₁ is C₆₋₁₀ aryl, and the C₆₋₁₀ aryl is optionally substituted with one to five substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy.





In some embodiments, in the compound of any one of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), or (Ig), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, R₃ is selected from the group consisting of H, halogen, and C₁₋₆ alkyl.









In some embodiments, in the compound of any one of Formula (If) or Formula (Ig), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof, R_m is C₁₋₆ alkyl, and the C₁₋₆ alkyl is optionally substituted with one or more halogens.









In some embodiments, in the compound of any one of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), or (Ig), the stereoisomer, the pharmaceutically acceptable salt, or the deuterated






compound thereof, R_9 is , R^{9a} is selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl.

- 5 In some embodiments, in the compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of the present disclosure, the compound is selected from the group consisting of:







































In some embodiments, the pharmaceutically acceptable salt of the present disclosure is selected from a sodium salt, a calcium salt, a potassium salt, a magnesium salt and a lithium salt.











In some embodiments, the compound of the present disclosure is selected from the group consisting of







































and








Yet still another aspect of the present disclosure provides a compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

5










Yet still another aspect of the present disclosure provides a compound, selected from the

group consisting of:










and




In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is selected from the group consisting of:






In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is selected from the group consisting of:




In some embodiments, in the compound or the pharmaceutically acceptable salt thereof of the present disclosure, the compound is selected from the group consisting of:



In some embodiments, in the compound or the pharmaceutically acceptable salt thereof of the present disclosure, the compound is selected from the group consisting of:




In some embodiments, the compound of the present disclosure is




In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is


5




In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is




In some embodiments, the compound of the present disclosure is




In some embodiments, the compound of the present disclosure is




5 In some embodiments, the compound of the present disclosure is



In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is




In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is




5


In some embodiments, the compound of the present disclosure is




In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is




In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is




5 In some embodiments, the compound of the present disclosure is




In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is




In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is




5 In some embodiments, the compound of the present disclosure is



In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is



In some embodiments, the pharmaceutically acceptable salt of the compound of the present disclosure is



Pharmaceutical composition

Another aspect of the present disclosure provides a pharmaceutical composition that comprise the compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of the present disclosure, and a pharmaceutically acceptable
5 excipient.

In some embodiments, the pharmaceutical composition comprising the compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of the present disclosure may be prepared with one or more pharmaceutically acceptable excipients, the excipients may be selected in accordance with conventional practice. Tablets may contain
10 excipients, including flow aids, fillers, binders, and the like. Aqueous compositions may be prepared in a sterile form and may generally be isotonic when intended to be delivered by means other than oral administration.

In some embodiments, the compositions may comprise excipients, such as those set forth in Rowe et al, Handbook of Pharmaceutical Excipients, 6th edition, American
15 Pharmacists Association, 2009. Excipients may include ascorbic acid and other antioxidants, chelating agents such as ethylenediaminetetraacetic acid, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid, and the like. In some embodiments, the compositions are provided in solid dosage forms, including solid oral dosage forms.

The pharmaceutical composition may be prepared by any of the methods well known in the art of pharmacy, including oral administration. Such methods include the step of bringing
20 into association the active ingredient (*e.g.*, a compound of the present disclosure or a pharmaceutical salt thereof) with one or more pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical compositions are prepared by uniformly and
25 intimately bringing into association the active ingredient with liquid excipients or finely divided solid excipients or both, and then, if desired, shaping the product. Techniques and formulations generally are found in Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams and Wilkins, Philadelphia, Pa., 2006.

In some embodiments, the pharmaceutical compositions of the present disclosure are
30 presented in unit dosage form, including but not limited to capsules, sachets, or tablets, each containing a predetermined amount of the active ingredient. In one embodiment, the pharmaceutical composition is a tablet.

The pharmaceutical composition disclosed herein comprises one or more of the compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated

compound thereof of the present disclosure, as well as pharmaceutically acceptable excipients and, optionally, other therapeutic agents. The pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration.

When intended for oral use, for example, tablets, lozenges, ingots, aqueous or oil

5 suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups, or elixirs may be prepared. Compositions for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more excipients, including sweeteners, flavoring agents, coloring agents, and preservatives, to provide palatable formulations. Tablets containing the active ingredient
10 with a non-toxic pharmaceutically acceptable excipient are acceptable and said excipient is suitable for the production of tablets. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch,
15 gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

20 The amount of active ingredients that may be combined with the inactive ingredients to produce a dosage form may vary depending upon the intended treatment subject and the mode of administration. For example, in some embodiments, a dosage form for oral administration to humans may contain approximately 1 to 1000 mg of active material formulated with an appropriate and convenient amount of a pharmaceutically acceptable
25 excipient. In some embodiments, the pharmaceutically acceptable excipient varies from about 5% to about 95% of the total compositions (weight: weight).

In some embodiments, the pharmaceutical composition of the present disclosure does not contain an agent that affects the rate at which the active ingredient is metabolized. Thus, it is understood that pharmaceutical compositions comprising a compound of the present
30 disclosure in one aspect do not comprise an agent that would affect (e.g., slow, hinder or retard) the metabolism of a compound of the present disclosure or any other active ingredient administered separately, sequentially or simultaneously with a compound of the present disclosure. It is also understood that any of the methods, kits, articles of manufacture, and the like detailed herein in one aspect do not comprise an agent that would affect (e.g., slow,

hinder or retard) the metabolism of a compound of the present disclosure or any other active ingredient administered separately, sequentially or simultaneously with a compound of the present disclosure.

In some embodiments, the above-described pharmaceutical compositions are for use in humans or animals.

The present disclosure also includes compounds of the present disclosure which are administered as a single active ingredient of a pharmaceutically acceptable composition that may be prepared by conventional methods known in the art, for example, by combining the active ingredient to a pharmaceutically acceptable, therapeutically inert organic and/or inorganic carrier or excipient, or by mixing therewith.

The present disclosure provided herein are uses of the compounds of the present disclosure as a second or other active ingredient, said second or other active ingredient being synergistic with other active ingredients in known drugs, or the compounds of the present disclosure being administered with such drugs.

The compounds of the present disclosure may also be used in the form of a prodrug or other suitably modified form that releases the active ingredient in vivo.

Method of treatment

Another aspect of the present disclosure provides a method for treating a GLP-1R-mediated disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of the compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of the present disclosure, or a pharmaceutical composition of the present disclosure.

In some embodiments, the GLP-1R-mediated disease or condition is selected from the group consisting of T1D (type 1 diabetes), T2DM (type 2 diabetes mellitus), pre-diabetes, idiopathic T1D (idiopathic type 1 diabetes), LADA (latent autoimmune diabetes in adults), EOD (early onset diabetes), YOAD (young onset adult diabetes), MODY (maturity onset diabetes of the young), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, overweight, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD (non-alcoholic fatty liver disease), NASH, fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction,

stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, parkinson's disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, alzheimer's disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, crohn's disease, colitis, irritable bowel syndrome, polycystic ovary syndrome and substance addiction.

In some embodiments, the GLP-1R-mediated disease or condition is selected from the group consisting of weight management, chronic weight management, chronic kidney disease, atherosclerotic cardiovascular disease, heart failure; heart failure with reduced ejection fraction; heart failure with preserved ejection fraction; diabetes prevention, obstructive sleep apnea.

The compound of the present disclosure (also referred to herein as the active ingredients) or the pharmaceutical composition of the present disclosure can be administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intratumoral, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with for example the condition of the recipient. An advantage of certain compound disclosed herein is that they are orally bioavailable and can be dosed orally.

A compound of the present disclosure may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer. In one variation, the compound is administered on a daily or intermittent schedule for the duration of the individual's life.

The dosage or dosing frequency of a compound of the present disclosure may be adjusted over the course of the treatment, based on the judgment of the administering physician.

The compound may be administered to an individual (e.g., a human) in an effective amount. In some embodiments, the compound is administered once daily.

The compound can be administered by any useful route and means, such as by oral or

parenteral (e.g., intravenous) administration. Therapeutically effective amounts of the compound may include from about 0.00001 mg/kg body weight per day to about 10 mg/kg body weight per day, such as from about 0.0001 mg/kg body weight per day to about 10 mg/kg body weight per day, or such as from about 0.001 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.01 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.05 mg/kg body weight per day to about 0.5 mg/kg body weight per day, or such as from about 0.3 mg to about 30 mg per day, or such as from about 30 mg to about 300 mg per day.

A compound of the present disclosure may be combined with one or more additional therapeutic agents in any dosage amount of the compound of the present disclosure (e.g., from 1 mg to 1000 mg of the compound). Therapeutically effective amounts may include from about 1 mg per dose to about 1000 mg per dose, such as from about 50 mg per dose to about 500 mg per dose, or such as from about 100 mg per dose to about 400 mg per dose, or such as from about 150 mg per dose to about 350 mg per dose, or such as from about 200 mg per dose to about 300 mg per dose. Other therapeutically effective amounts of the compound of the present disclosure are about 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or about 500 mg per dose. Other therapeutically effective amounts of the compound of the present disclosure are about 100 mg per dose, or about 125, 150, 175, 200, 225, 250, 275, 300, 350, 400, 450, or about 500 mg per dose. A single dose can be administered hourly, daily, or weekly. For example, a single dose can be administered once every 1 hour, 2, 3, 4, 6, 8, 12, 16 or once every 24 hours. A single dose can also be administered once every 1 day, 2, 3, 4, 5, 6, or once every 7 days. A single dose can also be administered once every 1 week, 2, 3, or once every 4 weeks. In some embodiments, a single dose can be administered once every week. A single dose can also be administered once every month.

Kits that comprise the compound e, the stereoisomers, the pharmaceutically acceptable salts, or the deuterated compound thereof, are also included in the present disclosure

In some embodiments, a kit further includes a label and/or instructions for the use of the compounds in the treatment of the indications, such as the diseases or conditions described herein.

In some embodiments, the kit comprises a compound of the present disclosure, or pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, or one to three, or one to four) additional therapeutic agents.

EXAMPLES

Example 1 Synthesis

The compounds of the disclosure may be prepared using methods disclosed herein and routine modifications thereof which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein.

The synthesis of typical compounds of Formula (I), or a pharmaceutically acceptable salt thereof, e.g., compounds having structures described by one or more of Formula (I), or other formulas or compounds disclosed herein, may be accomplished as described in the following examples.

General Syntheses

Typical embodiments of compounds in accordance with the present disclosure may be synthesized using the general reaction schemes and/or examples described below. It will be apparent, given the description herein that the general schemes may be altered by substituting the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Starting materials are typically obtained from commercial sources or synthesized using published methods for synthesizing compounds that are embodiments of the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group, the identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein. Group labels (e.g., R1, R2) used in the reaction schemes herein are for illustrative purposes only and unless otherwise specified, do not necessarily match by name or function the labels used elsewhere to describe compounds of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (Ia), (Ib), (Ic), (Id), (Ie), (If), and (Ig), or aspects or fragments thereof.

Synthetic Reaction Parameters

The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given; other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in

the art by routine optimization procedures.

Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable
5 conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts (1999) *Protecting Groups in Organic Synthesis*, 3rd Edition, Wiley, New York, and references cited therein.

Furthermore, the compounds of the present disclosure may contain one or more chiral
10 centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents
15 well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.

The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co.
20 (Milwaukee, Wisconsin, USA). Others may be prepared by procedures or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's *Reagents for Organic Synthesis*, Volumes 1-15 (John Wiley and Sons, 1991), Rodd's *Chemistry of Carbon Compounds*, Volumes 1-5, and Supplemental (Elsevier Science Publishers, 1989) *organic Reactions*, Volumes 1-40 (John Wiley, and Sons, 1991), March's
25 *Advanced Organic Chemistry*, (John Wiley, and Sons, 5th Edition, 2001), and Larock's *Comprehensive Organic Transformations* (VCH Publishers Inc., 1989).

The terms "solvent", "inert organic solvent", or "inert solvent" refer to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), N, N-dimethylformamide
30 ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like). Unless specified to the contrary, the solvents used in the reactions of the present disclosure are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.

The term "q.s." means adding a quantity sufficient to achieve a stated function, e.g., to


bring a solution to the desired volume (i.e., 100%).

Compounds as provided herein may be synthesized according to the general schemes provided below. In the Schemes below, it should be appreciated that each of the compounds shown therein may have protecting groups as required present at any step. Standard

5 protecting groups are well within the prevue of one skilled in the art.

Intermediate preparation:

Preparation of intermediate A



To a solution of **A-1** (5 g, 18.65 mmol), potassium carbonate (5.16 g, 37.3 mmol) and sodium iodide (0.28 g, 1.86 mmol) in DMF (30 mL), was added dropwise bromoacetonitrile (3.36 g, 28.0 mmol). The mixture was heated to 70°C and stirred for 16 hours. Then the mixture was cooled down to room temperature. Water (60 mL) was added into the mixture to get a suspension. The suspension was filtered to obtain a brown solid, 4 g, with a yield of 49.0%.

A suspension of **A-2** (2.0 g, 6.51 mmol), **A-3** (1.71 g, 7.16 mmol), cesium carbonate (3.18 g, 9.77 mmol) and Pd(dppf)₂Cl₂ (0.5 g, 0.6 mmol) in dioxane (20 mL) was heated to 100 °C under N₂. The mixture was stirred for 8 hours. The reaction solution was cooled to room temperature, and water (30 mL) and ethyl acetate (30 mL) were added to extract an organic phase. The organic phase was concentrated under vacuum and then purified by column chromatography to obtain 1.2 g of white solid. The solid was dissolved in methanol. Pd/C (0.12 g, 30% wt.) was added into the mixture. The mixture was stirred overnight at room temperature under hydrogen. The mixture was filtered to get a filtrate. The filtrate was collected to concentrate to afford a solid. The solid was prepared by chiral Pre-HPLC to obtain **A-4**, 0.6 g, with a yield of 27.3%.

To a solution of **A-4** (0.6 g, 1.76 mmol) in methanol/water (4 mL/2 mL), was added sodium hydroxide (0.28 g, 7.05 mmol) at room temperature. The mixture was stirred for 4

hours. The mixture was adjusted to pH 5.0 with dilute hydrochloric acid. Ethyl acetate (5 mL) was added into the mixture to extract an organic phase. The organic phase was concentrate under vacuum to afford solid **A-5**, 0.53 g, with a yield of 96.3%.


To a solution of **A-5** (300 mg, 1.1 mmol) in dichloromethane (10 mL), was added
5 thionyl dichloride (520 mg, 4.4 mmol) and 1 drop of DMF at room temperature. The mixture was stirred for 6 hours. The mixture was concentrated to obtain an oil. To a solution of oil in dichloromethane (5 mL), was added a solution of *N*-methylaniline (180 mg, 1.65 mmol) and triethylamine (222 mg, 2.2 mmol) in dichloromethane (10 mL) at ice bath. Then warm the mixture to room temperature, and the mixture was stirred for 1 hour. Water (10 mL) was
10 added into the mixture to extract an organic phase. The organic phase was concentrated under vacuum to afford **A-6**, 350 mg, 87.9%.

To a solution of **A-6** (100 mg, 0.25 mmol) and (4R)-4-methyl-1,3,2-dioxolane 2,2-dioxide (103.6 g, 0.75 mmol) in THF (5 mL), was added dropwise lithium bis
(trimethylsilylamine) (1 mL, 1M in THF) at -20°C. Then the mixture was warm to room
15 temperature, and stirred for 24 hours. Water (5 mL) was added dropwise into the mixture to quench the reaction. Then ethyl acetate (10 mL) was added into the mixture to extract an organic phase. The organic phase was concentrated under vacuum to obtain an oil. The oil was purified by column chromatography to obtain **A-7**, 40 mg with a yield of 36.4%.

To a solution of **A-7** (10 mg, 0.023 mmol) in DMSO (2 mL), was added hydroxylamine
20 aqueous solution (0.6 mL, 50%) at room temperature. The mixture was stirred for 16 hours. Water (10 mL) and ethyl acetate (10 mL) were added into the mixture for extraction to get an organic phase. The organic phase was concentrated under vacuum to obtain an oil. The oil was dissolved in DMSO (3 mL), followed adding CDI (10 mg, 0.062 mmol) and DBU (10 mg, 0.066 mmol). The mixture was stirred at room temperature for 6 hours. Water (10 mL)
25 and ethyl acetate (10 mL) were added into the mixture to extract to get an organic phase. The organic phase was concentrated under vacuum to obtain **A-8**, 10 mg, with a yield of 88.2%.

To a solution of **A-8** (220 mg, 0.44 mmol) in ethylene glycol methyl ether (3 mL), was added potassium hydroxide (494 mg, 8.8 mmol). The mixture was heated to 130°C and stirred for 5 hours. After cooling down the mixture to room temperature, the mixture was
30 adjusted to pH 5.0 with hydrochloric acid (6 N). Ethyl acetate (10 mL) was added into the mixture for extraction to afford an organic phase. The organic phase was dried with anhydrous sodium sulfate, and concentrated under vacuum to obtain intermediate **A**, 180 mg, with a yield of 99.0%.

Preparation of intermediate B1




To a solution of **A-1** (120 g, 447.58 mmol) and **B1-1** (103.43 g, 492.34 mmol) in a mixture solution of dioxane (1200 mL) and H_2O (300 mL), was added Cs_2CO_3 (123.72 g, 895.16 mmol) and $\text{Pd(dppf)}_2\text{Cl}_2$ (18.28 g, 22.38 mmol). The mixture was stirred for 12 hours at 90°C . After cooling down the mixture, saturated NH_4Cl (500 mL) solution and ethyl acetate was added and extracted to obtain an organic phase. The organic phase was concentrated and purified by column chromatography to afford a white solid. The solid was dissolved in THF (1000 mL). Then Pd/C (12 g, 50% wt.) was added into the mixture. The mixture was stirred for 4 hours under H_2 . The mixture was filtrated and concentrated to afford **B1-2**, 120 g.

To a solution of **B1-2** (80 g, 292.69 mmol) in DMF (1000 mL), was added NaH (23.42 g, 585.38 mmol, 60%) at 0°C . The mixture was stirred for 30 mins. Then chloroacetonitrile was added dropwise into the mixture and stirred for 3 hours at room temperature. A saturated NH_4Cl solution (500 mL) was added dropwise into the mixture. The solution was stirred for 10 mins, and a solid was precipitated. The mixture was filtrated to afford **B1-3**, 75 g.



For the subsequent reactions, the preparation of intermediate A can be referred to in order to obtain **B1**.

Preparation of intermediates B, C, A1, A2, A3, A4 and A5

Following the preparation methods of intermediates A and B1, the following intermediates can be prepared:



Preparation of intermediate D




5 **D-1** (2.0 g, 8.4 mmol), **D-2** (1.29 g, 8.4 mmol) and pyridine hydrochloride (0.97 g, 8.4 mmol) were dissolved in toluene (10 mL). The mixture was heated to reflux for 1 hour. After cooling the reaction mixture, water (10 mL) and ethyl acetate (10 mL) were added into the mixture to extract to an organic phase. The organic phase was concentrated under vacuum to afford compound **D-3**, 2.4g, a yield of 76.4%.

10 To a solution of **D-3** (2.0 g, 5.34 mmol) in dichloromethane (20 mL), was added dropwise a solution of 2- isocyanate -1, 1- dimethoxyethane (0.84 g, 6.41 mmol) in dichloromethane (5 mL) at room temperature. The mixture was stirred at room temperature

for 2 hours. Water (20 mL) was added into mixture to extract to get an organic phase. The organic phase was concentrated under vacuum to afford **D-4**, which was used without purification in the next step.

To a solution of **D-4** in dichloromethane (20 mL), was added formic acid (10 mL) under an ice bath. The mixture was stirred overnight at room temperature. Water (20 mL) was added into the mixture. The mixture was extracted to separate out an organic phase. The organic phase was concentrated to obtain a crude product. The crude was slurry washed with a mixture of ethyl acetate and n-heptane to obtain **D-5**, 1.2 g.

Preparation of intermediates E and F



10

To a solution of **E-1** (5.0 g, 24.12 mmol) and triethylamine (7.31 g, 72.36 mmol) in dichlorohexane (25 mL), was added dropwise MsCl (6.08 g, 53.07 mmol) under ice bath. The mixture was stirred at room temperature for 30 min. The mixture was added water (20 mL) to extract to get an organic phase. The organic phase was dried by anhydrous sodium sulfate, and concentrated under vacuum to obtain **E-2**, 7.5g, with a yield of 85.6%.

15

To a solution of **E-2** (3.0 g, 8.25 mmol) in DMF (30 mL), was slowly added NaCN (850 mg, 17.3 mmol). The mixture was stirred 1 hour at 60°C. After cooling, the mixture was added sodium hypochlorite saturated solution (30 mL) and stirred for 1 hour. Then ethyl acetate (30 mL) was added into the mixture. The mixture was extracted to get an organic phase. The organic phase was concentrated under vacuum to obtain **E-3**, 1.54 g, with a yield of 82.8%.

20

E-3 (1.2 g, 5.33 mmol) was dissolved in a methanol solution of hydrogen chloride (1M, 7 mL). The mixture was stirred overnight at room temperature. Water was added into the mixture and the mixture was stirred for 2 hours. Ethyl acetate (20 mL) was added into the mixture. An organic phase was separated by extraction from the mixture. The organic phase


25

was concentrated under vacuum to afford an oil. The oil was purified by column chromatography to afford **E-4**, 0.6 g, with a yield of 43.6%.


E-4 (0.5 g, 1.9 mmol) and potassium tert-butoxide (1.09 g, 9.7 mmol) were added into THF (5 mL). The mixture was stirred overnight at room temperature. The mixture was
5 adjusted to pH 7.0 with dilute hydrochloric acid. Ethyl acetate was added into the mixture for extraction to afford an organic phase. The organic phase was concentrated under vacuum and purified by column chromatography to afford **E-5**, 0.34 g with a yield of 68%.

E-5 (0.2 g, 0.88 mmol), D-2 (126 mg, 0.88 mmol) and pyridine hydrochloride (0.1 g, 0.88 mmol) were dissolved into toluene (4 mL). The mixture was heated to reflux for 1 hour.
10 After cooling the mixture, water (10 mL) and ethyl acetate (10 mL) were added into the mixture. The mixture was extracted to get an organic phase. The organic phase was concentrated to afford compound **E**, 260 mg, with a yield of 81.2%.

Intermediate **F** was prepared by the same method:



15 Preparation of intermediate G



G-1 (5.0 g, 41.5 mmol), ethyl 3-bromopyruvate (8.90 g, 45.61 mmol) and cesium carbonate (20.3 g, 62.2 mmol) were dissolved in DMF (100 mL). The mixture was heated to 65°C and stirred for 4 hours. The mixture was cooled to room temperature, and water (200
20 mL) was added into the mixture. A solid was precipitated and the mixture was filtered to obtain **G-2**, 4.80 g, with a yield of 58.4%.


G-2 (4.0 g, 20.2 mmol), (Boc)₂O (6.6 g, 30.3 mmol) and triethylamine (6.13g, 60.5 mmol) were dissolved in THF (40 mL). The mixture was stirred overnight at room

temperature. Water (50 mL) and ethyl acetate (50 mL) were added into the mixture to extract to separate out an organic phase. The organic phase was concentrated under vacuum to obtain **G-3**, 5.6 g and 93.2%.

To a solution of **G-3** (5.6 g, 18.8 mmol) in THF (50 mL), was added potassium tert-butoxide (10.5g, 94 mmol) at room temperature. The mixture was stirred overnight. The mixture was adjusted to pH 7.0 with dilute hydrochloric acid. Then ethyl acetate was added into the mixture for extraction to separate an organic phase. The organic phase was concentrated under vacuum to afford a crude. The crude was purified by column chromatography to afford **G-4**, 3.6 g, with a yield of 76%.


G-4 (2.0 g, 7.93 mmol), **D-2** (1.22 g, 7.93 mmol) and pyridine hydrochloride (0.9 g, 7.93 mmol) were dissolved in toluene (40 mL). The mixture was heated to reflux for 1 hour. After cooling the reaction solution, water (40 mL) and ethyl acetate (40 mL) were added to the mixture. The mixture was extracted to get an organic phase. The organic phase was concentrated under vacuum to afford compound **G**, 1.2 g, with a yield of 39%.


Preparation of intermediate **H**



To a solution of compound **G** (200 mg, 0.52mmol) in DCM (2 mL), was added DAST (165 mg, 1.0 mmol) under an ice bath. The mixture was stirred at 0°C overnight. Saturated sodium bicarbonate solution (4 mL) and DCM (4 mL) were added into the mixture. The mixture was extracted to separate an organic phase. The organic phase was concentrated under vacuum and purified by column chromatography to obtain compound **H**, 0.12 g, with a yield of 56.8%.


Preparation of intermediate **I**





Compound **I-1** (5.0g, 23.3 mmol), cyclopropylboronic acid (3.99 g, 46.5 mmol), copper acetate (3.48 g, 23.2 mmol), 2, 2' bipyridine (3.9 g, 23.3 mmol) and sodium carbonate (4.9 g, 46.5 mmol) were added into dichloroethane. The mixture was stirred overnight at 70°C. After
 5 cooling down the mixture, the mixture was filtered to afford a filtrate. The filtrate was extracted with water and dichloromethane to separate an organic phase. The organic phase was concentrated under vacuum and then purified by column chromatography to obtain **I**, 3.6 g, with a yield of 61%.


Preparation of intermediate J



10


To a solution of **I-1** (2.0 g, 9.3 mmol) in DMF (20 mL), was added iodocyclobutane (1.78 g, 9.8 mmol) and Cs₂CO₃ (4.55 g, 13.9 mmol). The mixture was stirred 6 hours at 50-60°C. Water (50 mL) was added into the mixture, and then a solid was precipitated. The
 15 suspension was filtrated to afford **J**, 1.6 g, yield: 63.9%.

Preparation of intermediate J-1




To a solution of **I-1** (1.0 g, 4.65 mmol) in DMF (10 mL), was added (iodomethyl)cyclopropane (0.89 g, 4.9 mmol) and Cs_2CO_3 (2.27 g, 6.98 mmol). The mixture was stirred 4 hours at 50-60°C. Water (50 mL) was added into the mixture, and then a solid was precipitated. The suspension was filtrated to afford **J-1**, 0.87 g, yield: 69.51%.

Preparation of intermediates **K**, **L**, **M** and **N**



According to the preparation method of intermediates **K**, **L**, **M** and **N** would be obtained.

Preparation of intermediate **O**





O-1 (1 eq.) and (1R, 2R)-(-)-N, N'-dimethyl-1, 2-cyclohexanediamine (0.5 eq.), CuI (0.5 eq.), bromide (1.5 eq.) and potassium carbonate (3 eq.) were added to NMP. The mixture was stirred overnight at 100-110 °C. After cooling down, the mixture was filtered to afford a filtrate, then water (10 V) and ethyl acetate (10 V) was added into the filtrate. The mixture

was extracted to separate out an organic phase. The organic phase was concentrated under vacuum and then purified by column chromatography to obtain the target compound.


The following compounds can be prepared by this method:

5






Preparation of intermediate P



P-1 (1.0 g, 4.46 mmol), 2-fluoro-5-iodo-1,3-xylene (1.12 g, 4.46 mmol), CuI (0.8 g, 4.46 mmol), TMEDA (0.52 g, 4.46 mmol) and potassium carbonate (0.92 g, 6.69 mmol) were added into dioxane (10 mL). The mixture was stirred overnight at 100~110°C. After the mixture was cooled, the mixture was filtered to get a filtrate. Ethyl acetate (20 mL) and water (20 mL) was added into the filtrate to extract to separate an organic phase. The organic phase was concentrated under vacuum, and then purified by column chromatography to obtain **P**, 0.6 g, with a yield of 38.8%.

Preparation of intermediate Q




To a solution of acetonitrile (15.57 g, 379.34 mmol, Purity 100 %) in tetrahydrofuran (300 mL) at -78°C under N₂, was added dropwise Lithium bis(trimethylsilyl)amide (63.47 g, 379.34 mmol). The mixture was stirred for 1 h at -78°C. A solution of **Q-1** (45.0 g, 189.67 mmol) in THF (5 mL) was added dropwise into the above solution. The resulting mixture was allowed to warm to -50°C over 30 min. The reaction mixture was quenched with saturated NH₄Cl (aq.) (100 mL) and extracted with EA (150 mL). The mixture was separated to get an organic layer which was washed with brine, and dried over MgSO₄. The organic layer was

concentrated under vacuum and purified by silica gel column chromatography (PE / EtOAc: 0%-50%) to give a yellow oil.

To a solution of benzyl N-(4-cyano-3-oxobutyl)carbamate (246.26 mg, 1 mmol) and Triethylamine (202.38 mg, 2 mmol) in dichloromethane (10 mL), was added dropwise cyclopropanecarbonyl chloride (209.06 mg, 2 mmol). The mixture was stirred for overnight at room temperature. The reaction mixture was quenched with water (10 mL) and extracted with dichloromethane (10 mL). The mixture was separated to get an organic layer which was washed with brine, dried over MgSO_4 . The organic layer was concentrated under vacuum and purified by silica gel column chromatography (PE / EtOAc: 0%-50%) to give an oil.

Q-3 (150 mg, 0.47 mmol) and Pd/C (15mg, 30%wt) were added into MeOH (15 mL). The mixture was stirred 3 hours under H_2 . The mixture was filtrated and concentrated under vacuum to get a crude. The crude was purified by SFC to get the title compound, 32mg, yield: 40.8%. ^1H NMR (d-DMSO, 500MHZ): δ 4.12(d, 1H, $J=8.0\text{Hz}$), 3.35(m, 1H), 3.12-3.07(m, 2H), 2.63-2.55(m, 2H), 1.47-1.32(m, 5H).

Preparation of intermediate R



To a solution of **R-1** (10.0 g, 68.87 mmol) and triethylamine (13.9 g, 138 mmol) in dichloromethane (100 mL), was added $(\text{Boc})_2\text{O}$ (18.0 g, 82.64 mmol). The mixture was stirred for overnight at room temperature. The reaction mixture was quenched with water (100 mL) and extracted with dichloromethane (100 mL) to get an organic layer. The organic layer was washed with brine, dried over MgSO_4 , and concentrated under vacuum to get **R-2**, 15.3 g, yield: 90.56%.

R-2 (15.0 g, 61.1 mmol) was dissolved in $\text{NH}_3/\text{CH}_3\text{OH}$ (10M, 300 mL). The mixture was stirred for 4 hours in an autoclave at 90~100°C. After cooling, the mixture was concentrated under vacuum to get a crude **R-3** without purification for the next step reaction.

R-3, TFAA (6.90 mL, 49.5mmol) and pyridine (8.0 mL, 99.0 mmol) were added into a three-neck bottle. The mixture was stirred at room temperature for 1 h. The reaction mixture was quenched with H_2O (100 mL) and extracted with EtOAc to afford an organic layer. The

organic layer was washed with brine (100 mL), dried over Na₂SO₄, and concentrated under vacuum and then purified by flash chromatography (PE / EtOAc: 20 / 1) to afford **R-4**, 5.3 g.


R-4 (5.3 g, 26.7 mmol) was dissolved in HCl/EtOAc (4M, 30 mL). The mixture was stirred for 2 hours at room temperature. A solid was precipitated. The mixture was filtrated to afford **R-5**, 3.2 g, 88.9 %.

To a solution of **R-5** (3.2 g, 23.7 mmol) in EtOH (20 mL), was added Et₃N (7.22 g, 71.3 mmol) and methyl acrylate (2.15 g, 24.9 mmol) at room temperature. The mixture was stirred 3 hours at 70°C. Then the mixture was cooled to room temperature, and (Boc)₂O (6.74 g, 30.9 mmol) was added into the mixture. The solution was stirred at room temperature overnight and then diluted with H₂O (50 mL). The mixture was extracted with EtOAc to afford an organic layer. The organic layer were washed with brine (50 mL), dried over Na₂SO₄, concentrated and then purified by flash chromatography (PE / EtOAc: 10 / 1) to afford **R-7**, 4.3 g, yield: 63.6%.


To a solution of **R-7** (4.0g, 14.1 mmol) in THF (50 mL), was added t-BuOK (2.37 g, 21.1 mmol). The mixture was stirred at room temperature for 1 h and then quenched with 2N HCl solution. The mixture was diluted with H₂O (50 mL) and extracted with EtOAc to afford an organic layer. The organic layer were washed with brine, dried over Na₂SO₄, concentrated under vacuum, and then purified by flash chromatography to afford **R**, 2.5 g, yield: 70.4%.

Preparation of intermediate S

Following the synthetic route of intermediate **R**, the intermediate **S** was obtained by a SFC separation.



Preparation of intermediate T




To a solution of **T-1** (10.0 g, 59.3 mmol) in THF (100 mL), was added boron tribromide (120 mL, 1M in DCM). The mixture was stirred for 3 hours at room temperature. The mixture was quenched with Na₂CO₃ (aq.) and extracted with DCM. The organic layer was

washed with brine, dried over Na₂SO₄, and concentrated under vacuum to afford **T-2**, 8.5 g, yield: 92.7%.

To a solution of **T-2** (8.0 g, 51.8 mmol) in DCM, was added Et₃N (7.8 g, 77.6 mmol). The mixture was cooled to 0 °C, and Cbz-Cl (9.71 g, 56.9 mmol) was added into the mixture. After the mixture was stirred for 2 hours, the mixture was quenched with Na₂CO₃ (aq.) and extracted with DCM. The organic layer were washed with brine, dried over Na₂SO₄, and concentrated under vacuum to afford **T-3**, 11.2 g, yield: 74.9%.


A solution of **T-3** (10.0 g, 34.6 mmol), Pd/C (1.0 g, 30%wt) and 0.5 mL HCl (1M in H₂O) in MeOH (150) mL was stirred under 50 psi H₂ at room temperature for 2 hours. The mixture was filtrated and concentrated under vacuum to get a residue. The residue was dissolved into DCM. The solution was washed by NaHCO₃ (aq) and brine. The organic layer were dried over Na₂SO₄, concentrated under vacuum and purified by flash chromatography to afford a racemate. Then, the racemate was purified by SFC to afford **T**, 1.2 g, yield of 21.8%.

Preparation of intermediate AA



To a solution of compound **AA-1** (1.0 g, 4.35 mmol) in ethanol (10 mL), was added hydrogen peroxide (30%, 10 mL) at room temperature. The mixture was stirred overnight. The reaction solution was filtered to afford **AA**, 1.1 g, yield: 96.6%.

Preparation of intermediate AB




AB-1 (5.0 g, 20.2 mmol) was dissolved in sulfuric acid (25 mL, 98%) at -20 °C. Potassium nitrate (2.1 g, 20.2 mmol) was added into the mixture in batches. The mixture was stirred for 4 hours. The reaction solution was poured into an ice water, and a solid was precipitated. The solid was dried and then purified by column chromatography to obtain **AB-2** 0.7 g, yield: 11%.

AB-2 (0.7 g, 2.4 mmol) was dissolved in methanol (5 mL). The saturated ammonium chloride (5 mL) and iron powder (0.54 g, 9.6 mmol) was added into the mixture. The mixture was heated to 80°C for 3 hours. After the mixture was cooled to room temperature, ethyl acetate (20 mL) was added into the mixture to extract to afford an organic layer. The organic layer was concentrated under vacuum to afford **AB-3**, 0.54 g, yield: 86%.


To a solution of **AB-3** (0.54 g, 2.0 mmol) in dichloromethane (5 mL), was added triethylamine (0.20 g, 2.0 mmol) and (Boc)₂O (0.45 mmol) at room temperature. The mixture was stirred at room temperature overnight. Iodomethane (0.29 g, 2.0 mmol) was added dropwise to the reaction solution and stirred for 1 hour. The reaction solution was concentrated under vacuum. The residue was added into ethyl hydrogen chloride acetate solution (5 mL, 2N). The mixture was stirred at room temperature for 1 hour. The mixture was precipitated and filtered to produce **AB**, 0.32 g, yield: 49.7%.

Preparation of intermediate AC



D-3 (290 mg, 0.77 mmol), 1*H*-imidazole-1-sulfonyl azide (139.99 mg, 0.81 mmol) and potassium carbonate (212.84 mg, 1.54 mmol) were added to methanol (3 mL) at 0 °C. Copper sulfate hydrate (1.9 mg, 0.0077 mmol) was added into the mixture. The mixture was stirred for 12 hours at room temperature. The mixture was extracted with ethyl acetate and water to afford an organic phase. The organic phase was washed with 1N hydrochloric acid, saturated sodium bicarbonate, and brine. Then the solution was dried over anhydrous sodium sulfate and concentrated under vacuum to obtain **AC** as an oil, 0.15 g, 48%.


Preparation of intermediate AD



AD-1 (2.0 g, 7.84 mmol), TMSCN (1.16 g, 11.8 mmol), triethylamine (1.59 g, 15.7 mmol), cuprous iodide (1.49 g, 7.8 mmol), and palladium tetrakis(triphenylphosphine) (900 mg, 0.8 mmol) were added into dioxane (20 mL). The mixture was heated under nitrogen to 70 °C. The reaction was stirred overnight. The mixture was cooled to room temperature, water and ethyl acetate was added to extracted to get an organic layer. The organic layer was concentrated and then purified by column chromatography to produce **AD-2**, 1.1 g, yield: 51.5%.


To a solution of **AD-2** (1.1 g, 4.0 mmol) in methanol (10mL), was added potassium carbonate (1.1g, 8.1 mmol). The mixture was stirred at room temperature for 4 hours. Water and ethyl acetate was added into the mixture to extract to get an organic phase. The organic phase was concentrated under vacuum and then purified by column chromatography to obtain **AD**, 0.35g, yield: 43.3%.

Preparation of intermediate AE




To a solution of **AC** (100 mg, 0.25 mmol) and **AD** (55 mg, 0.27 mmol) in PEG200 (2 mL), was added CuI (9.5 mg, 0.05 mmol). The reaction was stirred at 50 °C for 2 h. After the mixture was cooled to room temperature, the reaction solution was filtered. The filtrate was washed by brine to get an organic phase. The organic phase was concentrated under vacuum and purified by pre-HPLC (C18) to yield **AE**, 123 mg, 82%.

Preparation of intermediate AF




To a solution of **AF-1** (300 mg, 1.00 mmol) in DMSO (10 mL), was added diphenyl(vinyl)sulfonium triflate (0.40 g, 1.1 mmol) and DBU (0.46 g, 3 mmol). The mixture was stirred 2 hours at room temperature. Ethyl acetate (50 mL) and water (20 mL) were added dropwise into the reaction mixture, and the organic phase was extracted from the mixture. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and then concentrated under vacuum. The residue was purified by column chromatography to yield **AF**, 154 mg, with a yield of 47.22%.

Preparation of compound 1




Intermediate **A** (180 mg, 0.44 mmol), **O-6** (280 mg, 0.57 mmol), HATU (250.95mg, 0.66 mmol) and DIPEA (170 mg, 1.32 mmol) were dissolved in DMF (5 mL). The mixture was stirred at room temperature for 3 hours. Water was added into the mixture to extract with dichloromethane to afford an organic phase. The organic phases was concentrated under vacuum. The residue was purified by pre-HPLC (acetonitrile: 0.1% formic acid aqueous solution) to afford compound **1**, 200 mg, with a yield of 51%.

Preparation of the sodium salt of compound 19



To a solution of compound **19** (1 g, 1.14 mmol) in a mixture solution of dichloromethane (5 mL) and methanol (5 mL), was added a solution of NaOH (50 mg, 1.25 mmol) in MeOH (1mL). The mixture was stirred overnight. The reaction mixture was concentrated under vacuum. Then the residue was slurry washed with diethyl ether to afford the sodium salt of compound **19**, 0.95 g with a yield of 95%. Melting point: 255-260°C.

Preparation of the Calcium salt of compound 19









The sodium salt of compound **19** (0.5g, 0.55 mmol) was added into THF (5 mL). Calcium acetate (89.34mg, 0.56 mmol) was added into the reaction mixture. After the reaction mixture became clear, the mixture was stirred for 8 hours. The reaction mixture was concentrated under vacuum, then the residue was slurry washed with a mixture of dichloromethane (1 mL) and diethyl ether (10 mL) to afford a white solid, 0.45 g, with a yield of 88%. Melting point: 272-277°C.




According to the preparation method described in this paper, the following compounds were prepared by using appropriate starting materials and intermediates and, if necessary, appropriate protective group chemistry. The structures were confirmed by MS and ¹HNMR.





Table 1. The MS and ¹HNMR of the compounds




Compounds	Structures	MS	¹ HNMR
1		909.39	¹ H NMR (500 MHz, Chloroform- <i>d</i>) δ 11.15 (s, 1H), 8.37 – 8.29 (m, 2H), 8.21 – 8.14 (m, 1H), 7.89 – 7.82 (m, 1H), 7.62 – 7.56 (m, 1H), 7.51 – 7.41 (m, 4H), 7.25 – 7.20 (m, 1H), 7.11 – 7.04 (m, 1H), 5.24 – 5.14 (m, 1H), 4.57 – 4.49 (m, 1H), 4.14 – 4.05 (m, 1H), 3.86 – 3.61 (m, 3H), 3.08 – 2.90 (m, 3H), 2.49 – 2.32 (m, 3H), 2.26 – 2.23 (m, 6H), 2.08 – 1.91 (m, 2H), 1.86 – 1.69 (m, 2H), 1.61 – 1.57 (m, 3H), 1.39 – 1.31 (m, 2H), 1.29 – 1.22 (m, 5H), 1.19 (s, 3H), 1.01 – 0.98 (m, 3H).




Compounds	Structures	MS	¹ H NMR
2		923.41	¹ H NMR (500 MHz, Chloroform- <i>d</i>) δ 10.92(s, 1H), 8.38 – 8.28 (m, 2H), 8.18 (d, <i>J</i> = 6.0 Hz, 1H), 7.89 – 7.82 (m, 1H), 7.63 – 7.57 (m, 1H), 7.52 – 7.40 (m, 4H), 7.22 (d, <i>J</i> = 2.0 Hz, 1H), 7.12 – 7.04 (m, 1H), 5.23 – 5.13 (m, 1H), 4.53 – 4.47 (m, 1H), 4.14 – 4.05 (m, 1H), 3.86 – 3.78 (m, 1H), 3.76 – 3.62 (m, 2H), 3.08 – 2.90 (m, 3H), 2.48 – 2.31 (m, 3H), 2.24 (s, 6H), 2.14 – 1.98 (m, 7H), 1.97 – 1.92 (m, 1H), 1.87 – 1.77 (m, 3H), 1.75 – 1.69 (m, 1H), 1.59 (d, <i>J</i> = 7.8 Hz, 2H), 1.24 (s, 3H), 1.19–1.03 (s, 6H).
3		881.36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 8.36 – 8.27 (m, 2H), 8.14 (d, <i>J</i> = 4.9 Hz, 1H), 7.83 – 7.75 (m, 1H), 7.67 – 7.63 (m, 1H), 7.54 (d, <i>J</i> = 8.9 Hz, 1H), 7.47 – 7.36 (m, 3H), 7.25 (d, <i>J</i> = 2.0 Hz, 1H), 7.10 – 7.03 (m, 1H), 5.68 – 5.50 (m, 1H), 4.74 – 4.60 (m, 1H), 3.93 (s, 3H), 3.78 – 3.57 (m, 2H), 3.09 – 2.94 (m, 3H), 2.67 – 2.60 (m, 1H), 2.52 – 2.39 (m, 3H), 2.24 (s, 6H), 2.21 – 2.14 (m, 1H), 2.08 – 2.00 (m, 1H), 1.98 – 1.92 (m, 1H), 1.86 – 1.79 (m, 1H), 1.75 – 1.68 (m, 1H), 1.26 – 1.15 (m, 6H), 0.99 (d, <i>J</i> = 5.9 Hz, 3H).
4		895.38	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.16 (s, 1H), 8.36 – 8.28 (m, 2H), 8.14 (d, <i>J</i> = 4.9 Hz, 1H), 7.82 – 7.75 (m, 1H), 7.67 – 7.62 (m, 1H), 7.54 (d, <i>J</i> = 8.9 Hz, 1H), 7.46 – 7.37 (m, 3H), 7.25 (d, <i>J</i> = 2.0 Hz, 1H), 7.10 – 7.04 (m, 1H), 5.07 – 5.00 (m, 1H), 4.55 – 4.46 (m, 1H), 3.93 (s, 3H), 3.71 – 3.61 (m, 2H), 3.05 – 2.85 (m, 3H), 2.49 – 2.42 (m, 1H), 2.37 – 2.29 (m, 2H), 2.26 – 2.16 (m, 7H), 2.08 – 1.89 (m, 5H), 1.89 – 1.81 (m, 1H), 1.77 – 1.71 (m, 1H), 1.23 (s, 3H), 1.18 (s, 3H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).





Compounds	Structures	MS	¹ HNMR
5		907.38	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.21 (s, 1H), 8.39 – 8.29 (m, 3H), 7.94 – 7.88 (m, 1H), 7.68 – 7.58 (m, 2H), 7.46 – 7.38 (m, 3H), 7.25 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 – 7.05 (m, 1H), 5.63 – 5.57 (m, 1H), 4.70 – 4.63 (m, 1H), 4.56 – 4.50 (m, 1H), 3.74 – 3.59 (m, 2H), 3.10 – 3.03 (m, 1H), 3.02 – 2.94 (m, 2H), 2.67 – 2.60 (m, 1H), 2.49 – 2.39 (m, 2H), 2.36 – 2.30 (m, 1H), 2.27 – 2.17 (m, 7H), 2.08 – 2.01 (m, 1H), 1.97 – 1.92 (m, 1H), 1.86 – 1.78 (m, 1H), 1.75 – 1.68 (m, 1H), 1.39 – 1.29 (m, 2H), 1.29 – 1.20 (m, 5H), 1.18 (s, 3H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).
6		903.32	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.23 (s, 1H), 8.38 – 8.28 (m, 2H), 8.14 (d, <i>J</i> = 4.9 Hz, 1H), 7.81 – 7.75 (m, 1H), 7.68 – 7.63 (m, 1H), 7.54 (d, <i>J</i> = 8.9 Hz, 1H), 7.46 – 7.37 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.10 – 7.04 (m, 1H), 6.94 (s, 1H), 4.33 – 4.25 (m, 1H), 4.09 – 4.03 (m, 1H), 3.93 (s, 3H), 3.74 – 3.67 (m, 1H), 3.66 – 3.58 (m, 1H), 3.07 – 2.94 (m, 3H), 2.49 – 2.41 (m, 1H), 2.38 – 2.28 (m, 2H), 2.24 (s, 6H), 2.07 – 2.00 (m, 1H), 1.99 – 1.91 (m, 1H), 1.87 – 1.78 (m, 1H), 1.75 – 1.68 (m, 1H), 1.23 (s, 3H), 1.18 (s, 3H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).
7		919.36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 8.39 – 8.28 (m, 2H), 8.14 (d, <i>J</i> = 4.9 Hz, 1H), 7.81 – 7.75 (m, 1H), 7.68 – 7.64 (m, 1H), 7.54 (d, <i>J</i> = 8.9 Hz, 1H), 7.45 – 7.38 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 – 7.05 (m, 1H), 5.27 – 5.19 (m, 1H), 4.89 – 4.76 (m, 2H), 3.93 (s, 3H), 3.74 – 3.58 (m, 2H), 3.03 – 2.94 (m, 1H), 2.50 – 2.38 (m, 1H), 2.38 – 2.28 (m, 2H), 2.24 (s, 6H), 2.08 – 1.99 (m, 1H), 1.98 – 1.90 (m, 1H), 1.87 – 1.78 (m, 1H), 1.76 – 1.68 (m, 1H), 1.60 (d, <i>J</i> = 7.5 Hz, 3H), 1.25 – 1.15 (m, 6H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).




Compounds	Structures	MS	¹ H NMR
8		897.36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.26 (s, 1H), 8.36 – 8.29 (m, 2H), 8.17 – 8.11 (m, 1H), 7.83 – 7.75 (m, 1H), 7.68 – 7.63 (m, 1H), 7.57 – 7.51 (m, 1H), 7.47 – 7.40 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.10 – 7.03 (m, 1H), 5.11 – 4.96 (m, 3H), 3.93 (s, 3H), 3.74 – 3.58 (m, 2H), 3.02 – 2.95 (m, 1H), 2.49 – 2.28 (m, 3H), 2.24 (s, 6H), 2.08 – 2.00 (m, 1H), 1.98 – 1.91 (m, 1H), 1.87 – 1.78 (m, 1H), 1.75 – 1.68 (m, 1H), 1.60 (d, <i>J</i> = 7.8 Hz, 3H), 1.27 – 1.15 (m, 6H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).
9		895.38	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.19 (s, 1H), 8.36 – 8.29 (m, 2H), 8.14 (d, <i>J</i> = 4.9 Hz, 1H), 7.83 – 7.76 (m, 1H), 7.68 – 7.63 (m, 1H), 7.57 – 7.51 (m, 1H), 7.48 – 7.37 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 – 7.04 (m, 1H), 4.89 (d, <i>J</i> = 6.7 Hz, 1H), 4.18 – 4.08 (m, 1H), 3.93 (s, 3H), 3.87 – 3.79 (m, 1H), 3.75 – 3.58 (m, 2H), 3.05 – 2.88 (m, 3H), 2.51 – 2.44 (m, 1H), 2.37 – 2.29 (m, 2H), 2.24 (s, 6H), 2.08 – 2.00 (m, 1H), 1.98 – 1.89 (m, 2H), 1.87 – 1.78 (m, 1H), 1.75 – 1.69 (m, 1H), 1.25 – 1.15 (m, 6H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H), 0.68 – 0.57 (m, 2H), 0.49 – 0.39 (m, 2H).
10		895.38	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.29 (s, 1H), 8.36 – 8.29 (m, 2H), 8.14 (d, <i>J</i> = 4.9 Hz, 1H), 7.81 – 7.76 (m, 1H), 7.67 – 7.64 (m, 1H), 7.54 (d, <i>J</i> = 8.9 Hz, 1H), 7.46 – 7.37 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.10 – 7.04 (m, 1H), 5.22 – 5.14 (m, 1H), 4.11 – 4.05 (m, 1H), 3.96 – 3.85 (m, 4H), 3.74 – 3.58 (m, 2H), 3.04 – 2.90 (m, 3H), 2.35 (s, 2H), 2.24 (s, 6H), 2.07 – 1.91 (m, 2H), 1.86 – 1.78 (m, 1H), 1.75 – 1.68 (m, 1H), 1.65 – 1.47 (m, 7H), 1.25 – 1.16 (m, 6H).




Compounds	Structures	MS	¹ H NMR
11		895.38	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.21 (s, 1H), 8.34 – 8.23 (m, 2H), 8.14 (d, <i>J</i> = 4.9 Hz, 1H), 7.82 – 7.76 (m, 1H), 7.67 – 7.63 (m, 1H), 7.54 (d, <i>J</i> = 8.9 Hz, 1H), 7.46 – 7.37 (m, 3H), 7.24 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 – 7.04 (m, 1H), 3.96 – 3.83 (m, 5H), 3.74 – 3.59 (m, 2H), 3.01 – 2.95 (m, 1H), 2.91 – 2.84 (m, 2H), 2.51 – 2.44 (m, 1H), 2.37 – 2.19 (m, 12H), 2.07 – 2.00 (m, 1H), 1.97 – 1.92 (m, 1H), 1.87 – 1.79 (m, 1H), 1.75 – 1.69 (m, 1H), 1.26 – 1.16 (m, 6H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).
12		898.00	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 8.13 (d, <i>J</i> = 5.2 Hz, 1H), 7.68 – 7.63 (m, 1H), 7.53 (d, <i>J</i> = 9.0 Hz, 1H), 7.51 – 7.41 (m, 2H), 7.37 (d, <i>J</i> = 4.9 Hz, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.10 – 7.05 (m, 1H), 5.22 – 5.11 (m, 1H), 4.34 – 4.29 (m, 2H), 4.10 – 4.03 (m, 1H), 3.96 – 3.87 (m, 4H), 3.74 – 3.59 (m, 2H), 3.04 – 2.89 (m, 3H), 2.48 – 2.42 (m, 1H), 2.38 – 2.29 (m, 2H), 2.24 (s, 6H), 2.07 – 1.91 (m, 3H), 1.86 – 1.68 (m, 3H), 1.60 (d, <i>J</i> = 8.0 Hz, 3H), 1.23 (s, 3H), 1.18 (s, 3H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).
13		923.41	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.21 (s, 1H), 8.37 – 8.29 (m, 2H), 8.25 (d, <i>J</i> = 4.9 Hz, 1H), 7.85 – 7.78 (m, 1H), 7.67 – 7.62 (m, 1H), 7.48 – 7.37 (m, 4H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 – 7.04 (m, 1H), 5.22 – 5.13 (m, 1H), 4.13 – 3.84 (m, 4H), 3.73 – 3.59 (m, 2H), 3.03 – 2.89 (m, 3H), 2.49 – 2.20 (m, 9H), 2.08 – 1.91 (m, 2H), 1.87 – 1.68 (m, 2H), 1.63 – 1.45 (m, 4H), 1.23 (s, 3H), 1.18 (s, 3H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H), 0.61 – 0.38 (m, 4H).
14		881.36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.09 (s, 1H), 8.37 – 8.28 (m, 2H), 8.14 (d, <i>J</i> = 4.9 Hz, 1H), 7.82 – 7.75 (m, 1H), 7.66 – 7.61 (m, 1H), 7.54 (d, <i>J</i> = 8.8 Hz, 1H), 7.46 – 7.37 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 – 7.06 (m, 1H), 5.22 – 5.14 (m, 1H), 4.12 – 4.03 (m, 3H), 3.95 – 3.85 (m, 4H), 3.07 – 2.89 (m, 3H), 2.42 – 2.21 (m, 9H), 1.99 – 1.73 (m, 8H), 1.60 (d, <i>J</i> = 8.0 Hz, 3H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H).




Compounds	Structures	MS	¹ H NMR
15		867.35	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.11 (s, 1H), 8.36 – 8.28 (m, 2H), 8.14 (d, <i>J</i> = 4.9 Hz, 1H), 7.82 – 7.76 (m, 1H), 7.66 – 7.61 (m, 1H), 7.54 (d, <i>J</i> = 8.9 Hz, 1H), 7.46 – 7.38 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.08 – 7.03 (m, 1H), 5.24 – 5.12 (m, 1H), 4.11 – 4.02 (m, 1H), 3.96 – 3.87 (m, 4H), 3.81 (d, <i>J</i> = 6.0 Hz, 2H), 3.72 (d, <i>J</i> = 6.2 Hz, 2H), 3.04 – 2.80 (m, 3H), 2.52 – 2.43 (m, 1H), 2.39 – 2.28 (m, 2H), 2.24 (s, 6H), 2.15 – 2.00 (m, 4H), 1.60 (d, <i>J</i> = 8.0 Hz, 3H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).
16		869.36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.16 (s, 1H), 8.37 – 8.28 (m, 2H), 8.14 (d, <i>J</i> = 4.9 Hz, 1H), 7.81 – 7.76 (m, 1H), 7.66 – 7.64 (m, 1H), 7.54 (d, <i>J</i> = 8.9 Hz, 1H), 7.45 – 7.37 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.10 – 7.05 (m, 1H), 5.02 – 4.95 (m, 1H), 4.61 (d, <i>J</i> = 1.0 Hz, 2H), 3.93 (s, 3H), 3.71 – 3.62 (m, 2H), 3.03 – 2.94 (m, 1H), 2.49 – 2.40 (m, 1H), 2.38 – 2.21 (m, 8H), 2.06 – 1.81 (m, 3H), 1.77 – 1.70 (m, 1H), 1.57 (d, <i>J</i> = 7.0 Hz, 3H), 1.27 – 1.15 (m, 6H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).
17		981.38	¹ H NMR (500 MHz, Chloroform- <i>d</i>) δ 10.79 (s, 1H), 8.37 – 8.29 (m, 2H), 8.21 – 8.14 (m, 1H), 7.89 – 7.82 (m, 1H), 7.62 – 7.56 (m, 1H), 7.51 – 7.41 (m, 4H), 7.25 – 7.20 (m, 1H), 7.11 – 7.04 (m, 1H), 5.24 – 5.14 (m, 1H), 4.59 – 4.49 (m, 3H), 4.14 – 4.05 (m, 1H), 3.86 – 3.61 (m, 5H), 3.08 – 2.90 (m, 3H), 2.49 – 2.32 (m, 3H), 2.26 – 2.23 (m, 6H), 2.08 – 1.91 (m, 2H), 1.86 – 1.69 (m, 2H), 1.61 – 1.57 (m, 3H), 1.39 – 1.31 (m, 2H), 1.19 (s, 3H), 1.01 – 0.98 (m, 3H).





Compounds	Structures	MS	¹ HNMR
18		923.04	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ C11.16 (s, 1H), 8.37 – 8.29 (m, 2H), 8.25 (d, <i>J</i> = 4.9 Hz, 1H), 7.85 – 7.78 (m, 1H), 7.67 – 7.62 (m, 1H), 7.48 – 7.37 (m, 4H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 – 7.04 (m, 1H), 5.22 – 5.13 (m, 1H), 4.13 – 3.84 (m, 4H), 3.73 – 3.59 (m, 2H), 3.03 – 2.89 (m, 3H), 2.49 – 2.20 (m, 9H), 2.08 – 1.91 (m, 2H), 1.87 – 1.68 (m, 2H), 1.63 – 1.45 (m, 4H), 1.23 (s, 3H), 1.18 (s, 3H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H), 0.61 – 0.38 (m, 4H).
19		881.36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.76(s, 1H), 8.28(s, 1H), 7.69-7.63(m, 1H), 7.56-7.50(m, 2H), 7.42-7.40(m, 1H), 7.28-7.26(m, 1H), 7.19-7.18(m, 2H), 7.09-7.08(m, 1H), 6.96-6.93(m, 2H), 5.59-5.58(m, 1H), 4.41-4.36(m, 1H), 3.97-3.96(m, 3H), 3.85-3.83(m, 1H), 3.63-3.62(m, 1H), 3.46-3.44(m, 3H), 3.19-3.17(m, 1H), 2.87-2.85(m, 3H), 2.26(s, 6H), 1.79-1.75(m, 1H), 1.70-1.63 (m, 4H), 1.44(d, <i>J</i> =12.0Hz, 3H), 1.36-1.30(m,2H), 1.19-1.12(m, 7H).
20		895.38	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.72 (s, 1H), 8.34 (s, 1H), 7.63 (d, <i>J</i> = 8.9 Hz, 1H), 7.55 – 7.29 (m, 4H), 7.28 – 7.00 (m, 5H), 6.90 (d, <i>J</i> = 16.7 Hz, 2H), 5.55 (d, <i>J</i> = 6.8 Hz, 1H), 5.30-5.27 (m, 1H), 4.35-4.33 (m, 1H), 3.92-3.75(m, 3H), 3.59 (t, <i>J</i> = 12.6 Hz, 1H), 3.43 (d, <i>J</i> = 13.8 Hz, 4H), 3.14 (d, <i>J</i> = 12.9 Hz, 1H), 2.94 – 2.76 (m, 3H), 2.65 – 2.52 (m, 3H), 2.43 (d, <i>J</i> = 9.6 Hz, 1H), 2.28 – 2.20 (m, 6H), 1.86 (dq, <i>J</i> = 10.5, 4.2, 3.0 Hz, 3H), 1.80 – 1.52 (m, 10H), 1.40 (d, <i>J</i> = 6.7 Hz, 3H), 1.29 (s, 2H), 1.21 – 1.08 (m, 3H).





Compounds	Structures	MS	¹ HNMR
21		895.44	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.72 (s, 1H), 8.35 – 8.23 (m, 3H), 7.86 – 7.78 (m, 1H), 7.66 – 7.62 (m, 1H), 7.48 – 7.38 (m, 4H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 – 7.03 (m, 1H), 5.21 – 5.13 (m, 1H), 4.10 – 3.87 (m, 4H), 3.60 – 3.46 (m, 4H), 3.02 – 2.88 (m, 3H), 2.53 – 2.28 (m, 3H), 2.24 (s, 6H), 2.17 – 2.07 (m, 2H), 1.89 – 1.79 (m, 2H), 1.60 (d, <i>J</i> = 8.0 Hz, 3H), 1.53 – 1.45 (m, 1H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H), 0.59 – 0.39 (m, 4H).
22		874.44	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.68 (s, 1H), 9.16 (s, 1H), 8.36 (d, <i>J</i> = 6.0 Hz, 1H), 8.17 (d, <i>J</i> = 6.0 Hz, 1H), 7.64 (t, <i>J</i> = 2.0 Hz, 1H), 7.46 – 7.35 (m, 5H), 7.29 – 7.15 (m, 3H), 7.09 – 7.02 (m, 1H), 5.60 (t, <i>J</i> = 5.7 Hz, 1H), 4.70 – 4.62 (m, 1H), 3.58 – 3.47 (m, 4H), 3.09 – 2.96 (m, 3H), 2.95 (s, 3H), 2.67 – 2.61 (m, 1H), 2.45 – 2.26 (m, 4H), 2.24 (s, 6H), 2.17 – 2.06 (m, 2H), 1.89 – 1.76 (m, 2H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H).
23		902.33	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.54 (s, 1H), 9.16 (s, 1H), 8.36 (d, <i>J</i> = 6.0 Hz, 1H), 8.17 (d, <i>J</i> = 6.0 Hz, 1H), 7.64 (t, <i>J</i> = 2.0 Hz, 1H), 7.47 – 7.36 (m, 5H), 7.25 – 7.15 (m, 3H), 7.09 – 7.03 (m, 1H), 4.89 (d, <i>J</i> = 6.7 Hz, 1H), 4.16 – 4.07 (m, 1H), 3.89 – 3.81 (m, 1H), 3.58 – 3.47 (m, 4H), 3.04 – 2.89 (m, 6H), 2.40 – 2.26 (m, 3H), 2.24 (s, 6H), 2.16 – 2.07 (m, 2H), 1.97 – 1.79 (m, 3H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H), 0.58 – 0.54 (m, 4H).
24		888.34	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.81 (s, 1H), 9.16 (s, 1H), 8.36 (d, <i>J</i> = 6.0 Hz, 1H), 8.17 (d, <i>J</i> = 6.0 Hz, 1H), 7.64 (t, <i>J</i> = 2.1 Hz, 1H), 7.48 – 7.35 (m, 5H), 7.31 – 7.18 (m, 3H), 7.08 – 7.03 (m, 1H), 5.04 (t, <i>J</i> = 4.8 Hz, 1H), 4.55 – 4.48 (m, 1H), 3.59 – 3.48 (m, 4H), 3.02 – 2.86 (m, 6H), 2.48 – 2.42 (m, 1H), 2.37 – 2.28 (m, 2H), 2.24 (s, 6H), 2.23 – 2.16 (m, 1H), 2.15 – 2.01 (m, 3H), 2.00 – 1.89 (m, 2H), 1.88 – 1.80 (m, 2H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).





Compounds	Structures	MS	¹ H NMR
25		888.32	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.76 (s, 1H), 9.16 (s, 1H), 8.34 (d, <i>J</i> = 6.0 Hz, 1H), 8.17 (d, <i>J</i> = 6.0 Hz, 1H), 7.64 (t, <i>J</i> = 2.1 Hz, 1H), 7.47 – 7.36 (m, 5H), 7.27 – 7.16 (m, 3H), 7.10 – 7.02 (m, 1H), 3.92 – 3.83 (m, 2H), 3.57 – 3.48 (m, 4H), 3.01 – 2.96 (m, 1H), 2.95 (s, 3H), 2.91 – 2.85 (m, 2H), 2.40 – 2.18 (m, 13H), 2.15 – 2.07 (m, 2H), 1.88 – 1.80 (m, 2H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H).
26		895.32	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.29 (s, 1H), 9.16 (s, 1H), 8.37 (d, <i>J</i> = 6.0 Hz, 1H), 8.18 (d, <i>J</i> = 6.0 Hz, 1H), 7.64 (s, 1H), 7.64 (d, <i>J</i> = 4.1 Hz, 0H), 7.43 (d, <i>J</i> = 7.5 Hz, 1H), 7.42 – 7.37 (m, 4H), 7.23 – 7.17 (m, 3H), 7.08 – 7.03 (m, 1H), 6.94 (s, 1H), 4.31 – 4.23 (m, 1H), 4.11 – 4.03 (m, 1H), 3.59 – 3.47 (m, 4H), 3.06 – 2.96 (m, 3H), 2.95 (s, 3H), 2.40 – 2.33 (m, 1H), 2.36 – 2.26 (m, 2H), 2.24 (s, 6H), 2.16 – 2.07 (m, 2H), 1.88 – 1.79 (m, 2H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H).
27		888.32	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.28 (s, 1H), 8.76 (s, 1H), 8.36 (d, <i>J</i> = 6.0 Hz, 1H), 8.17 (d, <i>J</i> = 6.0 Hz, 1H), 7.64 (s, 1H), 7.46 – 7.37 (m, 5H), 7.23 – 7.17 (m, 3H), 7.08 – 7.03 (m, 1H), 5.22 – 5.14 (m, 1H), 4.10 – 4.02 (m, 1H), 3.95 – 3.87 (m, 1H), 3.59 – 3.47 (m, 4H), 3.03 – 2.89 (m, 6H), 2.43 – 2.37 (m, 1H), 2.30 – 2.25 (m, 1H), 2.24 (s, 6H), 2.16 – 2.07 (m, 2H), 1.88 – 1.79 (m, 2H), 1.66 – 1.56 (m, 5H), 1.56 – 1.50 (m, 1H), 1.53 – 1.46 (m, 1H).





Compounds	Structures	MS	¹ H NMR
28		922.28	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.31(s, 1H), 9.16 (s, 1H), 8.37 (d, <i>J</i> = 6.0 Hz, 1H), 8.18 (d, <i>J</i> = 6.0 Hz, 1H), 7.64 (s, 1H), 7.64 (d, <i>J</i> = 4.1 Hz, 0H), 7.43 (d, <i>J</i> = 7.5 Hz, 1H), 7.42 – 7.37 (m, 4H), 7.23 – 7.17 (m, 3H), 7.08 – 7.03 (m, 1H), 6.94 (s, 1H), 4.31 – 4.23 (m, 1H), 4.11 – 4.03 (m, 1H), 3.59 – 3.47 (m, 4H), 3.47 – 3.40 (m, 1H), 3.06 – 2.99 (m, 1H), 3.03 – 2.94 (m, 2H), 2.40 – 2.33 (m, 1H), 2.36 – 2.26 (m, 2H), 2.24 (s, 6H), 2.16 – 2.07 (m, 2H), 1.88 – 1.79 (m, 2H), 1.79 – 1.58 (m, 4H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H).
29		885.34	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.29 (s, 1H), 8.36 – 8.29 (m, 2H), 7.65 (d, <i>J</i> = 3.8 Hz, 2H), 7.56 – 7.49 (m, 1H), 7.47 – 7.33 (m, 4H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 – 7.04 (m, 1H), 5.23 – 5.11 (m, 3H), 4.11 – 4.02 (m, 1H), 3.96 – 3.87 (m, 1H), 3.74 – 3.62 (m, 2H), 3.13 – 2.89 (m, 3H), 2.51 – 2.43 (m, 1H), 2.38 – 2.29 (m, 2H), 2.24 (s, 6H), 2.17 – 2.09 (m, 1H), 2.00 – 1.87 (m, 2H), 1.78 – 1.71 (m, 1H), 1.60 (d, <i>J</i> = 8.0 Hz, 3H), 1.20 (d, <i>J</i> = 25.2 Hz, 6H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).
30		899.38	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.51 (s, 1H), 8.36 – 8.29 (m, 2H), 7.67 – 7.63 (m, 1H), 7.57 – 7.51 (m, 1H), 7.43 (d, <i>J</i> = 7.5 Hz, 1H), 7.41 – 7.36 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.10 – 7.04 (m, 1H), 5.22 – 5.15 (m, 1H), 5.14 (s, 1H), 5.12 (s, 1H), 4.10 – 4.02 (m, 1H), 3.95 – 3.87 (m, 1H), 3.74 – 3.61 (m, 2H), 3.65 (s, 3H), 3.13 – 3.04 (m, 1H), 3.03 – 2.89 (m, 2H), 2.52 – 2.43 (m, 1H), 2.38 – 2.28 (m, 2H), 2.24 (s, 6H), 2.18 – 2.09 (m, 1H), 1.99 – 1.86 (m, 2H), 1.79 – 1.71 (m, 1H), 1.60 (d, <i>J</i> = 8.0 Hz, 3H), 1.23 (s, 3H), 1.18 (s, 3H), 0.99 (d, <i>J</i> = 6.0 Hz, 3H).





Compounds	Structures	MS	¹ HNMR
31		907.34	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.73 (s, 1H), 8.37 (d, <i>J</i> = 6.0 Hz, 1H), 8.18 (d, <i>J</i> = 6.0 Hz, 1H), 7.81 – 7.75 (m, 2H), 7.75 – 7.69 (m, 2H), 7.66 – 7.62 (m, 1H), 7.43 (d, <i>J</i> = 7.5 Hz, 1H), 7.40 (d, <i>J</i> = 5.1 Hz, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.08 – 7.03 (m, 1H), 6.94 (s, 1H), 4.31 – 4.23 (m, 1H), 4.11 – 4.03 (m, 1H), 3.59 – 3.47 (m, 4H), 3.06 – 2.99 (m, 1H), 3.03 – 2.94 (m, 2H), 2.72 – 2.63 (m, 4H), 2.41 – 2.26 (m, 3H), 2.24 (s, 6H), 2.16 – 2.07 (m, 2H), 1.88 – 1.79 (m, 2H), 1.51 – 1.47 (m, 6H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H).
32		879.29	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.76 (s, 1H), 8.37 (d, <i>J</i> = 6.0 Hz, 1H), 8.18 (d, <i>J</i> = 6.0 Hz, 1H), 7.81 – 7.75 (m, 2H), 7.75 – 7.69 (m, 2H), 7.66 – 7.62 (m, 1H), 7.43 (d, <i>J</i> = 7.5 Hz, 1H), 7.40 (d, <i>J</i> = 5.1 Hz, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.08 – 7.03 (m, 1H), 6.94 (s, 1H), 4.31 – 4.23 (m, 1H), 4.11 – 4.03 (m, 1H), 3.59 – 3.47 (m, 4H), 3.06 – 2.99 (m, 1H), 3.03 – 2.94 (m, 2H), 2.41 – 2.26 (m, 3H), 2.24 (s, 6H), 2.16 – 2.07 (m, 2H), 1.88 – 1.79 (m, 2H), 1.51 – 1.47 (m, 6H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H).
34		906.32	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.31 (s, 1H), 8.41 – 8.29 (m, 2H), 7.99 – 7.89 (m, 1H), 7.64 – 7.54 (m, 2H), 7.46 – 7.36 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 – 7.08 (m, 1H), 5.26 – 5.16 (m, 1H), 4.57 – 4.52 (m, 3H), 4.11 – 3.81 (m, 2H), 3.55 – 3.49 (m, 4H), 3.13 – 2.85 (m, 6H), 2.42 – 2.33 (m, 3H), 2.30 (s, 6H), 2.15 – 2.11 (m, 2H), 1.88 – 1.79 (m, 2H), 1.61 (d, <i>J</i> = 8.0 Hz, 3H), 1.01 – 0.95 (m, 3H).





Compounds	Structures	MS	¹ HNMR
35		920.34	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.27 (s, 1H), 8.40 – 8.29 (m, 2H), 7.97 – 7.87 (m, 1H), 7.65 – 7.55 (m, 2H), 7.48 – 7.39 (m, 3H), 7.22 (d, <i>J</i> = 2.0 Hz, 1H), 7.13 – 7.09 (m, 1H), 5.29 – 5.19 (m, 1H), 4.55 – 4.52 (m, 1H), 4.13 – 3.80 (m, 2H), 3.79 – 3.61 (m, 2H), 3.58 – 3.49 (m, 4H), 3.16 – 2.89 (m, 8H), 2.43 – 2.35 (m, 3H), 2.28 (s, 6H), 2.16 – 2.13 (m, 2H), 1.85 – 1.79 (m, 2H), 1.63 (d, <i>J</i> = 8.0 Hz, 3H), 1.01 – 0.95 (m, 3H).
36		906.32	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.17 (s, 1H), 8.40 – 8.29 (m, 2H), 7.97 – 7.87 (m, 1H), 7.65 – 7.55 (m, 2H), 7.48 – 7.39 (m, 3H), 7.22 (d, <i>J</i> = 2.0 Hz, 1H), 7.13 – 7.09 (m, 1H), 5.29 – 5.19 (m, 1H), 4.55 – 4.52 (m, 1H), 4.13 – 3.80 (m, 2H), 3.79 – 3.61 (m, 2H), 3.58 – 3.49 (m, 4H), 3.16 – 2.89 (m, 5H), 2.43 – 2.35 (m, 3H), 2.28 (s, 6H), 2.16 – 2.13 (m, 2H), 1.85 – 1.79 (m, 2H), 1.63 (d, <i>J</i> = 8.0 Hz, 3H), 1.01 – 0.95 (m, 3H).
37		892.30	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.18 (s, 1H), 8.41 – 8.29 (m, 2H), 7.99 – 7.89 (m, 1H), 7.64 – 7.54 (m, 2H), 7.46 – 7.36 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 – 7.08 (m, 1H), 5.26 – 5.16 (m, 1H), 4.57 – 4.52 (m, 3H), 4.11 – 3.81 (m, 2H), 3.55 – 3.49 (m, 4H), 3.13 – 2.85 (m, 3H), 2.42 – 2.33 (m, 3H), 2.30 (s, 6H), 2.15 – 2.11 (m, 2H), 1.88 – 1.79 (m, 2H), 1.61 (d, <i>J</i> = 8.0 Hz, 3H), 1.01 – 0.95 (m, 3H).
38		876.31	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.18 (s, 1H), 8.41 – 8.29 (m, 2H), 7.99 – 7.89 (m, 1H), 7.64 – 7.54 (m, 2H), 7.46 – 7.36 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 – 7.08 (m, 1H), 5.26 – 5.16 (m, 1H), 4.57 – 4.52 (m, 1H), 4.11 – 3.81 (m, 4H), 3.55 – 3.49 (m, 4H), 3.13 – 2.85 (m, 3H), 2.42 – 2.33 (m, 3H), 2.30 (s, 6H), 2.15 – 2.11 (m, 2H), 1.88 – 1.79 (m, 2H), 1.61 (d, <i>J</i> = 8.0 Hz, 3H), 1.01 – 0.95 (m, 3H).




Compounds	Structures	MS	¹ H NMR
39		888.33	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.20 (s, 1H), 8.43 – 8.33 (m, 2H), 7.95 – 7.87 (m, 1H), 7.69 – 7.59 (m, 2H), 7.48 – 7.39 (m, 3H), 7.22 (d, <i>J</i> = 2.0 Hz, 1H), 7.13 – 7.09 (m, 1H), 6.43 – 6.40 (m, 1H), 5.29 – 5.19 (m, 1H), 4.55 – 4.52 (m, 1H), 4.13 – 3.80 (m, 2H), 3.79 – 3.61 (m, 2H), 3.58 – 3.49 (m, 4H), 3.16 – 2.89 (m, 5H), 2.43 – 2.35 (m, 3H), 2.28 (s, 6H), 2.16 – 2.13 (m, 2H), 1.85 – 1.79 (m, 2H), 1.63 (d, <i>J</i> = 8.0 Hz, 3H), 1.01 – 0.95 (m, 3H).
42		867.35	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.15 (s, 1H), 8.41 – 8.36 (m, 3H), 7.90 – 7.80 (m, 1H), 7.67 – 7.55 (m, 2H), 7.46 – 7.37 (m, 2H), 7.11 – 7.07 (m, 1H), 6.52 – 6.43 (m, 2H), 5.34 – 5.25 (m, 1H), 4.63 – 4.51 (m, 1H), 4.17 – 3.87 (m, 2H), 3.69 – 3.49 (m, 4H), 3.12 – 2.96 (m, 3H), 2.44 – 2.33 (m, 9H), 2.22 – 2.13 (m, 2H), 1.91 – 1.83 (m, 2H), 1.45 – 1.25 (m, 9H), 1.14 – 1.08 (m, 5H).
43		867.35	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.14 (s, 1H), 8.42 – 8.38 (m, 3H), 7.88 – 7.77 (m, 2H), 7.69 – 7.59 (m, 2H), 7.49 – 7.39 (m, 2H), 6.73 – 6.54 (m, 1H), 6.44 – 6.35 (m, 1H), 5.33 – 5.24 (m, 1H), 4.65 – 4.53 (m, 1H), 4.19 – 3.88 (m, 2H), 3.71 – 3.59 (m, 4H), 3.16 – 2.99 (m, 3H), 2.48 – 2.38 (m, 9H), 2.26 – 2.16 (m, 2H), 1.97 – 1.87 (m, 2H), 1.43 – 1.23 (m, 9H), 1.12 – 1.08 (m, 5H).
48		866.37	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.60 (s, 1H), 8.48 – 8.38 (m, 2H), 7.98 – 7.88 (m, 1H), 7.68 – 7.58 (m, 2H), 7.47 – 7.37 (m, 3H), 7.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.16 – 7.12 (m, 1H), 6.47 – 6.44 (m, 1H), 5.36 – 5.26 (m, 1H), 4.72 – 4.62 (m, 1H), 4.37 – 3.95 (m, 2H), 3.77 – 3.68 (m, 4H), 3.13 – 2.95 (m, 3H), 2.47 – 2.38 (m, 9H), 2.27 – 2.17 (m, 5H), 1.94 – 1.87 (m, 2H), 1.44 – 1.24 (m, 5H), 1.12 – 1.08 (m, 6H).



Compounds	Structures	MS	¹ H NMR
49		840.35	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.51 (s, 1H), 8.47 – 8.37 (m, 2H), 7.97 – 7.87 (m, 1H), 7.69 – 7.59 (m, 2H), 7.49 – 7.39 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.14 – 7.12 (m, 1H), 6.48 – 6.44 (m, 1H), 5.36 – 5.26 (m, 1H), 4.71 – 4.62 (m, 1H), 4.36 – 3.95 (m, 2H), 3.79 – 3.68 (m, 4H), 3.12 – 2.96 (m, 5H), 2.45 – 2.38 (m, 9H), 2.25 – 2.16 (m, 5H), 1.95 – 1.87 (m, 2H), 1.45 – 1.24 (m, 3H), 1.11 – 1.08 (m, 4H).
50		873.36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.50 (s, 1H), 8.48 – 8.38 (m, 2H), 7.98 – 7.88 (m, 1H), 7.68 – 7.58 (m, 2H), 7.47 – 7.37 (m, 3H), 7.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.16 – 7.12 (m, 1H), 5.36 – 5.26 (m, 1H), 4.73 – 4.62 (m, 1H), 4.36 – 3.95 (m, 2H), 3.79 – 3.68 (m, 6H), 3.12 – 2.96 (m, 2H), 2.45 – 2.38 (m, 9H), 2.25 – 2.16 (m, 5H), 1.95 – 1.87 (m, 2H), 1.45 – 1.24 (m, 3H), 1.11 – 1.08 (m, 4H).
53		901.39	¹ H NMR (500 MHz, Chloroform- <i>d</i>) δ 10.94 (s, 1H), 8.36 – 8.29 (m, 2H), 8.21 – 8.14 (m, 1H), 7.89 – 7.82 (m, 1H), 7.62 – 7.56 (m, 2H), 7.51 – 7.41 (m, 4H), 7.25 – 7.20 (m, 1H), 7.11 – 7.04 (m, 1H), 5.24 – 5.14 (m, 1H), 4.57 – 4.49 (m, 1H), 4.14 – 4.05 (m, 1H), 3.35 (s, 2H), 3.86 – 3.61 (m, 3H), 3.08 – 2.90 (m, 3H), 2.49 – 2.32 (m, 3H), 2.26 – 2.23 (m, 6H), 2.08 – 1.91 (m, 2H), 1.86 – 1.69 (m, 2H), 1.61 – 1.57 (m, 7H), 1.39 – 1.31 (m, 5H), 1.19 (s, 6H), 1.01 – 0.98 (m, 3H).
55		888.32	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.15 (s, 1H), 8.42 – 8.38 (m, 3H), 7.90 – 7.82 (m, 1H), 7.65 – 7.56 (m, 1H), 7.44 – 7.41 (m, 2H), 7.13 – 7.09 (m, 1H), 6.54 – 6.53 (m, 1H), 6.51 – 6.46 (m, 2H), 5.33 – 5.23 (m, 1H), 4.61 – 4.49 (m, 1H), 4.15 – 3.85 (m, 2H), 3.67 – 3.47 (m, 8H), 3.09 – 2.91 (m, 3H), 2.42 – 2.29 (m, 4H), 2.24 – 2.11 (m, 8H), 1.92 – 1.82 (m, 2H), 1.42 – 1.25 (m, 4H), 1.11 – 1.07 (m, 3H).

Compounds	Structures	MS	¹ HNMR
58		904.30	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.77 (s, 1H), 8.40 – 8.29 (m, 2H), 7.97 – 7.87 (m, 1H), 7.65 – 7.55 (m, 2H), 7.48 – 7.39 (m, 3H), 7.22 (d, <i>J</i> = 2.0 Hz, 1H), 7.13 – 7.09 (m, 1H), 6.43 – 6.40 (m, 1H), 5.29 – 5.19 (m, 1H), 4.55 – 4.52 (m, 1H), 4.13 – 3.80 (m, 2H), 3.79 – 3.61 (m, 2H), 3.58 – 3.49 (m, 4H), 3.16 – 2.89 (m, 5H), 2.43 – 2.35 (m, 3H), 2.28 (s, 6H), 2.16 – 2.13 (m, 2H), 1.85 – 1.79 (m, 2H), 1.63 (d, <i>J</i> = 8.0 Hz, 3H), 1.02 – 0.96 (m, 3H).
65		882.36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.62 (s, 1H), 8.40 – 8.28 (m, 3H), 7.96 – 7.86 (m, 1H), 7.60 – 7.58 (m, 1H), 7.47 – 7.36 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 – 7.03 (m, 1H), 5.23 – 5.13 (m, 1H), 4.56 – 4.49 (m, 1H), 4.12 – 3.85 (m, 2H), 3.59 – 3.47 (m, 4H), 3.04 – 2.88 (m, 3H), 2.39 – 2.27 (m, 3H), 2.24 (s, 6H), 2.14 – 2.08 (m, 2H), 1.88 – 1.79 (m, 2H), 1.60 (d, <i>J</i> = 8.0 Hz, 3H), 1.39 – 1.20 (m, 4H), 1.01 – 0.95 (m, 3H).
66		882.36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.52 (s, 1H), 8.40 – 8.28 (m, 3H), 7.96 – 7.86 (m, 1H), 7.62 – 7.58 (m, 2H), 7.47 – 7.33 (m, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 – 7.03 (m, 1H), 5.23 – 5.13 (m, 1H), 4.56 – 4.49 (m, 1H), 4.12 – 3.85 (m, 2H), 3.59 – 3.47 (m, 4H), 3.04 – 2.88 (m, 3H), 2.39 – 2.27 (m, 3H), 2.24 (s, 6H), 2.14 – 2.08 (m, 2H), 1.88 – 1.79 (m, 2H), 1.60 (d, <i>J</i> = 8.0 Hz, 3H), 1.39 – 1.20 (m, 4H), 1.01 – 0.95 (m, 3H).
67		883.35	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.70 (s, 1H), 8.40 – 8.28 (m, 3H), 7.96 – 7.86 (m, 1H), 7.60 – 7.58 (m, 1H), 7.47 – 7.34 (m, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 – 7.03 (m, 1H), 5.23 – 5.13 (m, 1H), 4.56 – 4.49 (m, 1H), 4.12 – 3.85 (m, 2H), 3.59 – 3.47 (m, 4H), 3.04 – 2.88 (m, 3H), 2.39 – 2.27 (m, 3H), 2.24 (s, 6H), 2.14 – 2.08 (m, 2H), 1.88 – 1.79 (m, 2H), 1.60 (d, <i>J</i> = 8.0 Hz, 3H), 1.39 – 1.20 (m, 4H), 1.01 – 0.95 (m, 3H).

Compounds	Structures	MS	¹ H NMR
68		868.34	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.64 (s, 1H), 8.40 – 8.28 (m, 3H), 7.96 – 7.86 (m, 1H), 7.60 – 7.58 (m, 1H), 7.47 – 7.36 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 – 7.03 (m, 1H), 5.23 – 5.13 (m, 1H), 4.56 – 4.49 (m, 1H), 4.12 – 3.85 (m, 2H), 3.59 – 3.47 (m, 4H), 3.04 – 2.88 (m, 3H), 2.39 – 2.27 (m, 3H), 2.24 (s, 6H), 2.14 – 2.08 (m, 2H), 1.88 – 1.79 (m, 2H), 1.39 – 1.20 (m, 4H), 1.01 – 0.95 (m, 4H).
69		868.34	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.74 (s, 1H), 8.40 – 8.28 (m, 3H), 7.96 – 7.86 (m, 1H), 7.63 – 7.58 (m, 2H), 7.47 – 7.33 (m, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 – 7.03 (m, 1H), 5.23 – 5.13 (m, 1H), 4.56 – 4.49 (m, 1H), 4.12 – 3.85 (m, 2H), 3.59 – 3.47 (m, 4H), 3.04 – 2.88 (m, 3H), 2.39 – 2.27 (m, 3H), 2.24 (s, 6H), 2.14 – 2.08 (m, 2H), 1.88 – 1.79 (m, 2H), 1.39 – 1.20 (m, 4H), 1.01 – 0.95 (m, 4H).
70		882.36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.76 (s, 1H), 8.40 – 8.28 (m, 3H), 7.96 – 7.86 (m, 1H), 7.67 – 7.58 (m, 2H), 7.47 – 7.36 (m, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 – 7.03 (m, 1H), 5.23 – 5.13 (m, 1H), 4.56 – 4.49 (m, 1H), 4.12 – 3.85 (m, 2H), 3.59 – 3.47 (m, 4H), 3.04 – 2.88 (m, 3H), 2.39 – 2.27 (m, 3H), 2.24 (s, 6H), 2.14 – 2.08 (m, 2H), 1.88 – 1.79 (m, 2H), 1.60 (d, <i>J</i> = 8.0 Hz, 3H), 1.39 – 1.20 (m, 4H), 1.01 – 0.95 (m, 3H).
74		882.36	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.61 (s, 1H), 8.40 – 8.29 (m, 3H), 7.96 – 7.86 (m, 1H), 7.67 – 7.58 (m, 3H), 7.47 – 7.36 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 5.23 – 5.13 (m, 1H), 4.56 – 4.49 (m, 1H), 4.12 – 3.85 (m, 2H), 3.59 – 3.47 (m, 4H), 3.04 – 2.88 (m, 3H), 2.39 – 2.27 (m, 3H), 2.24 (s, 6H), 2.14 – 2.08 (m, 2H), 1.88 – 1.79 (m, 2H), 1.60 (d, <i>J</i> = 8.0 Hz, 3H), 1.39 – 1.20 (m, 4H), 1.01 – 0.95 (m, 3H).

Compounds	Structures	MS	¹ HNMR
75		868.34	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.65 (s, 1H), 8.41 – 8.36 (m, 3H), 7.90 – 7.80 (m, 1H), 7.65 – 7.55 (m, 1H), 7.46 – 7.37 (m, 2H), 7.11 – 7.07 (m, 1H), 6.52 – 6.43 (m, 2H), 5.34 – 5.25 (m, 1H), 4.63 – 4.51 (m, 1H), 4.17 – 3.87 (m, 2H), 3.69 – 3.49 (m, 4H), 3.12 – 2.96 (m, 3H), 2.44 – 2.33 (m, 9H), 2.22 – 2.13 (m, 2H), 1.91 – 1.83 (m, 2H), 1.45 – 1.25 (m, 9H), 1.14 – 0.95 (m, 5H).
76		888.32	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.78 (s, 1H), 8.41 – 8.29 (m, 2H), 7.99 – 7.89 (m, 1H), 7.64 – 7.54 (m, 2H), 7.50–7.49(m, 1H), 7.46 – 7.36 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 – 7.08 (m, 1H), 5.26 – 5.16 (m, 1H), 4.57 – 4.52 (m, 3H), 4.11 – 3.81 (m, 2H), 3.55 – 3.49 (m, 4H), 3.45(s, 3H), 3.13 – 2.85 (m, 3H), 2.42 – 2.33 (m, 3H), 2.30 (s, 6H), 2.15 – 2.11 (m, 2H), 1.88 – 1.79 (m, 2H), 1.61 (d, <i>J</i> = 8.0 Hz, 3H), 1.01 – 0.95 (m, 3H).
77		854.33	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.78 (s, 1H), 8.41 – 8.29 (m, 2H), 7.99 – 7.89 (m, 1H), 7.64 – 7.54 (m, 2H), 7.50–7.49(m, 1H), 7.46 – 7.36 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 – 7.08 (m, 1H), 5.26 – 5.16 (m, 1H), 4.53 – 4.50 (m, 1H), 4.11 – 3.81 (m, 2H), 3.55 – 3.49 (m, 4H), 3.28(s, 3H), 3.13 – 2.85 (m, 3H), 2.42 – 2.33 (m, 3H), 2.30 (s, 6H), 2.15 – 2.11 (m, 2H), 1.88 – 1.79 (m, 2H), 1.61 (d, <i>J</i> = 8.0 Hz, 3H), 1.01 – 0.95 (m, 3H).
78		866.37	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.78 (s, 1H), 8.41 – 8.29 (m, 2H), 7.99 – 7.89 (m, 1H), 7.64 – 7.54 (m, 2H), 7.50–7.49(m, 1H), 7.46 – 7.36 (m, 3H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 – 7.08 (m, 1H), 5.26 – 5.16 (m, 1H), 4.53 – 4.50 (m, 1H), 4.11 – 3.81 (m, 2H), 3.55 – 3.49 (m, 4H), 3.35(s, 3H), 3.13 – 2.81 (m, 5H), 2.66–2.63(m, 2H), 2.42 – 2.33 (m, 3H), 2.30 (s, 6H), 2.15 – 2.11 (m, 2H), 1.88 – 1.79 (m, 2H), 1.61 (d, <i>J</i> = 8.0 Hz, 3H), 1.01 – 0.95 (m, 3H).

Compounds	Structures	MS	¹ HNMR
79		857.33	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.78 (s, 1H), 8.41 – 8.29 (m, 2H), 7.99 – 7.89 (m, 1H), 7.64 – 7.54 (m, 2H), 7.50-7.49(m, 1H), 7.46 – 7.36 (m, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 – 7.08 (m, 1H), 5.26 – 5.16 (m, 1H), 5.10-5.08(s, 2H), 4.53 – 4.50 (m, 1H), 4.11 – 3.81 (m, 2H), 3.55 – 3.49 (m, 4H), 3.13 – 2.85 (m, 3H), 2.42 – 2.33 (m, 3H), 2.30 (s, 6H), 2.15 – 2.11 (m, 2H), 1.88 – 1.79 (m, 2H), 1.61 (d, <i>J</i> = 8.0 Hz, 3H), 1.01 – 0.95 (m, 3H).
80		901.39	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.76 (s, 1H), 8.37 (d, <i>J</i> = 6.0 Hz, 1H), 8.18 (d, <i>J</i> = 6.0 Hz, 1H), 7.81 – 7.75 (m, 2H), 7.75 – 7.69 (m, 2H), 7.66 – 7.62 (m, 1H), 7.43 (d, <i>J</i> = 7.5 Hz, 1H), 7.40 (d, <i>J</i> = 5.1 Hz, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.08 – 7.03 (m, 1H), 6.94 (s, 1H), 4.31 – 4.23 (m, 1H), 4.11 – 4.03 (m, 1H), 3.89(s, 2H), 3.59 – 3.47 (m, 4H), 3.06 – 2.99 (m, 1H), 3.03 – 2.94 (m, 2H), 2.72 – 2.63 (m, 4H), 2.41 – 2.26 (m, 3H), 2.24 (s, 6H), 2.16 – 2.07 (m, 2H), 1.88 – 1.79 (m, 2H), 1.75(d, <i>J</i> =6.4Hz, 3H), 1.51 – 1.47 (m, 6H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H).
81		925.39	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.76 (s, 1H), 8.37 (d, <i>J</i> = 6.0 Hz, 1H), 8.18 (d, <i>J</i> = 6.0 Hz, 1H), 7.81 – 7.75 (m, 2H), 7.75 – 7.69 (m, 2H), 7.66 – 7.62 (m, 1H), 7.43 (d, <i>J</i> = 7.5 Hz, 1H), 7.40 (d, <i>J</i> = 5.1 Hz, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.08 – 7.03 (m, 1H), 6.94 (s, 1H), 4.31 – 4.23 (m, 1H), 4.11 – 4.03 (m, 1H), 3.89(s, 2H), 3.59 – 3.47 (m, 4H), 3.06 – 2.99 (m, 1H), 3.03 – 2.94 (m, 2H), 2.72 – 2.63 (m, 4H), 2.41 – 2.26 (m, 3H), 2.24 (s, 6H), 2.16 – 2.07 (m, 4H), 1.88 – 1.79 (m, 2H), 1.75(d, <i>J</i> =6.4Hz, 3H), 1.14-0.89 (m, 7H).

Compounds	Structures	MS	¹ HNMR
82		899.37	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.76 (s, 1H), 8.37 (d, <i>J</i> = 6.0 Hz, 1H), 8.18 (d, <i>J</i> = 6.0 Hz, 1H), 7.81 – 7.75 (m, 2H), 7.75 – 7.69 (m, 2H), 7.66 – 7.62 (m, 1H), 7.43 (d, <i>J</i> = 7.5 Hz, 1H), 7.40 (d, <i>J</i> = 5.1 Hz, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.08 – 7.03 (m, 1H), 6.94 (s, 1H), 4.31 – 4.23 (m, 1H), 4.11 – 4.03 (m, 1H), 3.89(s, 2H), 3.59 – 3.47 (m, 4H), 3.06 – 2.99 (m, 1H), 3.03 – 2.94 (m, 2H), 2.72 – 2.63 (m, 4H), 2.41 – 2.26 (m, 3H), 2.24 (s, 6H), 2.19 – 2.01 (m, 6H), 1.88 – 1.79 (m, 2H), 1.75(d, <i>J</i> =6.4Hz, 3H), 1.51 – 1.47 (m, 4H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H).
84		933.38	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.72 (s, 1H), 8.37 (d, <i>J</i> = 6.0 Hz, 1H), 8.18 (d, <i>J</i> = 6.0 Hz, 1H), 7.81 – 7.75 (m, 2H), 7.75 – 7.69 (m, 2H), 7.66 – 7.62 (m, 1H), 7.43 (d, <i>J</i> = 7.5 Hz, 1H), 7.40 (d, <i>J</i> = 5.1 Hz, 2H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.08 – 7.03 (m, 1H), 6.94 (s, 1H), 4.31 – 4.21 (m, 5H), 4.11 – 4.03 (m, 1H), 3.89(s, 2H), 3.59 – 3.47 (m, 4H), 3.06 – 2.99 (m, 1H), 3.03 – 2.94 (m, 2H), 2.72 – 2.63 (m, 4H), 2.41 – 2.26 (m, 1H), 2.24 (s, 6H), 2.16 – 2.07 (m, 2H), 1.88 – 1.79 (m, 2H), 1.75(d, <i>J</i> =6.4Hz, 3H), 1.36 – 1.35(m, 6H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H).

Example 2 *In vitro* activity evaluation

hGLP-1R cAMP Assay

1. Cell line and reagent preparation

- 5 1) Cell line: Flp-In-293-GLP1R
- 2) Medium: DMEM + 10% FBS + 1 X Penicillin-Streptomycin + 200 µg/ mL HB
- 3) Test buffer: 1 X HBSS + 20 mM HEPES + 0.1%BSA + 500 µM IBMX

2. Agonist test

- a) Flpin-293-GLP1R cells were incubated in a 384-well assay plate (6007680-50, PE)
- 10 using a complete medium with 2,000 cells per well.
- b) Prepared a 4 X complex working solution with assay buffer.
- c) Added 5 µL of 4 X Compound Working Solution to the cell plate and incubated at 37°C for 30 minutes.

d) Diluted the Eu-cAMP tracer (1/50) with lysis buffer and added 10 µl/well to the assay plate.

e) Diluted Ulight-anti-cAMP (1/150) with lysis buffer and added 10 µl/well to the assay plate.

5 f) The assay plate was incubated at constant temperature for 1 hour.

g) Read the plate on Envision 2105 plate reader at 665 nM and 615 nM.

3. Data Analysis

3.1 The formula for calculating % Activity was as follows

$$\% \text{ Activity} = 100 - (\text{Signal}_{\text{compd}} - \text{Signal}_{\text{Ave_PC}}) / (\text{Signal}_{\text{Ave_VC}} - \text{Signal}_{\text{Ave_PC}}) \times 100.$$

10 3.2 Calculate EC₅₀ and plot the effect-dose curve for cmpds:

$$Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{((\text{LogEC}_{50} - X) * \text{HillSlope})})$$

X: logarithm of agonist concentration;

Y: percentage activity.

Table 2 shows the biological activity of the different compounds in the hGLP-1R

15 agonist cAMP stimulation assay.

Table 2. Bioactivity of compounds in hGLP-1R agonist cAMP stimulation assay

Compounds	hGLP-1R cAMP: EC ₅₀ (nM)	Compounds	hGLP-1R cAMP: EC ₅₀ (nM)
1	0.094	65	0.092
13	0.228	66	0.014
18	0.265	70	0.064
19	0.012	76	0.019
20	0.018	77	0.022
21	0.044	78	0.012
24	0.868	79	0.171
29	0.063	80	0.038
35	0.025	81	0.042
36	0.05	82	0.011
37	0.06	84	0.08
55	0.15	50	0.028

Example 3 Pharmacokinetic studies

1. Single-dose subcutaneous injection pharmacokinetic studies in Sprague-Dawley (SD) rats

20 Pharmacokinetic (PK) studies after a single-dose subcutaneous injection for compounds:


1, 13, 18, 19, 20, 21 and orforglipron. Protocol: Animals: Male Sprague-Dawley (SD) rats;

Vehicle: 80% MCT (Medium-Chain Triglycerides) + 20% benzyl alcohol; Dose: 30 mg/kg; Dosing concentration: 30 mg/ mL in the vehicle; Dosing volume: 1 mL/kg; Administration site: Subcutaneous injection at the back of the animal. Blood sampling time points: pre-dose, 1h, 2h, 8h, 24h, 48h, 72h, 96h, 120h, 144h, 216h, 312h, 480h, 696h. Blood samples were collected, and the blood samples were analyzed by LC-MS/MS. Pharmacokinetic parameters

Table 3. Drug exposure of different compounds after a single-dose subcutaneous injection

Compounds	Dosing route	Dose, mg/kg	AUC _{0-696h} , ng.h/ mL
1	Subcutaneous	30	60,272
13	Subcutaneous	30	23,399
18	Subcutaneous	30	51,234
19	Subcutaneous	30	234,473
20	Subcutaneous	30	77,688
21	Subcutaneous	30	61,479
Orforglipron	Subcutaneous	30	5,390

Note: AUC_{0-696h} was an important pharmacokinetic parameter, representing the area under the curve from 0 hour to the study endpoint time 696 hours, which indicates the drug exposure in the body during that time period.



The structure of orforglipron is shown above.

2. Single-dose oral administration pharmacokinetic (PK) studies in Sprague-Dawley (SD) rats

Pharmacokinetic (PK) studies after a single-dose oral administration for compounds: 19, 20, 65 and orforglipron. Protocol: Animals: Male Sprague-Dawley (SD) rats; Solvent: Solutol: PEG400: Tween80: Saline = 10:40:2:48 (v/v/v/v); Dose: 5mg/kg; Dosing concentration: 0.5mg/ mL in the solvent; Dosing volume: 10 mL/kg; Blood sampling time points: pre-dose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 8h, 12h, 18, 24h, 32h, 40h, 48h. Sample Collection: At each time point, approximately 0.15 mL of blood was drawn from the jugular

vein sinus, and the collected whole blood was placed in an anticoagulant tube containing EDTA-K2. After collecting blood samples, they were processed with protein precipitation and then analyzed by LCMSMS. Pharmacokinetic parameters were calculated by Phoenix WinNonlin 8.0 and summarized in Table 4.

5 **Table 4. Pharmacokinetic parameters of different compounds after a single-dose oral administration**

Compounds	Dosing route	Dose, mg/kg	C _{max} , ng/ mL	AUC _{0-48h} , ng.h/ mL
19	Oral	5	4,460	60,043
20	Oral	5	1,900	16,982
65	Oral	5	10,993	71,836
Orforglipron	Oral	5	799	7,222

Note: C_{max} refers to the maximum plasma concentration of a drug after administration.

10 **Example 4 Pharmacodynamic Study *In Vivo***

Animal screening: Within one week prior to the administration of the test compounds, 28 male cynomolgus monkeys were anesthetized with Zoletil (5.0 mg/kg, intramuscular injection, i.m.), and then 50% glucose was administered intravenously at a dose of 0.5 g/kg (1 mL/kg), completed within 30 seconds. Blood samples were collected at 10 time points: 45 minutes before glucose injection (non-anesthetized), 6 minutes before glucose injection (under anesthesia), and 1, 5, 10, 15, 20, 30, 40, and 60 minutes after glucose injection. At each time point, 10 µL of whole blood was collected from the saphenous vein for blood glucose testing using a glucometer. Approximately 1.5 mL of whole blood was collected at each time point from the saphenous vein into a vacuum blood collection tube containing a coagulant. The tube was immediately inverted gently several times to mix well, placed at room temperature, and then centrifuged at 4 °C (2000 g, 10 minutes) to obtain serum. The collected serum samples were stored in an ultra-low temperature freezer until all samples were tested for blood glucose, insulin, and C-peptide. For the selection of cynomolgus monkeys, 15 cynomolgus monkeys were chosen for the formal experiment based on the trends of changes in blood glucose, insulin, and C-peptide.

Formal Experiment:

Grouping: The 15 selected cynomolgus monkeys were randomly divided into 3 groups, with 5 animals in each group.

Sample preparation: An appropriate amount of the compound of the present disclosure was weighed and dissolved in the solvent: 5% DMSO / 10% Cremophor EL / 20% PEG400 / 65% 100 mM Glycine-NaOH pH 10 to prepare a suitable concentration for intravenous bolus injection.

5 **Dosing method:** 5 minutes before the glucose injection, the test substance was administered via intravenous bolus (iv bolus). The syringe was filled with the corresponding volume of the test substance for each animal, and the injection was completed within 30 seconds.

10 **Intravenous glucose tolerance test:** 5 minutes after the intravenous bolus administration of the test substance, the intravenous glucose tolerance test was initiated, with the animals remaining anesthetized throughout the procedure (anesthetized with Zoletil at 5.0 mg/kg, i.m.). 5 minutes after the intravenous bolus administration of the test substance, 50% glucose at a dose of 0.5g/kg (1.0 mL/kg) was administered intravenously, completed within 30 seconds.

15 **Sample collection:** Blood was collected 45 minutes before the glucose injection (non-anesthetized) and 6 minutes before the glucose injection (under anesthesia). After the glucose injection (under anesthesia), blood was collected at the following time points: 1, 5, 10, 15, 20, 30, 40, and 60 minutes. At each time point, 10 μ L of whole blood was collected from the saphenous vein for blood glucose testing using a glucometer. Approximately 1.5 mL of
20 whole blood was collected from the saphenous vein at each time point into a vacuum blood collection tube containing a coagulant. The tube was immediately inverted gently several times to mix well, placed at room temperature, and then centrifuged at 4 °C (2000 g, 10 minutes) to obtain serum. The collected serum samples were stored in an ultra-low temperature freezer until all samples were analyzed for blood glucose, insulin, and C-peptide.


25 **Sample Analysis:** The serum samples were analyzed for insulin, C-peptide, and blood glucose levels.

Results: The compound of the present disclosure significantly increased the secretion of insulin and C-peptide in cynomolgus monkeys, while blood glucose levels were reduced as well.

30

WHAT IS CLAIMED IS:

1. A compound of Formula (I), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:



Formula (I)

wherein,

X is selected from the group consisting of N and -CR^a; wherein R^a is selected from the group consisting of hydrogen, halogen, and C₁₋₆ alkyl;

wherein Y is -C(=O)-;

wherein each of Z₃, Z₄, Z₅, Z₆, Z₇, Z₈, Z₉, Z₁₀, Z₁₁, Z₁₂ and Z₁₃ is independently selected from the group consisting of N and C;

wherein Q₁ is selected from the group consisting of C₆₋₁₀ aryl and 5- to 10-membered heteroaryl, wherein C₆₋₁₀ aryl or 5- to 10-membered heteroaryl is optionally substituted by one to five substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy;

wherein Q₂ is selected from the group consisting of 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, and -NR^{Qa}R^{Qb}, or wherein two C₁₋₆ alkyl groups optionally together with the carbon atoms to which they are attached form C₃₋₈ carbocyclic ring; wherein R^{Qa} and R^{Qb} are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and (C₁₋₆ alkyl) carbonyl;

wherein each of R₁, R₂, R₃, R₁', R₂' and R₃' is independently selected from the group consisting of hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, cycloalkyl and heterocycloalkyl; wherein C₁₋₆ alkyl, cycloalkyl or heterocycloalkyl is optionally substituted

by one or more substituents independently selected from the group consisting of halogen, C₁₋₆ alkoxy and hydroxyl; or

wherein R₂ and R₃ together with the carbon atom to which they are attached form 4- to 8-membered heterocycloalkyl;

5 each of R₄, R₅ and R₆ is independently selected from the group consisting of hydrogen, halogen and C₁₋₆ alkyl;

each of R₇ and R₈ is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and C₃₋₁₅ cycloalkyl;


10 or R₇ and R₈ together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring, wherein the C₃₋₁₅ carbocyclic ring is optionally substituted by one to three C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxyl, -NR^{7a}R^{7b}, C₁₋₆ alkoxy and 3- to 12-membered heterocyclic, and R^{7a} and R^{7b} are independently selected from the
15 group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl; and any two C₁₋₆ alkyl optionally together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring;

n₁ is 0, 1, 2 or 3;

n₂ is 0, 1, 2, 3, 4 or 5;

20 n₃ is 0 or 1;

R₉ is selected from the group consisting of:



each of R^{9a}, R^{9b}, R^{9c}, R^{9d} and R^{9e} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, wherein C₁₋₆ alkyl is optionally substituted
25 with one or more substituents independently selected from the group consisting of halogen and C₁₋₆ alkoxy;


R^{9e} is selected from the group consisting of hydrogen and C₁₋₆ alkyl optionally substituted by one or more halogen;

R^{9f} is selected from the group consisting of hydrogen and C₁₋₆ alkyl;

30 R^{9h} is selected from the group consisting of hydrogen, C₁₋₆ alkyl, (C₁₋₆ alkyl) carbonyl, cyano and -S(=O)_{n9}-R⁹ⁱ; n₉ is 0, 1 or 2;

R⁹ⁱ is C₁₋₆ alkyl;

Z_1 is selected from the group consisting of:



5 wherein R^{za} is selected from the group consisting of hydrogen, C₁₋₆ alkyl and (C₁₋₆ alkyl) carbonyl, and each of R^{zb} and R^{zc} is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl;

n4 is 1, 2 or 3;

each of n5 and n6 is independently an integer selected from 0 to 10;






10 Z₂ is 5- to 10- membered heteroaryl; and Z₂ is substituted with one halogen and one of C₃-C₁₅ cycloalkyl and C₁-C₆ alkyl-C₃-C₁₅ cycloalkyl; wherein the cycloalkyl or alkyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, oxo, C₁₋₆ alkyl, C₁₋₆ alkoxy and (C₁₋₆ alkyl) carbonyl, wherein each of alkyl and alkoxy is optionally substituted with halogen.

15 2. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 1, wherein Z₂ is indazolyl.

3. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 2, wherein the indazolyl is substituted with one halogen and one of C₃-C₁₅ cycloalkyl and C₁-C₆ alkyl-C₃-C₁₅ cycloalkyl.


20 4. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 1-3, wherein Q₁ is C₆₋₁₀ aryl, and the C₆₋₁₀ aryl is optionally substituted with one to five substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy.

5. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the
25 deuterated compound thereof of any one of claims 1-4, wherein the compound is selected
from the group consisting of



and

6. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 1-4, wherein the compound has a structure of Formula (II),











Formula (II)


wherein ring A is selected from the group consisting of cyclopropyl, cyclobutyl, and cyclopentyl;

t is 0 or 1; and


R_{qm} and R_{qn} are each independently selected from the group consisting of hydrogen and
5 C₁₋₆ alkyl.

7. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 1, wherein the compound is selected from the group consisting of






69




70



74

and

8. A compound, a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof of Formula (III),



Formula (III)

5

wherein

X is $-\text{CR}^a$; R^a is H;

Y is $-\text{C}(=\text{O})-$;

$\text{Z}_3, \text{Z}_4, \text{Z}_5, \text{Z}_6, \text{Z}_8, \text{Z}_9, \text{Z}_{10}, \text{Z}_{12}$ and Z_{13} are C;

Z₇ and Z₁₁ are N;

Q₁ is C₆₋₁₀ aryl, wherein C₆₋₁₀ aryl is optionally substituted with one to five substituents independently selected from the group consisting of halogen and C₁₋₆ alkyl;

Q₂ is 3- to 12-membered heterocyclic, wherein 3- to 12-membered heterocyclic is optionally substituted with 1-3 substituents independently selected from the group consisting of halogen and C₁₋₆ alkyl, or wherein two C₁₋₆ alkyl groups optionally together with the carbon atoms to which they are attached form C₃₋₈ carbocyclic ring;

wherein each of R₁, R₂, R₁', and R₂' is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl;

R₃ and R₃' are independently selected from the group consisting of hydrogen and C₁₋₆ alkyl;


R₄, R₅ and R₆ are H;


each of R₇ and R₈ is independently selected from the group consisting of hydrogen and C₁₋₆ alkyl; or R₇ and R₈ together with the carbon atom to which they are attached form C₃₋₁₅ carbocyclic ring, wherein the C₃₋₁₅ carbocyclic ring is optionally substituted by one to three C₁₋₆ alkyl;

n₁ is 0 or 1;

n₂ is 0 or 1;


n₃ is 1;

R₉ is , and R^{9a} is H;


Z₁ is ;

Z₂ is 5- to 10- membered heteroaryl, and Z₂ is substituted with one halogen and one of C_{3-C15} cycloalkyl and C_{1-C6} alkyl-C_{3-C15} cycloalkyl; wherein the cycloalkyl or alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, oxo, C₁₋₆ alkyl, C₁₋₆ alkoxy and (C₁₋₆ alkyl) carbonyl, wherein each of alkyl and alkoxy is optionally substituted with halogen.


9. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the

deuterated compound thereof of claims 8, wherein Q₁ is , and R_{n1} and R_{n3} are each independently selected from the group consisting of H, methyl, and ethyl; R_{n2} is halogen.

10. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the

5 deuterated compound thereof of any one of claims 8-9, wherein Q₂ is , wherein R_{qm} and R_{qn} are each independently selected from the group consisting of H, methyl, and ethyl; or R_{qm} and R_{qn} together with the carbon atom to which they are attached to form C₃₋₆ cycloalkyl; p is 0, 1, or 2.

11. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the

10 deuterated compound thereof of any one of claims 8-10, wherein Z₂ is ;


wherein R_{Z1} is halogen;

m₁ is 1;

R_{Z2} is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl-C₃₋₈ cycloalkyl; and R_{Z2} is optionally substituted with one or more substituents selected from the


15 group consisting of halogen, C₁₋₆ alkyl, and C₁₋₆ alkoxy.

12. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the

deuterated compound thereof of any one of claims 8-11, wherein Z₂ is ;


R_{Z1} is selected from the group consisting of F, Cl, and Br;

R_{Z2} is selected from the group consisting of




20

13. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 8-10, wherein Z₂ is selected from the group consisting of




5 Z₂ is substituted with one halogen.

14. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 8-13, wherein Z₂ is selected from the group consisting of



10 15. A compound, a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof of Formula (IV),



wherein:

each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;

R_{Z1} is selected from the group consisting of halogen, C₁₋₃ alkyl, and C₃₋₈ cycloalkyl;

- 5 R_{Z2} is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl-C₃₋₈ cycloalkyl; and R_{Z2} is optionally substituted with substituents independently selected from the group consisting of halogen, -OH, C₁₋₆ alkyl, and C₁₋₆ alkoxy;

m₁ is 0, 1, 2 or 3.

16. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the
 10 deuterated compound thereof of claim 15, wherein
 R_m is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆ alkoxy;
 R_n is selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆ alkoxy;


m is 0, 1, 2, or 3;

- 15 R₃ is selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy.

17. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 15-16, wherein

- R_{Z1} is selected from the group consisting of F, Cl, Br, methyl, ethyl, n-Propyl, isopropyl and cyclopropyl;
 20 m is 0, 1, 2, or 3;

R_{z2} is selected from the group consisting of




R_m is independently selected from the group consisting of halogen, -CH₃, -CH₂CH₃ and -OCH₃;

5 R_n is selected from the group consisting of methyl, ethyl, F and Cl;

R₃ is methyl.

18. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the



deuterated compound thereof of any one of claims 15-17, wherein Q₂ is ,


wherein R_{qm} and R_{qn} are each independently selected from the group consisting of H, methyl,

10 and ethyl;


or R_{qm} and R_{qn} together with the carbon atom to which they are attached form a C₃₋₆ cycloalkyl; p is 0, 1, or 2.

19. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 15-18, wherein Q₂ is selected from the

15 group consisting of




20. A compound, a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof of Formula (V)



wherein:

each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;

Q₂ is selected from the group consisting of




R_n is selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy;

m is 0, 1, 2 or 3;


R₂₂ is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl-C₃₋₈ cycloalkyl; and R₂₂ is optionally substituted with substituents independently selected from the group consisting of halogen, hydroxyl, C₁₋₆ alkyl and C₁₋₆ alkoxy.

21. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 20, wherein R₂₂ is selected from the group consisting



15 R_n is selected from the group consisting of methyl, ethyl, F, and Cl.

22. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 20, wherein the compound has a structure of Formula (VI),




wherein:

each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;

R₂₂ is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl-C₃₋₈


- 5 cycloalkyl; and R₂₂ is optionally substituted with substituents independently selected from the group consisting of halogen, hydroxyl, C₁₋₆ alkyl and C₁₋₆ alkoxy;

Q₂ is selected from the group consisting of




23. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the
10 deuterated compound thereof of claim 22,

wherein R₂₂ is selected from the group consisting of




24. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the
15 deuterated compound thereof of claim 20, wherein the compound has a structure of Formula (VII),




R_{22} is selected from the group consisting of C_{3-8} cycloalkyl and C_{1-6} alkyl- C_{3-8} cycloalkyl; and R_{22} is optionally substituted with substituents independently selected from the group consisting of halogen, hydroxyl, C_{1-6} alkyl and C_{1-6} alkoxy;


5 Q_2 is selected from the group consisting of



25. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 24, wherein R_{22} is selected from the group consisting



10 26. A compound, a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof of Formula (VIII),



wherein each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;


R_m is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy;

R_{n1} and R_{n3} are each independently selected from the group consisting of hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy; R_{n2} is halogen;

R₃ is selected from the group consisting of hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy;

10 R_{Z1} is selected from the group consisting of hydrogen, halogen, C₁₋₃ alkyl and C₃₋₈ cycloalkyl;

R_{Z2} is selected from the group consisting of



15 R_{qm} and R_{qn} are each independently selected from the group consisting of H, methyl, and ethyl, or R_{qm} and R_{qn} together with the carbon atom to which they are attached to form a C₃₋₆ cycloalkyl.

27. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 26, wherein,

R_m is independently selected from the group consisting of halogen, -CH₃, -CH₂CH₃ and -OCH₃


R_{n1} and R_{n3} are each independently selected from the group consisting of hydrogen, methyl, and ethyl;

R_{n2} is F;

R_3 is methyl;

- 5 R_{z1} is selected from the group consisting of hydrogen, F, Cl, methyl, ethyl, n-propyl, isopropyl, and cyclopropyl.


28. A compound, a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof of Formula (IX),



Formula (IX)

- 10 wherein each of X, Z_4 and Z_6 is independently selected from the group consisting of N and CH;

Z_2 is selected from the group consisting of



- 15 R_n is selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl and C_{1-6} alkoxy;

m is 0, 1, 2 or 3.

29. The compound the stereoisomer, the pharmaceutically acceptable salt or the deuterated compound thereof of claim 28, wherein


R_m is selected from the group consisting of H, C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{1-6} alkoxy;

R₃ is selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy;


R₁₀ and R₁₁ is independently selected from the group consisting of H, F, Cl, methyl, ethyl, n-propyl, isopropyl, and cyclopropyl.

30. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 28-29, wherein R_m is independently selected from the group consisting of halogen, -CH₃, -CH₂CH₃ and -OCH₃; R_n is independently selected from the group consisting of -CH₃, -CH₂CH₃, F, and Cl; R₃ is -CH₃.

31. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the
10 deuterated compound thereof of any one of claims 28-30, wherein Z₂ is selected from the
group consisting of




32. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the









deuterated compound thereof of any one of claims 28-31, wherein Q_2 is ,
wherein R_{qm} and R_{qn} are each independently selected from the group consisting of H, methyl,
and ethyl; or R_{qm} and R_{qn} together with the carbon atom to which they are attached to form a








5 C_{3-6} Cycloalkyl; p is 0,1, or 2.

33. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the
deuterated compound thereof of any one of claims 28-32, wherein Q_2 is selected from the
group consisting of




10 34. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the
deuterated compound thereof of claim 28, wherein the compound is selected from the group
consisting of






and



35. A compound of Formula (X), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof,




Formula (X)

wherein:

each of X, Z₄ and Z₆ is independently selected from the group consisting of N and CH;
m is 0, 1, 2 or 3;

- 5 R_p is selected from the group consisting of -CH₂-P(=O)R^{zm}R^{zn} and -P(=O)OR^{zm}OR^{zn};
R_q is selected from the group consisting of halogen, -NH-C₁₋₆ alkyl, -C₁₋₆ alkyl, -O- C₁₋₆ alkyl, 3- to 12-membered heterocyclic, C₃-C₁₅ cycloalkyl and C₁-C₆ alkyl-C₃-C₁₅ cycloalkyl;
wherein each of R^{zm} and R^{zn} is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl and C₆₋₁₀ aryl; or R^{zm} and R^{zn} together with the phosphorous atom to
10 which they are attached form 5- to 8- membered heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with 1-3 C₁₋₆ alkyl.

36. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 35, wherein R_p is selected from the group consisting of



15 ;

R_m is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆ alkoxy;

R_n is selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆ alkoxy;


m is 0, 1, 2, and 3;

- 20 R₃ is selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy.

37. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 35-36, wherein R_m is selected from the

group consisting of H, methyl, ethyl and methoxy; R_n is selected from the group consisting of methyl, ethyl, F and Cl; R_3 is methyl.

38. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the




deuterated compound thereof of any one of claims 35-37, wherein Q_2 is , wherein






- 5 R_{qm} and R_{qn} are each independently selected from the group consisting of H, methyl, and ethyl; or R_{qm} and R_{qn} together with the carbon atom to which they are attached to form C₃₋₆ Cycloalkyl; p is 0, 1, or 2.

39. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 35-38, wherein Q_2 is selected from the


- 10 group consisting of




40. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 35, wherein the compound is selected from the group consisting of



and



41. A compound of Formula (XI), a stereoisomer, a pharmaceutically acceptable salt, or a deuterated compound thereof:



wherein:

Q₁ is C₆₋₁₀ aryl, and the C₆₋₁₀ aryl is optionally substituted with one to five substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl and C₁₋₆ alkoxy;

5 Q₂ is selected from the group consisting of 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl, wherein 3- to 12-membered heterocyclic, and 5- to 10-membered heteroaryl are optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₁₋₆ alkoxy, wherein two C₁₋₆ alkyl groups optionally together with the carbon atoms to which they are attached form a C₃₋₈ carbocyclic ring;


X₁, X₂, and X₃ are independently selected from the group consisting of N and C;

X₄, and X₅ are independently selected from the group consisting of N and C;

R_m is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy and C₁₋₆ haloalkoxy;


15 R₂₂ is selected from the group consisting of C₃₋₈ cycloalkyl and C₁₋₆ alkyl-C₃₋₈ cycloalkyl.

42. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 41, wherein




20 consisting of H, methyl, and ethyl; R_{n2} is halogen;


Q₂ is selected from the group consisting of







R_{Z2} is selected from the group consisting of



















43. The compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of claim 41, wherein the compound is selected from the group consisting of








44. A compound, a stereoisomer, a pharmaceutically acceptable salt, or a deuterated
10 compound thereof, the compound is selected from the group consisting of:









45. A pharmaceutical composition, comprising the compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 1-44, and a pharmaceutically acceptable excipient.

46. A method for treating a GLP-1R-mediated disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of the compound, the stereoisomer, the pharmaceutically acceptable salt, or the deuterated compound thereof of any one of claims 1-44, or the pharmaceutical composition of claim 45.

47. The method of claim 46, wherein the GLP-1R-mediated disease or condition is selected from the group consisting of T1D (type 1 diabetes), T2DM (type 2 diabetes mellitus), pre-diabetes, idiopathic T1D (idiopathic type 1 diabetes), LADA (latent autoimmune diabetes in adults), EOD (early onset diabetes), YOAD (young onset adult

- diabetes), MODY (maturity onset diabetes of the young), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity,
- 5 overweight, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke,
- 10 traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, parkinson's disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient
- 15 ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, alzheimer's disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, crohn's disease, colitis, irritable bowel syndrome, polycystic ovary
- 20 syndrome and substance addiction.

48. The method of claim 46, wherein the GLP-1R-mediated disease or condition is selected from the group consisting of weight management, chronic weight management, chronic kidney disease, atherosclerotic cardiovascular disease, heart failure, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, diabetes prevention,
- 25 and obstructive sleep apnea.